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Soft tissue sarcoma (STS) are tumours derived from tissues of mesenchymal 
origin. Local recurrence of the tumour following surgical resection is the 
characteristic challenge in the management of STS. There are currently no 
prognostic tests that can reliably predict which tumours have a higher or 
lower risk of recurrence. The aim of the studies contained in this thesis was to 
investigate aspects of STS biology to identify new prognostic markers. A large 
archive of STS was established with patient outcomes determined by 
questionnaire. Tissue was subsequently analysed using 
immunohistochemistry and reverse transcriptase-polymerase chain reaction 
to understand the role of two molecules – vascular endothelial growth factor 
(VEGF) and decorin – in influencing tumour behaviour. This study revealed 
that when the tissue stroma surrounding the tumour cells had a strong 
immunostaining intensity for decorin, the risk of tumour-related death was 
significantly reduced. In addition, STS with a high immunostaining for VEGF 
were more than 7 times more likely to recur, and 5 times more likely to cause 
the death of the dog. When the immunostaining characteristics for VEGF and 
decorin were combined with other patient and tumour features into a 
predictive algorithm called a nomogram, it was possible to determine, with 
almost 100% accuracy, which dogs would remain disease-free 3 years after 




subsequently demonstrated by treating dogs with haemangiosarcoma (HSA) 
– a mesenchymal tumour with many characteristics similar to STS – with 
thalidomide. Thalidomide is a potent antagonist of VEGF, but also has a 
number of other modulating influences on the tumour microenvironment. 
Dogs treated with thalidomide survived significantly longer than dogs that 
did not receive this drug, suggesting that thalidomide can slow the ability for 
residual microscopic tumour cells to develop into a grossly visible, and life-
threatening tumour. An analysis of metastatic lesions that developed in dogs 
treated with thalidomide revealed that immunostaining for VEGF was 
significantly reduced. This suggests that thalidomide may be a useful 
adjuvant therapy for dogs with STS that are considered to be at high risk of 
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CHAPTER 1 
Prologue 
1.1 Introduction and Problem Statement 
oft tissue sarcoma (STS) are tumours derived from tissues of 
mesenchymal origin.[1-4] They are remarkably common, 
representing between 9 and 15% of all cutaneous or 
subcutaneous tumours.[3, 5, 6] These neoplasms are therefore 
familiar to most veterinarians.  
Animals with a STS usually present with a subcutaneous mass that can range 
in size from <1cm to more than 10 cm.[3, 6] Because of their size and/or 
anatomical location, STS can provide the clinician with significant challenges 
with respect to surgical management. However, with adequate treatment, 
many dogs with STS can experience prolonged survival with mean survival 
times ranging from 1013 to 1796 days (3-5 years).[7, 8] 
Despite these favourable figures, currently almost one in five patients with a 
STS will die due to the neoplasm. Local recurrence is the most common event 
following surgery with estimates of recurrence rates ranging from 7 to 75% of 
patients.[1, 7-10]. Local tumour recurrence is consistently associated with 
reduced overall survival and tumour-related death; in one study, tumour 
recurrence was associated with a more than 5-fold increased risk of death 
(Hazard Ratio (HR) 5.2; P<0.0001; 95% Confidence interval (CI): 3.1–9.0); 
S 
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other investigators have reported similar findings.[1, 8, 11] There is currently 
insufficient evidence to determine whether adjuvant treatment with 
chemotherapy or radiotherapy can prevent or slow local or distant recurrence 
of a STS following surgery.[6, 12, 13] Development of additional adjuvant 
treatments to help manage STS is required. 
The ultimate goal of cancer surgery is to prevent local recurrence of the 
tumour. To ensure complete removal, standard recommendations for 
surgical margins around a STS have prescribed wide excision of the tumour, 
obtaining 3cm of normal tissue about the entire circumference of the tumour 
and one clean fascial plane deep to the tumour.[2, 3] These recommendations 
were established because an early clinical study on STS demonstrated high 
rates of local recurrence and short disease-free intervals when the tumour 
was removed without planned resection margins.[1] However, some studies 
have suggested that the extent of resection does not influence the disease-free 
interval or overall survival.[7, 14] Interpretation of current evidence suggests 
that no single width of surgical margin will provide effective treatment of 
every STS;[15, 16] it is possible that some tumours could be successfully 
managed with excision margins of just a few millimetres, while others require 
more extensive resections. However, there are currently no diagnostic tests 
that can reliably predict the amount of surgical margin required for an 
individual tumour.  
Surgeons currently rely on analysis of the resected tissue to determine 
whether a surgery has been successful and to establish whether the dog may 
be at risk of recurrence. This analysis includes determination of the tumour 
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grade, mitotic rate and whether the resection margins are clear of tumour 
cells.[5] With STS, higher rates of recurrence are reported with more 
aggressive, high grade tumours and/or when surgical margins about the 
tumour have been inadequate.[2, 5, 7-9, 11] However, many of the existing 
techniques used to analyse the resected tissue have limitations which can 
affect their accuracy.[5] Overall, this inaccuracy means that a STS will recur 
in almost 1 in 10 dogs despite post-operative analysis suggesting it was 
completely resected.[8, 9, 11, 17-22] Conversely, even when histology has 
identified tumour cells at the edge of the resected tissue margin, local 
recurrence does not occur in more than 70% of these dogs. These 
inconsistencies can have an adverse impact on the clinical management of a 
dog with a STS. The development of alternative prognostic markers that 
provide better correlation with actual patient outcomes are required. 
1.2 Research Aim 
The aim of this study is to investigate previously unexamined cell function 
pathways that may be important in determining STS biology using 
immunohistochemistry (IHC) and polymerase chain reaction (PCR) methods. 
By identifying new biomarkers that may be associated with increased or 
decreased rates of tumour recurrence after surgical excision, it is hoped these 
may provide a more accurate prognosis; the biomarkers could then be used to 
provide improved guidance on optimal tumour control. In addition, by 
examining molecular control pathways in STS it may be possible to identify 
opportunities for new adjuvant treatments to improve patient outcomes. 
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1.3 Overview of Thesis Structure 
Chapter 2 reviews the current knowledge and treatment guidelines for canine 
STS, and makes some comparisons with the equivalent human disease. 
Attention is given to the current limitations of determining surgical margins 
and tumour prognosis. A review of evidence that shows how the persistence 
of tumour cells after surgery, which ultimately leads to tumour recurrence, 
could lend support for the identification of relevant biomarkers. 
To support the laboratory analyses required for biomarker discovery, an 
archive of clinical material was required. A retrospective study was 
performed to determine the outcomes for 350 dogs treated with STS in first 
opinion practice. This is the largest study ever performed for this tumour 
type in the dog; the details of which are outlined in Chapter 3.  
In Chapter 4, the results of an immunohistochemistry study to examine the 
role of two possible prognostic markers, vascular endothelial growth factor 
(VEGF) and decorin, are described. These molecules are known to play 
important roles in the tumour microenvironment, with particular influence 
on angiogenesis and tumour cell migration. Chapter 5 details the results of a 
study using reverse-transcriptase polymerase chain reaction that was 
designed to validate and further characterise the expression of VEGF within 
the tumour tissues. 
Combining the discoveries of these proceeding studies, Chapter 6 describes 
the development and validation of a predictive algorithm that could allow a 
clinician to determine the likelihood that a particular STS will recur following 
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surgery. This algorithm uses characteristics of STS biology obtained from 
clinical examination and histologic analysis of the tumour to provide a 
prediction on whether or not a particular tumour is likely to recur after 
surgery. 
In Chapter 7, a prospective clinical study to investigate whether thalidomide 
can prolong the survival time of dogs with haemangiosarcoma (HSA) is 
described. Thalidomide is known to be a potent antagonist of VEGF. 
Haemangiosarcoma is a mesenchymal tumour with some cellular and 
molecular characteristics similar to STS.[23-25] This tumour type was chosen 
as a proxy for STS as it has a rapid disease progression and almost 100% 
incidence of metastatic disease. A similar study using STS would have taken 
several years and required hundreds of cases, due to the slow progression of 
this tumour and relatively low incidence of metastases.  
Finally, in Chapter 8, the VEGF immunostaining in HSA of dogs that received 
thalidomide was compared to the VEGF immunostaining in HSA of dogs that 
did not receive this drug.  
In Chapter 9, overall conclusions about the potential for the biomarkers 
described in this study will be discussed, and how they could be used to 
predict STS biology or to influence treatment decisions. The limitations of the 
research and possible direction of future studies will also be examined. 
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Chapter 2 
Background and a review of the literature  
2.1 Introduction 
oft tissue sarcomas (STS) are a heterogeneous group of 
mesenchymal tumours. Soft tissue sarcomas may arise anywhere 
in the body but develop most commonly on the appendicular 
skeleton. They typically present as a firm, discrete and expansile 
mass. When treated appropriately, the prognosis for the majority of dogs is 
good, provided that complete removal of the tumour has been achieved. 
However, more than 20% of dogs will ultimately die from their STS either 
because they develop a recurrence of their tumour that is not resectable or 
they develop distant metastases.  
Although they are common in dogs, many uncertainties surround the best 
options for clinical management of STS. The first part of this review provides 
an update on the current understanding of the diagnosis and management of 
canine STS. In the second part of this review, an in-depth analysis of the 
issues known to influence the prognosis of canine STS is provided.  
2.2 Soft tissue sarcoma 
Soft tissue sarcoma (STS) are tumours derived from mesenchymal tissues.[1-
4] This derivation means they can arise at virtually any anatomical site. They 
S 
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are common in the dog and represent approximately 15% of all skin and 
subcutaneous neoplasms.[3] Annual incidence rates of STS have been 
estimated to be between 35 and 142 tumours per 100,000 dogs at risk;[5] 
however, this data was derived almost 50 years ago from a veterinary cancer 
register that collated health data from a single county in California, USA. The 
reliability of this broad estimate for dogs living today is therefore difficult to 
determine. A more recent study from the United Kingdom (UK) evaluated the 
incidence of tumours using information from insurance records; this study 
revealed a similar incidence of 122/100,000 (95% CI 103-141) dogs/year.[6] 
In that study, soft tissue sarcoma was one of the most common malignant 
tumours to occur in the dog, second only to mast cell tumours. Again, this is a 
selected sample group as it has been estimated that only about 30% of dogs 
are covered by pet insurance in the UK.[7, 8] It is likely these owners are 
more motivated to seek veterinary investigation for various ailments, 
including palpable masses. 
While STS tend to grow slowly and are considered to have a low metastatic 
potential, local recurrence of the tumour following surgical resection is 
common and has been reported to occur in up to 75% of patients.[9] Local 
recurrence is the most frequent reason for treatment failure in the 
management of STS and is consistently associated with reduced patient 
survival.[1, 3, 5, 10-12] 
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2.3 Nomenclature of soft tissue sarcoma 
Soft tissue sarcoma develop from cells of mesenchymal origin, which includes 
muscle, neurovascular, connective and fatty tissues.[5, 13] Although the 
majority of masses will be subcutaneous or musculoskeletal in location, STS 
can also develop within cavity organs such as the lung, heart, liver, spleen, 
urogenital tract or gastrointestinal system, as well as retroperitoneal and 
mediastinal spaces. 
The term “soft tissue sarcoma” is used to describe a group of mesenchymal 
tumour types that all have similar biological behaviours.[5] The features that 
characterise a STS are outlined in Table 2.1. Despite being a heterogenous 
group of tumours, they have been grouped together because it can be difficult 
to distinguish different subtypes by light microscopy alone.[13] Their 
biological behaviour is also considered fairly similar, so treatment 
recommendations are proposed as if all tumours in the STS group respond 
similarly.  
There are several mesenchymal tumours that arise from soft tissue that are 
not considered to be STS.[13] This is because these tumours can usually be 
reliably identified on light microscopy or because their individual biological 
behaviour has a more defined character.[13] These mesenchymal tumours 
include: haemangiosarcoma, synovial cell sarcoma, gastrointestinal stromal 
tumours (GISTs), fibrosarcoma involving the oral cavity, and peripheral 
nerve sheath tumours that arise from the brachial or lumbosacral plexus. 
Some review papers have included rhabdomyosarcoma, lymphangiosarcoma 
and leiomyosarcoma to be part of the STS group,[3, 5] but most pathologists 
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generally consider these tumour types to be readily identifiable as individual 
tumours.[13] 
Table 2.1:  
Biological features that are common to soft tissue sarcoma (with modification from the 
original description by Withrow and MacEwan)[5] 
 
• an ability to arise from any anatomical site in the body 
• appear as distinct, encapsulated tumours but on microscopic 
evaluation they have poorly defined margins and will infiltrate along 
tissue planes 
• local recurrence is common after conservative excision 
• metastasis occurs through a haematogenous route. Lymph node 
metastasis is uncommon. 
• grossly detectable disease has a poor response to chemotherapy and 
radiation therapy 
 
The tumours that are typically included in the STS group arise from fibrous 
connective tissues, nervous tissues, adipose tissues, smooth muscle, skeletal 
muscle, and synovial tissues. They include fibrosarcoma, peripheral nerve 
sheath tumours (previously called neurofibrosarcoma or schwannoma), 
perivascular wall tumours (previously called haemangiopericytoma), 
liposarcoma, malignant fibrous histiocytoma, mesenchymoma, 
myxosarcoma, and undifferentiated sarcoma.[5, 9, 14] The term “spindle cell 
tumour” may also be used by some pathologists when a more precise identity 
of the STS subtype is not possible.[14] A summary of each of these tumour 
subtypes is detailed in Table 2.2. 
 
Table 2.2: 
Types of STS, as defined by their cell of origin and histological features that may be seen on light microscopy (modified from Dennis et al)[13] 
Histological name Previous names Cell of origin Histological features 
Fibrosarcoma  Fibrous tissue Interwoven bundles, herringbone pattern 
Pleiomorphic sarcoma Malignant fibrous histiocytoma Fibrous tissue 
Mix of fibroblastic and histiocytoid cells in storiform patterns, 
with a variable inflammatory infiltrate 
Myxosarcoma  Fibrous tissue Spindle-cells within a mucinous stroma 







Interwoven bundles, whorls 
Perivascular wall tumours  Haemangiopericytoma Pericyte Vascular growth pattern, perivascular whirling 
Mesenchymoma  Multiple cell types Multiple mesenchymal cell types, including osteoid, chondroid or collagenous matrix 
Liposarcoma  Lipoblast Polygonal cells with vacuolated cytoplasm 
Rhabdomyosarcoma  Skeletal myocyte Cytoplasmic striation, racket and strap cells 
Lymphangiosarcoma  Lymph tissue 
Irregular, anastomosing and arborising vascular channels lined 
by single layer of flattened spindle-shaped cells with scant 
cytoplasm; lumina have a paucity of erythrocytes 
Leiomyosarcoma  Smooth muscle Long, thin mesenchymal cells arranged in aggregates or linear bundles; nuclei elongated or cigar-shaped. 
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2.4 Causes of soft tissue sarcoma development 
There are sporadic cases reported in which dogs have developed a STS in 
association with known previous injuries, parasitic infections (e.g. Spirocera 
lupi), implants and trauma.[15-18] However, for the vast majority of canine 
STS, the cause of tumour development is unknown.  
In humans, analysis of the molecular genetics of STS has divided sarcomas 
into two main categories: (i) sarcomas with defined genetic alterations 
including specific chromosomal translocations and oncogenic mutations; and 
(ii) sarcomas with a "complex genomic profile" which may involve dozens of 
molecular abnormalities.[19, 20] The majority of STS seem to have the latter 
characteristic which suggests there is no common mutational pathway for 
development. This suggests tumour initiation and progression may be a 
random event, possibly exacerbated by the increased mutagenesis that can 
accompany localised areas of chronic inflammation.[21, 22] 
2.5 Clinical features of a soft tissue sarcoma 
There is no apparent breed disposition for STS, but middle-to-large breed 
dogs tend to be more commonly affected.[2-5] There is a variable ratio of 
males and females affected in different reported populations but overall, the 
sex or neuter status of the dog appears to have little, if any, influence on 
disease development or progression. Affected dogs tend to be middle-aged or 
older, with the median age at diagnosis reported to be between 10-11 years 
(range, 2 - 16 years).[3, 5, 13, 23, 24] 
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Soft tissue sarcoma are usually firm, plump masses that have expanded 
under the overlying skin (Figure 2.1). Tumours are most commonly located 
on the limbs, a location that may represent up to 60% of cases.[3, 5, 10] The 
trunk (including the tail) is involved in about 35% of cases and the head in 
5% of cases. They are not usually painful or associated with any notable 
discomfort for the patient. On palpation, the STS may appear to be firmly 
adherent to the underlying tissues, but in other cases the tumour can feel 
quite mobile and on palpation may wobble within the subcutaneous tissue. 
Clinical signs associated with the mass may be influenced by location. In 
most cases, there are no clinical signs evident apart from the palpable mass. 
However, if a large mass is deeply located within the muscles or is closely 
associated with a joint, it may interfere with musculoskeletal function. In 
these cases, a mechanical lameness may be the only presenting sign with the 
mass itself occult to palpation. 
2.6 Diagnosis 
The initial diagnostic investigation of a cutaneous or subcutaneous STS is 
usually by cytological evaluation of samples obtained by fine needle 
aspiration.[3, 5] Care is required with sample collection and interpretation 
because mesenchymal cells do not exfoliate readily during fine needle 
aspiration. In addition, the neoplastic cells of a STS can appear similar on 
cytology to reactive mesenchymal cells that could be present within an 
inflammatory lesion;[25] this similarity can lead to both false-positive and  
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Figure 2.1: 
Soft tissue sarcoma are a heterogenous group of tumours with a variety of clinical 
presentations. The physical characteristics of the tumour including size, mobility and location 
can impact on treatment strategies and prognosis. 
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false-negative results on cytology so interpretation needs to be performed in 
conjunction with the physical characteristics of the mass.[26] When 
compared to the final histologic diagnosis, cytology correctly identified a 
mass to be a mesenchymal tumour in 97% (67 of 69) cases, but a diagnosis of 
STS was accurate in only 67% (45 of 69) cases.[26] 
To achieve a more confident diagnosis that a palpable mass is a STS, 
incisional biopsies can be taken with a scalpel, biopsy punches, needle core 
biopsy instruments, or trephines.[27-29] Biopsies can be obtained under 
local anaesthetic, sedation or general anaesthesia depending on the 
temperament of the patient or the location of the tumour.[29] When only 
small sections of the tumour are obtained, multiple samples should be 
obtained from different locations to improve the diagnostic yield. The biopsy 
tract should be located where it can be removed at the time of definitive 
surgery, and care should be taken not to breach the lateral or deep 
boundaries of the tumour as this could allow the tumour to invade beyond its 
original location.[28] As well as giving more descriptive microscopic 
information about the mass, an advantage of an incisional biopsy is it can be 
used to determine the grade of the tumour. The tumour grade can, in turn, be 
used to infer some clues about the likely aggressiveness of the tumour.  
2.7 Tumour grades in soft tissue sarcoma 
A tumour grade – ranging from low (grade 1), intermediate (grade 2), or high 
(grade 3) – can be assigned to a STS based on various histological criteria, as 
outlined in Table 2.3. The histological grade of a STS is currently one of the 
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most validated criteria to predict outcome following surgery in canine 
patients.[9, 11] Higher tumour grades are associated with a more aggressive 
biologic behavior, which translates to increased rates of local recurrence, 
distant metastasis and shorter disease-free intervals.[9, 11, 13] 
Low grade (grade 1) tumours are the predominant form in veterinary 
medicine, but published incidences may be influenced by the source of 
affected patients. In studies reporting on tumours sourced from first opinion 
practices, low-grade tumours predominate (51-84%) and high-grade tumours 
tend to be uncommon (7%).[9] However, in studies derived from referral 
practices, high-grade tumours are more commonly represented with 
proportions from 22.7 to 29% reported.[11, 12] 
Given the importance of tumour grade in determining subsequent behaviour 
of the tumour, it would seem sensible to try and determine the grade of the 
STS prior to performing surgery. Unfortunately, the accuracy of pre-
treatment biopsies at determining grade is currently limited. In one study, 
29% of pre-treatment biopsies under-estimated and 12% over-estimated the 
final histological grade assigned to the tumour after resection.[30] This study 
concluded that while pre-treatment biopsies are relatively accurate at 
distinguishing high from low-grade sarcoma, a pre-treatment result of ‘low-
grade’ should be viewed with caution. This lack of accuracy of pre-operative 
analysis of the tumour is frustrating as one of the prime reasons for 
performing pre-operative interrogation of the STS would be to identify the 
low-grade subset that are known to be less aggressive in their behaviour. 
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However, if the biopsy actually under-estimates the grade of the tumour in 
almost a third of cases, performing a more conservative treatment may be 
inappropriate if the tumour is subsequently determined to be higher grade as 
this would increase the risk of treatment failure. This inconsistency needs to 
be resolved to allow pre-operative interrogation of a tumour to be more 
accurate and more commonplace. 
2.8 Staging of soft tissue sarcoma 
A staging system has been described for STS in dogs, and takes into account 
the size of the tumour, the involvement of local lymph nodes, and the 
presence of metastasis.[31] This staging system was modified from the 
system reported for human STS, developed by the American Joint Committee 
on Cancer. Modifications to the canine STS staging system have been 
published,[5] with inclusion of whether the tumour is located superficially or 
deep within the tissues due to similar modifications to the staging system for 
human STS. However, neither the original nor the updated versions of the 
canine staging system have ever been correlated with patient prognosis in 
clinical trials.  
Soft tissue sarcoma are thought to metastasise by a haematogenous route so 
secondary tumours are most likely to develop in the lungs; metastasis to the 
regional lymph nodes is rare.[11] Based on general oncologic principles, 
three- or four-view thoracic radiographs (or computed tomography (CT)) 
should be considered prior to surgery to check for pulmonary metastasis.[3]  
Chapter 2: Background – page 20 
Table 2.3: 
Grading System for Cutaneous and Subcutaneous Soft Tissue Sarcoma in the 
Dog (from Dennis et al.)[13] 
Differentiation Score 
 
Sarcomas most closely resembling normal adult 
mesenchymal tissue, by type (e.g. well-differentiated 
perivascular wall or peripheral nerve sheath tumours, well-
differentiated fibrosarcomas or well-differentiated 
liposarcomas)  
1 
Sarcomas for which histologic type can be determined, 
although differentiation is poor (e.g. poorly  differentiated 
liposarcoma, fibrosarcoma, poorly differentiated perivascular 
wall tumour or peripheral nerve sheath tumour)  
2 
Undifferentiated sarcomas, sarcomas of unknown type  3 
Mitotic index  Score 
 
0–9 mitoses per 10 high-power fields (400x) 1 
10–19 mitoses per 10 high-power fields (400x) 2 
>19 mitoses per 10 high-power fields (400x) 3 
Tumour necrosis Score 
 
No necrosis  0 
<50% necrosis  1 
³50% necrosis  2 
Histologic grade: (total score is a combination of scores for differentiation, mitotic, 
and tumour necrosis) 
 
Grade I = £3 
Grade II = 4–5 
Grade III = ³6 
 
Abdominal ultrasound may also be considered to allow detection of 
metastasis to the liver, kidney or other parenchymous organs. In reality, the 
incidence of detectable metastasis at the time of surgery for STS is low. In 
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one study that examined either 3-view inflated thoracic radiographs collected 
under general anaesthesia or thoracic CT scan, metastatic lesions were found 
in about 10% (16 of 131) of dogs with STS at the time of presentation for 
surgery; this included 5 dogs with grade 1 STS, 2 dogs with grade 2 STS and 9 
dogs with grade 3 STS.[32] The presence of metastasis increased with the 
known duration of the mass; for STS that had been present for >3 months, 
the risk of metastatic disease increased by a factor of three.[32] 
While STS are generally considered to have a low to moderate rate of 
metastasis developing in the months and years following removal of the 
primary mass, this is not well documented. Different authors have described 
metastatic rates ranging from 1.7 – 41%,[1, 11, 12, 33, 34] but this data is 
derived from retrospective studies so will be influenced by the scrutiny of 
investigation. Further analysis of the importance of staging in the prognosis 
of canine STS is detailed in a later section of this chapter. 
2.9 Treatment of soft tissue sarcoma 
Surgery is considered the most important therapy for the management of 
canine STS. Radiotherapy (RT) and chemotherapy can also play a role in the 
control of secondary metastasis and local recurrence; however, these 
modalities tend to be relatively ineffective in the treatment of a grossly visible 
tumour. Current advice using each of these modalities is outlined in further 
detail in the following sections. 
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2.9.1 Surgery 
Surgical strategies for STS are defined by the extent of resection about the 
gross boundaries of the tumour. These are based on the surgical margins that 
were described for the management of musculoskeletal tumours in 
humans.[35] 
The types of resection that have described for canine STS include:[5, 13, 23] 
• Intra-tumoural: when the capsule surrounding the tumour is 
penetrated and the gross tumour removed, often in a piecemeal 
fashion 
• Marginal: when the tumour is excised at the level of the 
pseudocapsule, or when the mass is ‘shelled-out’ from the surrounding 
tissues 
• Wide: when the tumour is excised with a cushion of normal tissue 
about all boundaries. The width of this tissue cushion may be 
anywhere from 1-50mm, or more. Some papers have also described a 
subclassification of Narrow when the width of tissue removed about 
the mass is small; in this instance the width of the tissue cushion is ill-
defined, but may be about 3-5mm 
• Radical: when an entire anatomic segment is removed e.g. 
amputation 
For wide and narrow resections, an en bloc surgical technique is performed. 
The resection margin is defined as the amount of skin and tissue removed by 
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the surgeon around the entire circumference of the tumour. An en bloc 
resection is performed by measuring the desired resection margin about the 
gross perimeter of the tumour with a ruler. Incision of the skin and 
subsequent dissection of the underlying tissues is then performed, with care 
taken to maintain this defined resection margin about the entire 
circumference of the tumour. The resection extends perpendicularly through 
the skin, subcutaneous tissues, and muscles until an appropriate deep margin 
is identified and penetrated. Muscles, non-vital nerves and blood vessels that 
branch into the resection field are cut about this measured lateral border of 
the surgical margin effectively isolating a ‘block’ of tissue ready to be elevated 
from the wound. 
Incision through a tissue boundary deep to the STS allows the tumour to be 
removed from the body in one contained piece. Identifying a defined deep 
boundary is an important aspect of the surgery. It is not normally possible to 
take a measured quantity of tissue from the deep boundary that is similar to 
that obtained from the lateral boundaries without encountering vital 
components of the skeleton or other internal organs. For this reason, the 
surgeon will make use of tissue barriers that are considered resistant to 
tumour invasion. Such tissue barriers include muscle, fascia, joint capsule, 
cartilage, or bone.[35] The importance of these tissue barriers is based on the 
recognition that during growth, STS tend to preferentially expand within the 
tissues along a path of least resistance. Cellular invasion will be constrained 
by these tougher tissue boundaries.[36] Some STS are capable of invading 
beyond these barriers, but the invasive path is usually via perforating 
vascular channels or surgically created openings, such as a biopsy tract. 
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Invasion through a tissue barrier may not occur until late in the disease 
course when the internal pressures of the expanding mass start to exceed the 
resistive pressures of the tissue barrier.[36] 
When considering resection margins in STS, it is important to recognise the 
importance of not only the width of the surgical margin relative to the 
pseudocapsule and surrounding reactive zone, but also the quality of any 
defined anatomical barriers around the tumour. The width of the surgical 
margin obtained about a STS has long been considered a factor important for 
effective control of the tumour. One of the first studies to publish the 
outcome of dogs treated for STS revealed overall rates of local recurrence of 
44% and median survival times (MST) of less than 2 years.[1] In the same 
study, STS with a mitotic index (MI) of 9 or more did poorly with local 
recurrence rates exceeding 60% and MST of less than 1 year. These authors 
concluded that radical surgery, including limb amputation, was justified 
given these poor rates of local control. A subsequent study used en bloc 
surgical margins incorporating a minimum of 3 cm of normal tissue laterally 
and one clean fascial plane deep to the tumour;[11] these margins were 
similar to those described for the surgical management of human STS at the 
time.[37] This study achieved recurrence rates of less than 15% and MST of 
1416 days – almost twice that of the original study. This paper was from a 
highly respected institution that had a pioneering influence on the emerging 
discipline of veterinary oncology so the resection margins utilised in this 
paper soon became the accepted standard for the management of all STS.[2, 
3, 5, 11] 
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Despite the favourable results reported after wide excision of STS, obtaining 
these excision margins may not always be an option in every case. Lateral 
margins of 3cm about the gross boundaries of the mass may be achievable 
when the tumour has arisen on parts of the body (e.g. the trunk) where 
adequate skin redundancy is available for wound closure or reconstruction. 
However, more than 50% of STS arise on the appendicular skeleton.[11, 24, 
38] Wide resections of tumours on the limb increase the risk that vital 
nerves, vascular structures, significant muscles or tendinous structures 
become involved in the resection, which may result in unnecessary morbidity 
or dysfunction. Other patient comorbidities or the financial constraints of the 
client may also prevent extensive surgery being performed. Several authors 
have challenged the requirement for wide surgical excision margins,[10, 24, 
39] with some studies suggesting the extent of resection performed did not 
influence the disease-free interval or overall survival.[9, 23, 24] This debate 
remains unresolved. In the second part of this Chapter, some of the issues 
and controversies that surround the role of surgical margins in the 
management of canine STS will be discussed in more detail.  
Different qualities of tissue are also believed to resist STS invasion to a 
variable extent, causing some surgeons to characterise different tissue layers 
as providing either a 'thick' or a 'thin' barrier.[40] A thick barrier is defined 
as a physically strong membranous tissue such as bone, joint capsule or 
structural fascia (e.g. the fascia lata or lumbar fascia), while a thin barrier is 
typified by weaker membranous tissue such as muscle, connective fascia, 
periosteum in adults, epineurium, etc. In an effort to standardise the surgical 
management of human STS, 'normal tissue equivalents' were assigned to 
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different tissue barriers: thus, a thick barrier was considered equivalent to 
3cm of normal tissue and a thin barrier was converted to 2cm of normal 
tissue.[40] Joint cartilage was considered to be the equivalent of 5cm of 
normal tissue. During removal of a STS, a surgeon working to these 
guidelines would attempt to remove the mass with a total of 5cm of tissue 
equivalents which would represent a combination of normal tissues, as well 
as thin and thick barriers. Because tissue barriers can be considered to help 
constrain invasion by the STS, there can be occasions where removal of an 
entire anatomical compartment is preferable to a measured en bloc resection 
margin. For example, a STS will occasionally arise within an individual 
muscle or muscle group. In those cases, removal of the whole “compartment” 
of tissue  - which may include a single muscle or group of muscles that 
surround the STS, removed from origin to insertion - may provide a superior 
outcome even if the actual measured quantity of tissue bounding the tissue is 
less than the 3 to 5 cm generally recommended.[36, 41] 
2.9.2 Radiotherapy 
Radiotherapy uses high-energy x-rays to disrupt cellular DNA, which 
ultimately causes apoptosis of the affected cell. Because cancer cells tend to 
have poor DNA repair mechanisms, RT has become an important modality 
for the treatment of many different types of cancer. For the management of 
cancer, RT may either be used in place of surgery or may be combined with 
surgery to allow resection margins to be reduced without compromising 
overall treatment success. In human STS management, RT is now considered 
an integral component of effective local therapy for STS, and has enabled a 
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reduction in resection margins without compromising local control rates.[42] 
Radiotherapy may be employed either before (neoadjuvant) or after 
(adjuvant) surgery. While there is no proven difference in disease outcome 
according to treatment sequence,[43-45] the negative impact of neoadjuvant 
radiation on wound healing can influence the decision on a case-by-case 
basis.[45] 
In veterinary patients, outcomes from curative-intent adjuvant RT after 
incomplete STS resection have been reported. Using hyperfractionated 
protocols of either 42 to 57 Gray (Gy) at between 3 - 4.2 Gy daily [46], or 63 
Gy delivered in 3 Gy fractions on alternate days,[47] overall MSTs of 1,082 - 
2,270 days and local recurrence rates of 16 - 31% have been described. The 
study with a higher rate of local recurrence included 8 of 37 (22%) dogs with 
oral mesenchymal tumours which will negatively bias these results as oral 
fibrosarcoma are not considered to be STS and are known to have high rates 
of local recurrence.[46] A more recent study reported on the use of 
hypofractionated RT after planned marginal resection of STS in dogs.[34] 
The treatment protocol used in this study consisted of four weekly doses of 
RT (6-9 Gy per dose) to a total treatment dose of 24-36Gy.[34] In that study, 
local recurrences developed in 18% of dogs, with metastatic disease occurring 
in 9%. Follow-up periods were 426-2035 days (median 1339 days). Although 
these studies suggest that using RT to treat surgical wounds where 
microscopic STS is known to persist can provide adequate local control in 
most cases, the actual efficacy of RT is difficult to assess from these papers. 
No control group was included in any of the studies, with outcomes 
compared to historical controls only. The premise for giving RT treatment 
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when microscopic tumour cells are detected at the resection margins is to try 
and prevent the inevitable regrowth of the tumour; however, as will be 
discussed in later section of this chapter, this inevitability is by no means 
assured and local recurrence may develop in less than 30% of dogs with 
incomplete margins.[9, 11] The potential for recurrence will also be affected 
by the grade of the tumour, with low grade tumours less likely to recur even 
when resection margins are incomplete.[9] Existing studies using adjuvant 
RT report recurrence rates of between 16 and 31%. In two of these studies, 
cases were derived after surgery was performed in first opinion practice, so 
there would have been a bias for more low-grade tumours to be 
represented.[46, 47] It is entirely possible that current RT protocols reduce 
the risk of recurrence by only a few percentage points. Further veterinary 
studies are required to enable better understanding of which patients are 
most likely to benefit from RT, with prospective and randomised trials 
performed to allow the true benefit of different RT protocols to be 
determined. 
2.9.3 Chemotherapy 
The value of chemotherapy in veterinary patients remains unclear and robust 
evidence is limited.[5] Only one study has been published evaluating the 
effect of adjuvant doxorubicin (30mg/m2) in high-grade STS; rates of local 
recurrence, metastasis and overall survival were similar to those observed in 
a historical population.[48] However, this paper described the outcomes for 
only 39 dogs that were managed almost 20 years ago. No control population 
was included, with outcomes compared to a historical population that had 
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been treated with surgery only more than 10 years previously. Both 
populations were analysed retrospectively, and the thoroughness of 
evaluation of each patient during the study period is uncertain. Other 
publications have described outcomes for dogs with STS using other 
chemotherapy drugs such as mitoxantrone or ifosfamide;[49, 50] these 
papers reported outcomes for a broad range of tumour types with a mixture 
of inclusion criteria and no control populations, so it is difficult to draw 
conclusions on their true efficacy in the prevention of local recurrence or 
metastasis in dogs with STS. 
In humans with STS, where development of metastatic disease remains the 
most significant cause of tumour-related death, the role of adjuvant 
chemotherapy (typically doxorubicin based) is also controversial. Results 
from two large meta-analyses have shown either no response,[51] or at best a 
small but significant benefit for local recurrence (Odds ratio (OR) 0.73; 95% 
CI, 0.56-0.94; P = 0.02), distant recurrence (OR 0.67; 95% CI, 0.56-0.82; P = 
0.0001), and overall survival (OR 0.67; 95% CI, 0.56-0.82; P= 0.0001).[52] 
Currently, adjuvant systemic chemotherapy is not given routinely for every 
human patient with a STS but may be incorporated into the treatment plans 
for high-grade tumours or for specific histologic types.[53] 
Because local recurrence of a STS, as opposed to metastatic disease, is 
considered the most common cause of tumour-related death in dogs, the use 
of different forms of chemotherapy to try and slow or prevent local 
recurrence after surgery has been investigated. In this context, low-dose 
continuous chemotherapy – or metronomic chemotherapy (MC) – has 
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received interest.[54, 55] Rather than being directly cytotoxic, MC is thought 
to inhibit tumour growth via a combination of anti-angiogenic and 
immunomodulatory effects.[56] One study compared 30 dogs treated with 
MC with 55 historical controls. This paper suggested that the use of MC led to 
significantly improved disease free intervals (p<0.0001).[54] However, 
selection bias in the control population may have skewed the conclusions of 
this study. In this study, the treated population included 30 dogs that were 
started on MC when histologic assessment had confirmed an incomplete 
resection margin. Although not explicitly stated, the outcomes of this 
treatment group was compared to a control population of 55 dogs where 
gross recurrence of the STS had occurred following surgery; these 55 dogs 
were derived from a total population of 1311 dogs treated for STS, 
representing a 6% overall recurrence rate. The recurrence rate in the treated 
population is not stated; from a visual interpretation of the Kaplan Meier 
curve it is estimated to be 4 of 30 dogs (13%). Because the end-point of this 
study was disease-free interval rather than the incidence of recurrence, the 
impact of this apparent selection bias is hard to predict; the presented data 
would suggest that treatment with metronomic chemotherapy significantly 
slows the development of local recurrence.[54] However, given the large 
discrepancy in population size between the treated and control groups where 
recurrence occurred, it is likely the observed difference in disease-free 
interval may be spurious. Further investigation is required to determine 
whether metronomic chemotherapy is effective in preventing or slowing the 
development of local recurrence in STS. 
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2.10 Prognosis 
The prognosis for the majority of dogs with STS is generally good if a 
complete resection can be achieved.[9, 11, 13] However, local recurrence can 
develop in up to 75% of dogs.[1, 10-12, 23, 24, 38, 39, 48] Rates of metastasis 
are less well-defined but may develop in between 1.7% and 41% of cases.[10, 
11, 13] Overall, about 20 to 30% of dogs will ultimately die of their disease.[9, 
11, 12, 24, 39, 48, 57, 58] Continued efforts to improve management options 
and to recognise those dogs at risk of recurrence and death remains 
important.  
In reality, the owner of a dog with a STS doesn’t want to hear that the 
prognosis for their dog is “generally good”, or that there is a 20-30% chance 
that their dog will die from the tumour despite treatment. They want to 
understand what the prognosis is for their own individual dog, and whether 
treatment will be successful in ensuring the tumour does not come back. The 
answers to these more specific questions are harder for a clinician to answer. 
Cancer is a heterogenous disease, and one individual tumour will not present 
with the same characteristics as another. Variations in tumour size, location 
and other patient factors will impact on the ability of a surgeon to remove the 
mass with an appropriate cushion of healthy tissue. The generalised 
prognostic figures quoted above are also derived from retrospective analyses 
of clinical cases performed at different institutions, with different surgeons 
working under different conditions in different geographic locations around 
the world. These differences introduce bias and limitations into the case 
selection and application of surgical strategies that may impact on the 
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characteristics of the tumour population being operated on, and the 
consistency of clinical management between different studies. Being 
retrospective in nature, determination of patient outcomes and the rates of 
local recurrence, metastasis and survival have the potential to be imprecise as 
relevant data may not have been collected in the first instance, or is reliant on 
recall or secondary knowledge. Finally, almost all of the studies have involved 
sample sizes of less than 100 animals, which restricts the statistical power 
necessary to correctly identify clinical features that may be influential in 
outcome.  
In light of these limitations in the existing literature, it is understandable that 
controversy exists into whether certain characteristics of a STS may influence 
the outcome of patients more than others, or whether particular treatment 
strategies are more effective than others. In the next section of this chapter, 
the evidence for some of the prognostic factors that may influence the 
outcome of STS in the dog will be examined. Comparative evidence from 
human STS will also be explored: this is because a similar debate on the 
factors that influence the management of STS has occurred in the human 
literature,[36, 59-61] and many of the treatment challenges posed by this 
tumour in humans are comparable to those that confront the veterinary 
surgeon. The individual prognostic factors that will be examined in the 
following section include: the histological type; histological grade and other 
known markers of proliferation; tumour size, location and palpable 
characteristics; the presence of metastasis; and finally the importance of 
surgical margins, including how resection margins are evaluated and the 
evidence to support what an appropriate width of resection margin is 
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required. To conclude, the importance of STS structure and how the tumour 
microenvironment may influence whether an individual STS may recur after 
surgery will be reviewed. 
2.10.1 Histologic type 
As discussed previously, all subtypes of STS have traditionally been 
considered as a single group for prognostic purposes largely because 
differentiating individual tumour types by light microscopy can be 
unreliable.[13] However, in human STS, there is increasing evidence that 
individual subtypes may exhibit differences in local invasiveness, metastatic 
potential and recurrence.[62, 63] In current studies on canine STS, any 
evidence for differences in outcome between various histologic subtypes is 
limited by small population sizes or a lack of rigour in histological 
diagnosis.[13] There is a need to develop better tests that allow individual 
subtypes with variances in clinical behaviour to be identified with more 
confidence. This may require the increased use of immunohistochemical 
markers, or even molecular profiling.[13] 
2.10.2 Histologic grade 
Histological grade is considered the most important prognostic factor in 
human STS,[64-66] and is also one of the most validated criteria to predict 
outcome following surgery in canine patients.[9, 11] In one study, the 
histologic grade of a STS was found to be a strong predictor of local 
recurrence after surgery with recurrence rates for low, intermediate and 
high-grade tumours varying from 7, 34 and 75 percent respectively.[9] The 
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findings of this paper are important, as it demonstrates a correlation between 
tumour grade and different rates of local recurrence for a cohort of STS that 
had all been resected with narrow margins. As discussed previously, current 
surgical advice for STS was derived from evidence generated from cases 
treated in referral or academic practice.[11] However, cases managed in 
referral practice are a selected population; they have been referred for 
treatment at a specialist centre either because their STS was showing a more 
aggressive clinical appearance (e.g. large size, recent rapid growth, or a fixed 
and immobile characteristic) or were located in locations that made surgery 
more challenging. Because of this selection bias, interpreting the prognosis 
for patients in response to certain treatments needs to take into the account 
the population pool from which the treatment cohort was derived. Outcomes 
are likely to be better in those studies with a higher proportion of low-grade 
tumours,[9, 23, 24] compared to studies with more high-grade tumours.[1, 
10-12, 38] It follows that treatment advice may need to be stratified according 
to the grade of the tumour. 
It is also well-recognised that the grading of tumours is subjective and 
variation in interpretation between different pathologists has been reported 
for STS and other tumour types.[67, 68] In one study on canine STS, the 
assigned grade or diagnosis of a mesenchymal tumour was modified in 5 out 
of 15 cases (33%) following review of the slides by a second pathologist.[68] 
In two of these cases, this revision led to an increase in grade (from grade 2 to 
grade 3), while in another two cases, the interpretation changed from a 
malignant mesenchymal tumour to a benign disease. In the final case, the 
diagnosis was modified from an oral sarcoma to a melanoma. These changes 
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have the potential to alter the potential prognosis for these patients. When 
the original histologic assessment under-estimated the aggression or 
metastatic potential of the tumour, these dogs may have been denied 
consideration for adjuvant therapy that could have prevented or slowed 
tumour recurrence. For the dogs diagnosed with a malignant neoplasm when 
their tumour was actually benign, their outcome would obviously be better 
than expected. However, these dogs may have been subjected to treatments 
in excess of that needed for their underlying disease. The impact of this high 
error rate for an important prognostic indicator like tumour grade has 
implications not only on the management for an individual dog, but also on 
the ability to interpret the treatment recommendations from existing 
literature. Development of more objective predictive markers that correlate 
reliably with tumour behaviour would be important to help support clinical 
decision making.  
2.10.3 Mitotic index and other proliferative markers 
As a measure of proliferative activity within the tumour, the MI can provide 
additional prognostic information about an individual tumour.[13] An MI of 
more than 9 mitotic figures per 10 high power fields (hpf) has been 
associated with increased (and earlier) rates of tumour recurrence, higher 
rates of metastasis and reduced overall survival in several studies.[1, 9, 11, 13, 
69] With an MI ≥9, MST range from 150 – 343 days, compared to 826 – 1138 
days with an MI <9.[1, 70] 
The histologic determination of MI is actually a single ‘snap-shot’ of the 
proliferative activity of cells frozen in time at the time of tumour fixation. The 
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use of various proliferative markers, such as Argyrophilic Nucleolar 
Organizer Region (AgNOR) and the Ki-67 protein, can provide additional 
information about the mitotic activity of a tumour as they detect chemical 
signals that may persist within the cell across the whole mitotic cycle.[69] In 
canine STS, increased AgNOR and Ki-67 scores have both been associated 
with reduced survival time and correlated with tumour grade and MI.[69] 
However, the use of these markers has not been routinely adopted in the 
evaluation of canine STS. 
2.10.4 Tumour size and growth rate 
Several canine and human studies have suggested that tumours larger than 
5cm (golf-ball sized) have shorter disease-free intervals or survival times.[11, 
64, 65, 71-74] However, other authors have not found any association 
between tumour size and outcome.[1, 24, 57] A STS with a history of sudden 
or rapid growth, or the presence of tumour necrosis and ulceration, has also 
been suggested to imply a more aggressive growth characteristic,[5] but this 
has not been validated in clinical trials. There may be confounders between 
tumour size and other prognostic factors that may influence outcome. Larger 
tumours may be more difficult to remove and may be more likely to impinge 
upon vital anatomical structures, which thus limits the ability to maintain an 
appropriate resection margin about the entire tumour. Soft tissue sarcoma 
resected in first opinion practice also tend to be smaller than those managed 
in referral practice,[11, 24] so the source of the tumour population also needs 
to be considered. 
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2.10.5 Palpable characteristics of the tumour 
Most STS are readily palpable and may appear to be quite discrete and 
encapsulated. Other tumours may be multi-lobulated, soft and have very 
indistinct borders. Although the superficial aspects of the mass may appear 
quite mobile, the base can be indistinct and potentially attached to 
underlying bone or fascia.[5] This difference in mobility between different 
tumours may be significant in terms of prognosis; tumours that feel more 
‘fixed’ to underlying tissues have significantly decreased disease free intervals 
(P<0.0001) and survival times (P=0.007).[24] It is hypothesised that more 
adherent tumours may have a different tumour microenvironment that 
causes them to be more infiltrative or enables greater migration of tumour 
cells into the periphery.[75] However, interpretation of tumour mobility is a 
highly subjective feature and the prognostic significance of this finding has 
been inconsistently reported by other authors.[13] This clinical finding needs 
to be validated in a prospective setting to see if it can help consistently 
predict prognosis. 
2.10.6 Presence of metastases 
The metastatic rate for dogs with soft tissue sarcoma has been reported to be 
between 1.7 and 41%.[10, 11, 13] The published metastatic rate for grade 1 and 
2 tumours is usually low, with most studies reporting incidences of less than 
15%.[11, 38, 47, 76] For high grade tumours, the quoted figure is consistently 
higher and may be as much as 44%.[11, 48, 69] Other authors have reported 
intermediate levels of metastasis for grade 2 tumours, with rates between 
27% and 33%.[69, 70] Metastasis is five times more likely when tumours 
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have a mitotic rate of 20 or more.[11] Other factors that have been associated 
with an increased risk of metastatic disease include the percentage of tumour 
necrosis and local tumour recurrence,[5] although this latter characteristic is 
inconsistently reported. The accuracy of all of the data relating to STS 
metastasis is uncertain. Determination of metastasis is largely reported from 
retrospective studies, so there will be considerable bias and variation in the 
intensity of investigation for the presence of metastatic disease. Metastasis 
may not develop until many weeks or months after surgery so the period of 
follow-up of patients since surgery will affect the reported incidence; in one 
study, the median interval from surgery to detection of a metastatic lesion 
was 365 days.[33] In many studies, no histological confirmation of metastatic 
disease was performed, and a diagnosis of metastasis was reliant on imaging 
findings only.[13] This raises the possibility that a newly discovered 
metastatic lesion may not necessarily be due to the previously resected STS; 
the majority of dogs with STS are elderly, so it is possible that some of these 
dogs could develop a new primary malignancy that may be occult to 
examination. 
2.10.7 Resection margins 
Wide resection of STS has long been considered an important requirement if 
adequate local control is to be achieved. In the first veterinary paper to 
describe outcomes for dogs STS, local recurrence developed in 25 of 103 
(34%) of patients with MSTs of less than 2 years.[1] This paper does not 
specifically state what resection margins were used about the tumour, other 
than stating the “the mass was resected with as much surrounding normal 
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tissue as permitted by the site”. This paper was published at a time when 
veterinary oncologic surgery in the UK was in its infancy, so it would seem 
unlikely that extensive resection margins of more than 1cm will have been 
attempted at that time. The next paper on STS was not published until 17 
years later and came from a respected oncologic centre in the USA. By that 
time, the importance of oncologic principles were becoming realised, using 
comparative evidence from human oncology.[77] In this paper, the STS were 
managed with wide resection margins that included 3cm lateral to the 
tumour and a deep fascial plane; these margins were based on the resection 
margins being described for human musculoskeletal tumours.[35, 36] Local 
recurrence was observed in 11 of 75 (15%) dogs,[11] with a median survival 
was almost 4 years. Subsequent studies where wide resection margins were 
used appeared to validate this finding, with local recurrence rates of 0 of 19 
(0%),[76] 4 of 54 (7.5%),[38] and 10 of 50 (20%)[78] dogs. Some studies 
showed that wide surgical margins were more likely to achieve complete 
tumour removal than marginal or narrow resection,[10, 38] or that 
recurrence was more common with a narrow or marginal excision.[24] 
However, statistically significant correlations between resection margins and 
local recurrence have not been determined.[24, 38] Radical excision has not 
been shown to improve survival times when compared to patients with other 
resection margins.[11] 
More recently, there have been several studies that have challenged the 
necessity of wide resection margins to minimise the chances of STS 
recurrence. Local recurrence rates of just 10.8% (follow-up 210-2202 days) 
were reported in 35 dogs with low-grade spindle cell tumours of the 
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extremities treated by marginal excision only.[23] In another prospective 
clinical study, 100% local disease control and 93% one-year disease free 
interval was achieved in 14 dogs with 1cm lateral resection margins and a 
single fascial plane beneath the tumour.[10] However, in that paper, patient 
follow-up times were only 12 months, which is inadequate for soft tissue 
sarcoma. In another paper examining outcomes for dogs with STS treated 
exclusively in first opinion practice, local recurrence rates of 20.8% were 
reported, despite marginal or narrow resections being performed in 77% of 
cases.[24] The median follow-up in that paper was 785 days.  
Overall, it must be concluded that a relationship between resection margins 
and overall survival or local tumour recurrence has not been demonstrated in 
the existing literature. Moreover, the quality of any such evidence, even when 
it is present, must be considered poor due to the effects of numerous 
confounders, including tumour size, location and grade. Although the size of 
the resection margin is a metric that may be of greatest immediate relevance 
to the surgeon, it is probable there are too many variables that influence the 
relevance of such a macroscopic measurement, and other prognostic markers 
may be of more relevance. 
2.10.8 Margin evaluation 
Irrespective of the actual width of resection margin performed, 
demonstration of a histological margin that is clear of tumour cells – 
described as a “histological tumour free margin (HTFM)” is considered the 
best predictor for improved local tumour control of a STS.[13, 79] When 
neoplastic cells are seen immediately adjacent to the resection margins when 
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examined using histology, tumour recurrence is more than ten times (95% CI 
1.33-82.42) more likely to occur.[11] 
Because of the association with increased local recurrence, obtaining a 
resection margin that is free of tumour cells on histological assessment is 
considered by many surgeons to be the ultimate goal of oncologic 
surgery.[80]. However, the histological assessment of surgical margins as an 
indicator of complete tumour removal in all planes can be highly flawed, 
either as a consequence of processing methodology or the practical realities 
of a commercial laboratory service.[13, 25] An important limitation of margin 
evaluation is that only a small fraction of the overall tumour circumference 
can be examined microscopically; most commercial veterinary laboratories 
evaluate neoplasm specimens using between three and six tissue sections. 
Pathologists therefore need to be strategic in assessing which sections of a 
large tumour bulk to evaluate.[25] Recommendations have been published to 
improve consistency in histologic processing and reporting.[25] 
Aside from the practical limitations that prevent evaluation of the entire 
tumour circumference, there are other technical factors that can influence the 
accuracy of margin evaluation. Due to the effects of tissue elasticity and the 
deformation that occurs from the effects of fixation in formaldehyde and 
subsequent processing steps required to get a section of the tumour onto a 
microscope slides,[13, 25] the final measured histologic margin of tissue 
surrounding the visible tumour boundary can be 35% to 42% smaller than 
the original measured surgical margin.[81] The extent of distortion has been 
found to differ for different tissues (e.g. skin, muscle, fat), based on their lipid 
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content.[82] Contraction of tissues will also differ between tumours, probably 
due to variances in stromal characteristics and microscopic infiltration about 
the tumour boundary.[81, 83] There is a compounding effect on specimens 
composed of a tumour and multiple tissue types (e.g. skin, subcutaneous, or 
musculoskeletal tumours) that causes different tissue layers to distort and 
twist.[25] Further distortion of the tissue will occur during histologic 
processing; this is due to the effects of alcohol and xylene washing that 
prepares the tissue to be infiltrated and embedded in paraffin wax, and the 
fragmentation that can occur during microtomy and mounting on a slide.[84] 
Due to the combined effects of these influences on tissue dimensions from 
excision to final interpretation on a microscope slide, the final measured 
histologic margin of tissue surrounding the visible tumour boundary was 
found to vary between 43% and 176% of the original measured surgical 
margin.[81, 82] This work suggests that the measured HTFM may actually 
bear little relevance to the actual surgical margin obtained; the histologic 
measurement of a tumour margin can under- or overestimate the actual 
extent of the tissue barrier that was maintained about the tumour during 
excision. Due to this variability in tissue shrinkage and deformation between 
patients, tissue and tumour types, extrapolating an optimal surgical resection 
margin from a desired HTFM will not be possible. 
Another limitation to the accuracy of margin assessment is the ability of the 
histologist to reliably identify fascial tissues as a distinctive structure. As 
discussed previously, a defined fascial boundary is widely acknowledged as a 
crucial aspect of the deep resection margin.[2, 11] While a fascial layer may 
appear distinct to the surgeon, the same structure is often difficult to identify 
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microscopically. From an oncologic perspective, if the pathologist cannot 
confidently recognise the fascial tissue that the surgeon utilised as a 
distinctive barrier during resection, the histological appearance of the deep 
margin may be interpreted as just a few cell layers of tissue, which raises 
concerns for an incomplete resection. Ultimately, the surgeon needs to 
interpret the histological findings in conjunction with the knowledge of their 
surgical plan. The surgeon knows best whether a thick or thin fascial barrier 
was utilised at any part of the dissection, which sections of the tissue 
appeared concerning at the time of surgery, or where margins were 
compromised due to proximity with vital anatomical structures. Coloured 
inks can be used to paint lateral and deep margins of the excised tissue.[25] 
Inking can help overcome the difficulties in margin evaluation that occurs 
when different tissue layers become distorted during fixing, as the 
pathologist is able to observe the inked margin on the microscopic specimen. 
If tumour cells are seen to abut the section of tissue inked by the surgeon, 
there can be more confidence that this resection margin may be 
incomplete.[25] 
The precise width of HTFM necessary to completely eliminate recurrence has 
not been investigated in the dog. Different studies use different criterion to 
define a HTFM width that equates to either a “complete margin” or 
“incomplete margin”, or often fail to describe one at all. When it is described, 
the widths of normal appearing tissue about the pseudocapsule may range 
from 1mm to 10mm.[9, 10, 23, 48, 76] These inconsistencies in the definition 
of what extent of HTFM is required to ensure complete excision of the STS 
makes it challenging to compare the outcomes from different clinical studies 
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based on different sizes of gross resection margin.[13] In one study, no 
recurrences were observed when a HTFM of >3mm was found between the 
tumour and surgical margins on histological review,[85] but this paper was 
limited to dogs with low grade spindle cell tumours only. Another study 
showed no local recurrences in 30 dogs with a HTFM of ≥1mm;[9] while no 
influence of tumour grade was detected, this study was performed on cases 
submitted from first opinion practice so high-grade tumours were 
uncommon, representing only 7% of the study population. Only one paper 
has so far demonstrated a statistically significant correlation between HTFM 
(>2mm, in this case), local recurrence (p<0.001) and disease free interval (p 
= 0.004);[86] this was a study of 20 dogs with STS with 30% grade 1 and 
70% grade 2 and 3 tumours. In all other studies where a HTFM was reported, 
interpretation of significance was affected by either inadequate case 
numbers,[10] inadequate follow-up times,[11, 76] or the inclusion of dogs 
undergoing re-excision of a recurrent STS or surgical scar.[12, 57] In two 
studies, no correlation between HTFM and local recurrence was evident.[9, 
38] Once again, the current literature provides inadequate or insufficient 
evidence with which to draw definitive conclusions about what extent of 
HTFM is required to prevent local recurrence. 
There is also confounding evidence that suggests tumour recurrence is not 
inevitable even when tumour cells are visible at the resection margins on 
histology. In studies where data on recurrence for canine STS with a positive 
HTFM has been reported, recurrence rates have ranged from as low as 17% 
and up to 100%;[9, 10, 23, 57, 76, 78, 86] across all studies, the mean rate of 
recurrence for an incompletely resected STS was 33% (38 of 114). Data from 
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these same studies reveals that STS can also recur even when the histological 
margins indicate complete resection has been achieved. Rates of recurrence 
in this instance can range from 0% up to 50%; across all studies, the mean 
rate of recurrence for a STS that was considered to have been completely 
resected on histologic examination was 10% (16 of 164).[9, 10, 23, 57, 76, 78, 
86, 87] A recent meta-analysis determined that having a HTFM of >0mm 
reduced the risk of recurrence by approximately 60%.[79] 
The inconsistencies between margin analysis and recurrence risk are not 
limited to canine STS; they have also been reported in human STS as well as 
many other neoplastic conditions.[88-95] Reasons for this inconsistency 
could be due to the inherent limitations of histological analysis that were 
described above. However, there are several tumour-related reasons that 
could explain why established histologic methods are unable to distinguish 
the STS that may have a higher risk of recurrence, irrespective of margin 
status. These reasons include the profile of the pseudocapsule, the presence 
of satellite nodules and the influence of the tumour microenvironment.  
2.10.9 Effect of the pseudocaspule and microscopic invasion 
One of the defining features of a STS is the pseudocapsule that surrounds the 
gross boundary of the tumour and creates a discernible circumscription to 
the tumour.[36] The pseudocapsule is formed initially by the compression 
and atrophy of the surrounding tissue as the tumour expands centrifugally. 
With continued expansion of the tumour, a reaction can develop between the 
capsule and normal tissue, which includes mesenchymal cell proliferation, an 
influx of inflammatory cells, haemorrhage, tissue oedema, and 
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angiogenesis.[36, 96] This area is termed the reactive zone and may 
sometimes be visible grossly as a discoloured area that surrounds the 
tumour. 
Historically, the pseudocapsule has not been considered to be a barrier to 
tumour invasion and dissection through this cleavage plane – equivalent to a 
marginal resection – would lead to high rates of local recurrence.[5, 36] 
However, as discussed above, it is now recognised that some STS can be 
successfully managed with marginal resection margins.[9] Other STS – 
particularly those of higher grade – may require a wider HTFM. The extent of 
HTFM required to achieve adequate local control is therefore not binary and 
may vary according to individual characteristics of the tumour contour, and 
the microscopic invasion of cells beyond the gross boundary of the STS. 
The peripheral contour of human STS has been described as either “pushing” 
(if no evidence of infiltrative growth was seen) or “infiltrative” (if the tumour 
contour was poorly defined, or satellite nodules were present).[97] A pushing 
growth pattern was more commonly observed with low-grade tumours, but a 
proportion (18%) of high-grade tumours can also display this characteristic. 
None of the tumours with a pushing growth pattern recurred after resection 
regardless of histologic margin, whereas local recurrence developed in 6 of 26 
(23%) people after marginal excision and 13 of 56 (23%) people after wide 
excision in STS with an infiltrative growth pattern. In a similar study, an 
almost 7-fold increase (HR = 6.7, p=0.005; 95% CI 1.82-26.13) in local 
recurrence was seen in STS that had an infiltrative contour.[98]  
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There are four retrospective studies of canine STS that make an attempt to 
describe the contour of the STS.[38, 76, 78, 86] Each paper used a different 
criteria to describe whether the STS had a contour that was considered more 
or less invasive or infiltrative, so they are not directly comparable. One study 
showed that tumours with an infiltrative pattern were almost three times 
more likely to relapse (HR 2.45, 95% CI 0.61-9.89), but this finding was not 
significant. However, a significant relationship between a shorter recurrence 
free interval and dogs with an infiltrative tumour contour was demonstrated 
in another study.[86] In a further study, no recurrence was seen in 19 of 19 
dogs with STS that were considered to have a less invasive/pushing growth 
pattern.[76] 
The histological descriptions of human STS have also revealed discrete 
microscopic clusters of neoplastic cells – satellites or skip metastases - that 
extend some distance from the pseudocapsular boundary. These microscopic 
clusters, or even individual cells, are separated from the pseudocapsule by 
microscopically normal tissue. In one study of human STS, microscopic 
tumour nodules have been identified between 1cm and 4cm from the main 
mass in 30% of cases.[99] Satellite nodules are more commonly observed 
with high grade than low grade lesions. When low grade STS do develop 
satellite nodules, they tend to be clustered close to the periphery of the 
pseudocapsule.[36, 37] The microscopic diffusion of tumour cells about the 
circumference for both mast cell tumour and STS has been described in the 
dog in only two studies.[78, 100] In one study, satellite lesions were 
described if there was at least 1mm of microscopically non-neoplastic tissue 
interposed between the satellite lesion and the neoplastic cells that remained 
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in contact with the main tumour bulk. In this study of 19 STS, satellite lesions 
were observed in 6% of tumours with a mean distance of 3.8mm (range 2.9 – 
17mm).[100] Almost 70% of the tumours in this study were low grade, and no 
high grade tumours were included. This may explain the relatively low 
incidence and distribution of the satellite lesions in this study, compared to 
what has been described in human STS.[99] In another study, satellite 
lesions were reported in 11 of 56 STS; these dogs had more than a 3.5 
increased risk of relapse (HR 3.68 95% CI 0.81 – 16.69) when compared to 
28 of 56 STS with an expansile profile, but this difference was not significant 
(p=0.09).[78] This study did not correlate the tumour profile with the grade 
of STS.  
Taken overall, this evidence suggests the pseudocapsule of the STS is actually 
a more complex and nebulous structure than originally presumed and likely 
plays an important role in influencing recurrence of a tumour after surgery. 
In some tumours, the fibrous pseudocapsule may actually provide an 
effective barrier against tumour growth and infiltration but this probably 
holds true for a proportion of (mostly) low-grade lesions only.[36, 96, 101] In 
those instances, successful local control could indeed be achieved with 
excision of the mass including a narrow rim of normal tissue, as has been 
suggested by some authors.[23, 24] However, in other tumours, the reactive 
zone that surrounds the pseudocapsule is an area of nascent and evolving 
neoplastic activity, with isolated clusters of neoplastic cells and a permissive 
stromal microenvironment that supports cancer initiation, 
neovascularization and tumour migration. In these cases, there is a higher 
likelihood for tumour recurrence if the plane of surgical excision passes 
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through this area.[99, 102] The description of isolated tumour nodules 
located several centimeters from the tumour pseudocapsule may also provide 
an explanation for why local recurrence could still occur following complete 
removal of the gross tumour;[36, 99, 103] there are likely complex 
mechanisms at play in the tumour microenvironment that impact on which 
tumours recur, and those that do not.[104-106] 
The influence of these differing tumour contours and extent of microscopic 
invasion of tumour cells into the surrounding tissues will likely have a 
profound, but as yet unmeasured impact on tumour recurrence. Because the 
presence of these characteristics cannot be reliably predicted for each 
individual tumour, there is an argument that wide surgical margins should be 
the appropriate strategy, as this would ensure that if satellite nodules are 
diffusely present around a particular STS they will be contained within the 
resected block of tissue.[1, 3, 5, 11] However, if it was that simple, existing 
data should demonstrate improved outcomes with increasing resection 
margins; as outlined above, the current literature does not support this 
correlation. This may suggest there are more complex elements involved. In 
human STS, the issue of ‘how much to resect’ has been circumvented by the 
routine inclusion of radiotherapy (adjuvant or neoadjuvant) into almost all 
treatment strategies.[44, 107-109] Radiotherapy in combination with surgery 
has allowed shrinkage of the resection margins without compromise for 
patient outcome.[42, 107] In the canine patient, routine inclusion of adjuvant 
RT is unlikely to become the standard of care for the treatment of STS, due to 
the costs and logistical challenges of delivering this treatment. Therefore, 
Chapter 2: Background – page 50 
efforts to develop novel prognostic markers or adjuvant treatments that are 
targeted to STS behaviour would assist efforts to manage this tumour. 
2.11 Conclusion 
STS is a complex disease and many uncertainties surround the biology of the 
tumour and the best options for clinical management. Historically, the 
tendency has been to recommend wide excision margins in all patients, but 
this is not fully supported by recent evidence. Nevertheless, it is accepted that 
inappropriately conservative treatment will affect the outcome for a patient 
with more aggressive disease. 
The “biologic aggressiveness of a soft tissue sarcoma” was recognised in 1981 
as the key factor in human STS to guide the selection of an appropriate 
surgical margin required to achieve local control.[36] Despite this awareness, 
the veterinary profession continues to struggle with the management of 
canine STS almost half a century later. Because there are no diagnostic tests 
that can reliably predict the amount of surgical margin required for a 
particular tumour, there is a mismatch between treatment and disease: some 
dogs are overtreated for their disease, resulting in large wound 
reconstructions or amputation when smaller surgical margins would have 
been effective. Other dogs are undertreated and suffer tumour recurrence 
and premature death due to inadequate initial treatment. Current evidence 
suggests it is not the extent of resection that influences successful patient 
outcome, but the biological behaviour of the tumour.[110] However, 
considerable deficiencies exist in the literature to help reliably determine the 
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prognosis for an individual patient. This highlights the need for more reliable 
and objective prognostic markers to be developed in canine and human 
STS.[13, 43, 72, 73, 109, 111-115] If prognostic markers for tumours with 
either favourable or aggressive behaviour could be identified and predicted 
with more confidence, more appropriate and targeted treatment could be 
provided. 
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Chapter 3: 
Retrospective study into prognostic influences on 
outcomes of 350 dogs treated with soft tissue sarcoma in 
primary veterinary care 
3.1 Introduction 
s discussed in the literature review, much of the current 
evidence for the behaviour of soft tissue sarcoma (STS) in 
dogs has been derived from cases managed in referral 
practice.[1-8] As a result, there is currently little known 
about the expected behaviour of a STS on a dog presented to a first opinion 
practice. It is suspected that first opinion veterinarians are more likely to 
refer a dog to a surgical specialist if it has a large STS or if it is located in a 
challenging location, but will continue to manage small, discrete and readily 
removal tumours themselves. Because scientific analysis of tumour 
management is mostly performed by specialists working in referral practice, 
it follows that most publications detailing the clinical behaviour of STS will 
be biased towards a more aggressive tumour subtype than those seen in first 
opinion practices.[3] This suggests that it is possible the currently 
recommended treatment guidelines are skewed and may not be appropriate 
for the STS managed in first opinion practices.  
A 
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In a small pilot study that was performed prior to this PhD study, the 
outcome of 104 dogs with a diagnosis of STS that were managed in first 
opinion practice was studied.[3] In that study, only one in five dogs died as a 
result of tumour recurrence, which is fewer than would have been expected 
given that less than 10% of patients received treatment with wide surgical 
margins. Interestingly, resection margins were not prognostic for survival or 
tumour recurrence in that study. The results supported the hypothesis that 
STS managed in first opinion practice may have a less aggressive biologic 
behaviour, but also raised additional questions about the role of resection 
margins in the management of this disease. Further investigation, using a 
larger number of dogs and a broader range of STS subtypes, was required.  
There were three aims of the study described in this chapter. Firstly, to 
determine the outcome for a larger cohort of dogs diagnosed with STS that 
were managed exclusively in first opinion practice. It was hypothesised that 
the recurrence rates and patient survival in this cohort would be better than 
the rates previously reported from studies of dogs with STS that were treated 
at referral clinics. The second aim was to evaluate clinical and histological 
features of the STS to determine if any of these features were correlated with 
differences in survival times or an increased tendency for local recurrence. 
The identification of such features may enable clinicians to be able to better 
predict the likely behaviour of a STS. The third aim was to establish an 
archive of histological tissue from these patients that could be used for novel 
biomarker discovery, as will be described in later chapters of this thesis.  
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3.2 Materials and Methods 
Data for all canine STS that had been examined by a large, commercial 
diagnostic pathology service in the United Kingdom (Abbey Veterinary 
Services) during 2003 were retrieved from their database. Cases were 
included if the tumour was a primary occurrence of a STS, adequate clinical 
notes were available for review, patient outcome could be determined by 
questionnaire or telephone contact with the submitting veterinarian, and 
tissue blocks were available for histological review. A minimum follow-up 
period of at least 3 months after surgery was also required. Cases were 
excluded if the sample was found to represent an incisional biopsy only taken 
for diagnostic purposes.  
A questionnaire that had been previously validated was sent to all 
veterinarians (Appendix 1).[3] Follow-up information requested from the 
veterinarian included the tumour size and location, any pre-operative 
evaluations performed, the extent of surgery undertaken, and the current 
status of the patient including dates of local recurrence, metastasis or death. 
The extent of resection margins obtained around the tumour were subdivided 
into four recognised subcategories of oncologic resection: Marginal, where 
the tumour was excised immediately about the pseudocapsule; Local, where 
the tumour was excised along with a margin of normal tissue that was less 
than 3cm wide; Wide, where the tumour was excised along with a margin of 
normal tissue that was greater than 3cm wide; and Radical, where the 
tumour was excised along with an entire body part such as a digit, tail or limb 
amputation. 
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Follow-up time was defined as the time from the date of surgery to the date of 
last follow-up or death. Local recurrence was defined as regrowth at the 
surgical site and metastasis was defined as occurrence of a STS at an 
anatomic location different from that of the initial surgery.  
The disease-free interval (DFI) was defined as the time between the date of 
surgery to the date of local or distant tumour development or metastasis, 
whichever occurred first. Dogs were censored if they were lost to follow-up or 
were reported to have died from causes unrelated to the STS. 
Soft tissue sarcomas were sub-classified into peripheral nerve sheath tumour 
(PNST), fibrosarcoma, giant cell tumour, perivascular wall tumour (PWT), 
myxosarcoma, or liposarcoma using light microscopy based on previously 
published criteria.[4] Immunohistochemistry was not used to assist with the 
differentiation of different STS subtypes. STS were also graded using criteria 
that have been described previously in the literature review (Table 3.1). 
Due to difficulties in orientating neoplasms or because the veterinarian had 
only submitted parts of the overall STS, it was not considered possible to 
confidently assess the completeness of surgical excision by histology.  
3.2.1 Statistical Analysis 
All statistical analyses were performed with R (R version 2.8.1, R Foundation 
for Statistical Computing, Vienna, Austria). Deaths from tumour, local 
recurrence or metastasis were defined end points for the study. Any cases 
with an unknown finding within the category being analysed were not 
included in the statistical evaluation of that characteristic. The Kaplan-Meier 
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method was used to compare survival times according to age, sex, neuter 
status, clinical signs, duration of signs, tumour size, tumour type, histological  
Table 3.1: 
Grading System for Cutaneous and Subcutaneous STS in the Dog (modified after 
Dennis MM, McSporran KD, Bacon NJ, et al.: Prognostic factors for cutaneous and 
subcutaneous STS in dogs. Vet Pathol 48:73-84, 2011)[4] 
Score Criteria Score = 1 Score = 2 Score = 3 
Differentiation 
Well-differentiated: 
Sarcomas most closely 
resembling normal adult 




Sarcomas for which 
histologic type can be 
determined, although 
differentiation is poor 
Poorly differentiated: 
Undifferentiated 
sarcomas, sarcomas of 
unknown type 
Mitotic score: 
0-9 mitoses per 10 
hpf 
10-19 mitoses per 10 hpf >19 mitoses per 10 hpf 
Necrosis score No Necrosis <50% necrosis >50% necrosis 
 
Histologic grade = Sum of (differentiation score + mitotic score + necrosis score) 
Grade I score = 3 Grade II score = 4 or 5  Grade III score = 6 
 
characteristics (i.e. differentiation, necrosis, mitotic score, grade), and the 
development of local or distant tumour recurrence. A value of p<0.05 was 
considered significant. Prognostic factors that on univariate analysis had a 
value of p<0.1 were included in a multi-variable analysis using Cox’s 
proportional hazards model to help evaluate their independent influence on 
outcome. Backward selection methods were used to create a fixed effects 
model, retaining only those values that had a p value of <0.05. The 
assumption of proportional hazards was assessed by plotting the Schoenfeld 
residuals as a function of time.[9] 
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Finally, logistic regression analysis was performed to identify categories of 
significance between patients whose tumours recurred within the first 365 
days (early recurrence) and a second group of patients whose tumours did 
not recur for more than 2 years after surgery (late recurrence).  
3.3 Results 
3.3.1 Cases included in the study 
A total of 1144 questionnaires were sent out; 632 were returned, 88 of which 
were incomplete, resulting in a 47.5% return rate. A further 67 cases were 
excluded from further analysis for any of the following reasons: an 
inadequate follow-up interval or the tumour was a recurrence from a 
previous surgery. A total of 477 cases remained for histological review. 
Tissue blocks were available for all 477 cases; however, 37 of these were 
excluded because the tissue sections produced from them were of poor 
quality and this poor quality prevented critical evaluation. A further 90 
tumours were discarded after histological review, as they were not considered 
to be consistent with STS on histology. This left 350 cases for final analysis. 
3.3.2 Demographics  
Of the 350 dogs included in the study, 195 were female and 155 were male; 
54% of the females and 34% of males were neutered. The median age at time 
of diagnosis was 10 years, with a range of 3 to 16 years. There were over 50 
different breeds reported, with the 4 most common being crossbreed (78 
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[22%]), Border collie (44 [13%]), Labrador retriever (34 [10%]), and boxer 
(26 [7%]) (Table 3.2). 
Table 3.2: 
Summary of soft tissue sarcomas included in the archive 
Characteristic Groups Number  
Age <=8 years >8 years 
93 
251 
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Time to Recurrence Early (<365 days) Late (>730 days) 
37 
13 
Local recurrence No Yes 
260 
73 
Died due to sarcoma No Yes 
238 
58 
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3.3.3 Tumour details 
Soft tissue sarcoma were located on the limbs in 211 (60%) cases, the trunk 
(including the tail (6) and perineal (3) area) in 123 (35%) cases and the head 
in 16 (5%) cases. 
Thirteen (4%) of the STS were reported to be less than 1cm in size, with 142 
tumours (41%) sized between 1-5cm and 68 (19%) being larger than 5cm in 
diameter. The size of 127 STS (36%) was not recorded in the clinical notes.  
The STS were described by the submitting veterinarians as mobile and 
discrete in 106 (30%) cases but were considered fixed to the surrounding 
tissues in 128 (37%) cases. In 116 (33%) cases, the veterinarians were unable 
to recall the gross nature of the tumour on palpation.  
3.3.4 Tumour management 
In 229 (65%) cases, no pre-operative investigations were performed prior to 
mass removal. Fine needle aspiration (FNA) of the mass was performed in 75 
cases (21%), with results providing confirmation or strong suspicion for a STS 
or spindle cell neoplasm in 59 cases (17%). Some respondents commented 
that FNA was principally used to rule out conditions such as lipoma or mast 
cell tumour and samples were not always submitted to an external laboratory 
for analysis. Incisional biopsy and histological examination had been 
performed prior to surgery in 15 (4%) cases. 
Clinical staging of tumours was infrequently performed. Pre-operative 
haematology and biochemical evaluations were performed in 16 (4%) cases. 
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Evaluation of the draining lymph node by FNA was performed in just 1 case. 
Thoracic radiographs were performed in 16 (4%) cases. Abdominal 
ultrasound was not performed in any case.  
The extent of surgical resection was described as marginal in 143 (41%) cases 
and local in 117 (33%) cases. Wide resections of 3cm or more about the 
tumour were performed in just 19 (5%) cases, with radical resections 
(amputation, which included 4 toe and 2 tail amputations) performed in 13 
(4%) cases. The extent of resection could not be recalled by the veterinarians 
in 58 (17%) cases. No information was available on the deep margins in any 
case. If a neoplastic condition was suspected from pre-operative biopsy or 
cytology, there was a tendency for a wider surgical excision to be performed 
(p=0.007). 
3.3.5 Histological analysis 
Tumours of presumed peripheral nerve origin (i.e. PNST) were most 
common (242 of 350, 70%). Fibrosarcoma were the next most common (66 
of 350, 18.8%) followed by PWT (22 of 350, 6%). Myxosarcoma, liposarcoma 
and giant cell tumour were diagnosed less commonly.  
There were 231 (66%) grade 1 tumours, 95 (27%) grade 2 and 22 (6%) grade 3 
tumours. Necrosis was absent in 242 (70%) cases, present and representing 
less than 50% of the tumour in 94 (27%), and present and representing more 
than 50% in 12 (3%) cases. The mitotic rate was distributed as 0-9 per 10 
high power fields (hpfs) (274, 78%), 10-19 per 10 hpfs (50, 14%) and >20 per 
10 hpfs (24, 7%). Tumour differentiation was classified as well-differentiated 
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in 170 STS (49%), moderately well-differentiated in 153 (44%) and poorly 
differentiated in 25 (7%). 
3.3.6 Clinical Outcomes 
Follow-up times ranged from 102 to 2192 days, with a median follow-up time 
of 785 days. Over 85% of the study population had a follow-up time of more 
than 12 months, with 35% of cases being followed for longer than 3.5 years 
(1290 days) (Table 3.3). 
From Kaplan Meier analysis, the overall mean survival time was 1796 days, 
equivalent to almost 5 years following surgery (Figure 3.1). The median 
survival time for all dogs was not reached; estimated 1-, 2-, and 5-year 
survival probabilities were 94%, 86% and 70%, respectively. 
During the study period, 277 dogs died, representing almost 80% of the study 
population. Death was attributed to the STS in 58 cases (16.5%). A reason for 
death or euthanasia was not recorded in 54 cases (15.4%). In 16 of these 
cases, local recurrence or metastasis had been documented, so death due to 
the STS was a possibility. 
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Table 3.3: 
Distribution of tumour types and outcome 
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Kaplan Meier plots showing survival outcome for all dogs with a soft tissue sarcoma 
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Figure 3.2: 
Kaplan Meier plots for survival time, where euthanasia was performed due to local 
recurrence of the tumour 
 
Local tumour recurrence occurred in 73 (20.8%) cases and did not occur in 
260 (74.2%) dogs (Figure 3.2). In 17 dogs (4.8%), the submitting veterinarian 
was unable to confirm whether recurrence had occurred or not. The median 
DFI was not reached. The mean DFI for all dogs was 637 days, with estimated 
1-, 2-, and 5-year disease-free probabilities being 89%, 78%, 66%, 
respectively.  
When all 73 dogs with STS recurrence were considered, recurrence was 
observed within 365 days of surgery in 37 (51%) dogs, with an additional 23 
(32%) dogs having tumours recurring between 365 days and 2 years after 
surgery. Overall, tumour recurrence was observed for 60 of 73 (83%) dogs 
within 2 years of surgery. Recurrence was observed between 2 and 4 years 
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after surgery in 11 of 73 (15%) dogs and more than four years after the 
original surgery in 2 of 73 (3%) dogs.  
Tumour grade was significantly associated with a risk of tumour recurrence 
(p = 0.0001). Low grade STS were significantly more likely to recur more 
than 2 years after surgery compared to medium or high grade tumours 
(p=0.03) (Figure 3.3). Additionally, STS that had a mitotic rate of less than 
10 per 10 hpfs were significantly more likely to recur more than 2 years after 
surgery than STS that had a mitotic rate of greater than 10 per 10hpfs 
(p=0.03). 
Figure 3.3: 
Low grade tumours were significantly more likely to recur more than 2 years (730 
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In the 73 dogs that had a STS recur at the original surgical site after excision, 
34 dogs were euthanised due to the presence of a sarcoma while 39 dogs 
apparently died due to causes unrelated to the recurrence of the sarcoma. 
Dogs that were euthanised because of a recurrent STS had a median post-
recurrence survival time of 708 days (range 124-1983 days) which was 
significantly shorter than the mean post-recurrence survival time of 1103 
days (range 159-2020 days) for dogs that died due to unrelated causes while a 
recurrent STS was present (log rank 51.0, p = <0.0001) (Figure 3.4). 
Figure 3.4: 
Death due to tumour recurrence was not inevitable. In this study, 16 dogs that 
developed local recurrence died from unrelated causes, with a mean survival time 
of 1008 days.  
 
Metastatic disease was reported to have developed in 40 (11%) dogs with STS. 
The median metastasis-free interval for these cases was 550 days (95% CI 
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381-718 days). Metastases were reported for all types of STS except PWT. 
Metastasis was reported in 8 of 14 grade 3 tumours (36%), 13 of 95 grade 2 
(14%) and 19 of 231 grade 1 tumours (8%). Metastasis was significantly more 
likely to occur in grade 3 than grade 1 STS (c2 =	16.7, p <0.0001). Sites of 
suspected metastasis included subcutaneous sites elsewhere on the body (9 of 
40), spleen (4 of 40), lungs (10 of 40), liver (5 of 40), central nervous system 
(CNS) (1 of 40), pelvis (1 of 40), bowel (1 of 40) and nasal chamber (1 of 40), 
or combinations of these sites (4 of 40). The site of metastasis was not 
recorded in 4 of 40 cases. A diagnosis of sarcoma metastasis was determined 
by either imaging alone (21 of 40) or histology alone (4 of 40). In 12 cases, 
the veterinarians did not indicate how a diagnosis of metastasis was 
confirmed. There was no correlation between the development of local 
recurrence and metastasis (c2 = 1.48, p = 0.2). 
3.3.7 Analysis of prognostic features influencing survival 
A number of individual clinical characteristics were analysed to show their 
relationship to long term patient survival after surgery. Patient age, tumour 
size, the palpable characteristics of the tumour, tumour type, grade, mitotic 
rate, percentage tumour necrosis and recurrence of the tumour were all 
found to have a significant influence on survival. Only patient sex and neuter 
status were not found to influence survival. The details of this analysis are 
presented in more detail below, with Kaplan-Meier graphs for each 
characteristic presented in Figure 3.5: 
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Age: Of the 66 dogs with a STS that were less than 8 years of age at 
diagnosis, only 9 (14%) dogs died due to neoplasia. This rate was significantly 
lower than dogs that were greater than 8 years of age at diagnosis, of which 
48 of 278 (17%) dogs died due to STS (c2 = 6.1, p=0.01). Dogs that were 8 
years of age or older had a more than double increased rate of death from 
their tumour compared to dogs less than 8 years of age (HR 2.25, p = 0.016, 
95% CI 1.2 – 4.3). 
Size: Dogs with a STS that was smaller than 1cm in size at the time of 
surgery were significantly less likely to die (1 of 13 dogs died, 8%) from their 
tumour compared to dogs with a tumour greater than 5cm (19 of 68, 28%) (c2 
= 9.6, p=0.002). 
Palpable characteristics: STS that were discrete and mobile within the 
tissues were significantly less likely to cause the death of the dog (8 of 106, 
7.5%), compared to tumours that were fixed and immobile (33 of 128, 25.8%) 
(c2 = 17.2, p = 0.0002). 
Grade: Only 31 of the 231 (13%) dogs with a low grade STS died as result of 
their tumour. By comparison, 9 of 22 (40.9%) dogs with a high grade tumour 
died from their STS. This difference was statistically significant (c2 = 17.6, 
p=0.0002).  
Differentiation: Seven out of 25 (28%) dogs with poorly differentiated STS 
died as a result of their tumour. This compared to 25 out of 170 (15%) and 26 
out of 153 (17%) with well differentiated and moderately differentiated 
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tumours, respectively. This difference was not statistically significant (c2 = 
4.2, p = 0.12). 
Mitotic rate: Nine out of 24 (37.5%) dogs that had a STS with a mitotic rate 
of greater than 20 per 10 hpfs died as a result of their tumour. This compares 
with tumour-related death in 41 of 274 (15%) dogs with a mitotic rate of less 
than 10, and 8 of 50 (16%) dogs with a mitotic rate between 10 and 20. This 
difference was statistically significant (c2 = 11.8, p=0.003). 
Necrosis: Half of the dogs (6 of 12) with a STS that was more than 50% 
necrotic on histological assessment died as a result of their tumour. This 
compared with just 14% (33 out of 209) for tumours with little or no necrosis, 
and 20% (19 out of 94) for tumours with <50% necrosis. This difference was 
statistically significant (c2 = 3.9, p=0.0001). 
Tumour recurrence: Tumour recurrence was associated with more than a 
five-fold risk of death (HR 5.2, p<0.0001; 95% CI 3.1-9.0). However, some 
dogs did experience prolonged survival despite tumour recurrence. In five 
cases, tumours were reported to have recurred within two months of the 
original surgery, yet these dogs were recorded as dying for non-tumour 
related reasons from between 174 and 401 days after surgery.  
Resection margins: Sarcoma-related death occurred in 24 of 143 (17%) 
dogs who underwent a marginal excision of their tumour, 14 of 117 (12%) 
dogs with local (<3cm) excision margins, 3 of 19 (16%) dogs with wide 
excision, and 4 of 13 (31%) with amputation. These differences were not 
statistically significant.  
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Sex: There were 195 female dogs, and 34 died (17.4%) as a result of their 
tumour. For male dogs, 24 of 155 dogs (15.4%) died from their tumour. This 
difference was not significant (c2 = 0.3, p=0.6). 
Neuter status: Fifteen of the 105 (14%) neutered females and 19 of the 90 
(21%) females who remained intact, died from their tumour. Seven of 55 
(13%) castrated dogs died from their tumour, while 17 of the 102 (17%) entire 
dogs died. Overall, of the 158 animals that had been neutered, tumour related 
death occurred in 22 (14%), while 36 of the 192 (19%) who remained entire 
died from their tumour. This difference was not significant (c2 = 0.3, p=0.6). 
When all prognostic factors with a significant influence on survival (to a value 
of p<0.1) were evaluated by multi-variable analysis, only the palpable 
characteristics and grade of the tumour were found to be significant. 
Tumours that were considered firmly attached to the underlying tissues were 
found to increase the likelihood of death by four times (HR 4.0, p=001; 95% 
CI 1.8-8.7). Compared to a dog with a grade 1 tumour, a dog with a grade 2 
tumour was almost twice as likely to die from their STS (HR 1.9, p = 0.04, 
95% CI 1.0 – 3.3), and one with a grade 3 tumour was more than 4 times 
more likely to die from tumour-related causes (HR 4.2, p = 0.0001, 95% CI 
2.0 – 9.0). 
The test of the proportional hazards assumption confirmed the model was a 
reasonable fit (p=0.13). 
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Figure 3.5: 
Kaplan Meier survival curves for individual tumour characteristics that had a 
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Figure 3.5 (continued): 
Kaplan Meier survival curves for individual tumour characteristics that had a 
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3.3.8 Analysis of prognostic features influencing local recurrence: 
When the same individual clinical characteristics were analysed to show their 
relationship to local recurrence of the tumour after surgery, tumour grade, 
mitotic rate, necrosis and the histological diagnosis were found to have a 
significant association with the disease-free interval. The remaining 
characteristics studied were not significantly associated with tumour 
recurrence. The details of this analysis are presented in more detail below, 
with relevant Kaplan Meier curves illustrated in Figure 3.6. 
Grade: Local recurrence of the STS occurred in 42 of 231 dogs (18.2%) with 
a low grade STS, compared to 6 of 22 (27.3%) dogs with high grade tumours. 
This difference was statistically significant (c2 = 6.8, p = 0.03).  
Mitotic rate: Eight out of 24 (33%) dogs that had a tumour with a mitotic 
rate of greater than 20 per 10 hpfs developed a local recurrence after surgery. 
This compares with a recurrence rate of 19% (52 of 274) dogs with a mitotic 
rate of less than 10, and 24% (12 of 50) for dogs with a mitotic rate between 
10 and 20. This difference was statistically significant (c2 = 6.67, p=0.04). 
Necrosis: Eight of the twelve dogs (67%) with a STS that was more than 
50% necrotic on histological assessment developed a local recurrence after 
surgery. This compared with just 16% (49 out of 242) for tumours with little 
or no necrosis, and 20% (15 out of 94) for tumours with <50% necrosis. This 
difference was statistically significant (c2 = 27.9, p<0.001). 
Differentiation: Seven out of 25 (28%) dogs with poorly differentiated STS 
developed local recurrence. This compared to 38 out of 170 (22%) and 27 out 
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of 153 (18%) with well differentiated and moderately differentiated tumours, 
respectively. This difference was not statistically significant (c2 = 2.7, p = 
0.23). 
Histologic diagnosis: Recurrence was observed in 51 of 242 (21%) PNST, 4 
of 12 (31%) myxosarcoma and 14 of 66 fibrosarcoma. Only 2 of 22 (10%) PWT 
developed local recurrence, but this difference was not significant. 
Resection margins: Local recurrence developed in 37 of 143 (26%) dogs 
after marginal excision, 23 of 117 (20%) dogs after local (<3cm) excision, 2 of 
19 (11%) dogs after wide excision, and none of the 13 (0%) dogs who 
underwent an amputation. Resection margins were not significantly 
associated with increased rates of recurrence.  
Sex: There were 195 female dogs, and 38 (19%) developed local recurrence of 
their tumour. For male dogs, 35 of 155 dogs (23%) developed local 
recurrence. This difference was not significant. 
Neuter status: Twenty-three of the 105 (22%) spayed females, and 15 of the 
90 (17%) females who remained intact, developed local tumour recurrence. 
Twelve of the 53 (23%) castrated dogs and 23 of the 102 (23%) entire dogs 
developed local recurrence. Overall, of the 158 animals that had been 
neutered, tumour recurrence occurred in 35 (22%), while 38 of the 192 (20%) 
who remained entire developed local recurrence. This difference was not 
significant (c2 = 0.3, p=0.6). 
On multivariable analysis, only tumour grade was significant for recurrence, 
with high grade tumours having an almost 6 times increased hazard for 
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recurrence compared to low grade tumours (HR 5.8 p<0.001; 95% CI 2.2-
14.8). 
Figure 3.6: 
Kaplan Meier survival curves showing influence of individual tumour characteristics 
on tumour recurrence
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3.4 Discussion 
This study showed that only 16.5% of dogs with STS that were treated at first 
opinion veterinary practices died due to their cancer. By comparison, in a 
study of STS treated at a referral practice, a mortality rate of 33% was 
reported.[7] Therefore, the results of this study support the hypothesis that 
the outcome for canine STS in a general population of dogs may be better 
than what has previously been reported in the literature.  
Although death is the definitive endpoint measure for a patient with cancer, 
preventing local regrowth of the tumour following surgical resection is 
perhaps the more important challenge in the management of STS. The 
current study has shown that recurrence is associated with a more than 5-fold 
increased risk of death, with STS recurring in around one out of five patients 
after surgery. This tendency for STS to recur after surgery was first reported 
by Bostock and Dye in 1980.[10] They reported recurrence rates of up to 60% 
following surgery for STS; due to this high rate of recurrence they 
recommended aggressive surgical resection to improve local control. When 
Kuntz and others (1997) showed that wide resection about the tumour 
reduced the recurrence rate to just 15%,[7] it became accepted that the 
appropriate margins for surgical resection of STS should comprise at least 
3cm of tissue lateral to the tumour, and one fascial plane deep to the tumour, 
as used in their study. Most textbooks and review papers that detail the 
treatment of STS emphasise the importance of this more aggressive surgical 
strategy.[5, 6, 11, 12] Despite those recommendations, the current study has 
found that patients with STS operated in first opinion practice can have 
Chapter 3: Retrospective clinical study into outcomes for canine STS – page 87 
similar or better outcomes than would have been predicted by the current 
literature despite only 5% of dogs receiving the wide resection margins 
recommended for effective control of STS. Recurrence was observed in 10% 
of dogs with wide margins and around a quarter of dogs that had a marginal 
excision, but this difference was not significant. On overall analysis, the 
current study suggests that the extent of surgical resection of the STS does 
not significantly influence the likelihood of tumour recurrence or overall 
survival. 
As discussed in the literature review, other authors have challenged the 
notion that wide surgical excision margins are essential in all dogs with 
STS.[1-3, 13] In a prospective clinical study, 100% local disease control and 
93% one-year disease-free interval was achieved in 14 dogs after removal of 
the tumour with just 1cm lateral margins and a single deep fascial plane.[1] 
Other authors have reported a 10% local recurrence rate for 35 dogs with 
spindle cell tumours of the extremities treated by marginal excision only.[13] 
In that study, no recurrence was observed in dogs where at least 3mm of 
normal tissue was found between the tumour and surgical margins on 
histological review. The results of the current study support these earlier 
studies and suggests that many STS do not recur after surgery, even when 
wide resection is not achieved.  
At the start of this PhD, it was speculated that STS selected for management 
in first opinion practice may have a tendency for a less aggressive behaviour 
than those reported in the first clinical publication on this tumour type in 
1980.[10] Since that study was published, our understanding of the 
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behaviour of soft tissue tumours has improved, together with the 
development of specialist services and the pet-owning public’s acceptance of 
cancer treatment. These events raise the possibility that STS now selected for 
management in first opinion practice will have an improved outcome 
because: 1) owners may present their animals for treatment of a mass sooner 
than previously; 2) potentially aggressive masses (i.e. large masses, those that 
had demonstrated a period of recent rapid growth, were located in a difficult 
location, or had recurred following a previous resection) are now more likely 
to be referred for specialist management. Evidence for such a selection bias 
was evident in this study population, with obvious differences in the 
proportion of tumour grades when compared to historical publications 
derived from referral practice. Grade is recognised as an important indicator 
of tumour aggression, and is one of the most validated criteria to predict 
recurrence after surgery.[4] In the current study, two-thirds of the tumours 
were classified as low grade, while high grade lesions represented only 6.3% 
of the population. By comparison, in studies derived from a referral 
population of tumours, the proportion of high grade tumours is almost 3 
times higher (i.e. between 17-29% of the sample population).[7, 14, 15] The 
trend for more low grade tumours to be excised in first-opinion practice is 
also supported by an analysis from pathology submissions to veterinary 
diagnostic laboratories in the United Kingdom where 87% of all canine STS 
submitted from first opinion practice over a three year period were classified 
as low grade, with considerably smaller numbers of intermediate (8%) and 
high grade (3%) tumours.[3] 
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The size of the STS managed in the current study also supports a selection 
bias when compared to other historical publications. Over two-thirds of the 
tumours in the current study were less than 5cm in size, with only 68 of 223 
(30%) being recorded as more than 5 cm. Although direct comparisons are 
difficult due to differences in reporting methods, papers derived from a 
referral population of surgical patients have described median tumour sizes 
of 4.7cm, 5cm or 6cm.[1, 7, 10] Larger tumours are generally considered to 
have poorer prognosis;[4, 7, 16] this is supported by results of the current 
study where STS larger than 5cm were associated with a more than 5 times 
increased daily hazard for death when compared to tumours that were <1cm 
in size. Tumour size probably affects prognosis by influencing the ability to 
achieve complete resection.[11] The increased proportion of small tumour 
sizes in the current study may suggest that first opinion practitioners are 
more prepared to operate on smaller masses but will refer larger masses for 
treatment at specialist centres. 
The impact of the bias identified in the current study is important. Most 
clinical studies on STS are performed at referral centres, so the prevailing 
literature represents a skewed population of tumours that are likely to be 
larger, located in challenging locations and have a more aggressive biological 
behaviour compared to the STS managed in first opinion practice. This bias 
alters our understanding of the true biology of STS within the general canine 
population and the treatment recommendations provided to veterinarians.  
If surgical margins are not influential on outcome, it follows that there must 
be other factors that influence recurrence of a STS after surgery. In order to 
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help predict which STS are more likely to recur after excision, a number of 
clinical and histological features were evaluated for their use to predict 
tumour recurrence or death of the dog. Of the factors that were evaluated, the 
age of the patient, tumour size, the palpable characteristics of the tumour, 
grade and the histologic type were all found to have prognostic significance 
for either patient survival, tumour recurrence or both. Possible explanations 
for these findings are detailed below: 
Age: The wide age range (3 – 16 years) for STS incidence in this study was 
similar to that reported in earlier studies.[7] In the current study, dogs less 
than 8 years of age were found to have a reduced chance of death from their 
tumour compared to dogs greater than 8 years old. Although significant, the 
actual difference was small (13.6% vs. 17.3%). A decision by an owner to 
euthanise their dog because of a recurrent STS may be influenced by many 
factors. In the older dog, for example, the presence of concurrent disease 
conditions such as arthritis, heart disease or other age-related disorders, may 
impact on an owner making an ‘end of life’ decision with criterion that would 
be different to those influencing the same decision in a younger dog.  
Tumour size: In the current study, dogs with tumours larger than 5cm had a 
significantly poorer outcome than dogs with tumours that were only 1cm in 
diameter. These results support several previous studies of canine and 
human STS that reported that patients with STS that were larger than 5cm in 
diameter have shorter disease-free intervals and survival times than patients 
with STS that were smaller than 5 cm in diameter.[7, 16-22] However, this 
association has not been reported consistently and other authors have not 
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found any association between tumour size and outcome.[3, 10, 23] There are 
a number of reasons why a larger STS would be associated with a worse 
outcome. It is possible that larger tumours are more difficult to remove than 
smaller tumours, with surgeons being less willing or able to maintain their 
chosen resection boundaries about the entire circumference of the mass. 
Resection of a large STS requires a detailed anatomic knowledge of the 
affected tissues, combined with a sound understanding of oncologic 
principles, surgical skills and peri-operative nursing care. It is possible that 
while an inexperienced surgeon can maintain a measured cushion of normal 
tissue about the tumour during the initial stages of a dissection, they become 
less confident once the surgery extends deeper and wider into the body. 
There may be a tendency for the dissection to stray into the relative safety of 
the cleavage plane that surrounds the pseudocapsule of the tumour, which 
increases the risk for microscopic deposits of tumour tissue to be left 
behind.[24] One study has reported a significant increase in the risk of an 
incomplete excision when the tumour was excised by a surgical resident 
compared with a specialist surgeon.[16] Similar variances are identified in 
human medicine, prompting demands for STS to only be operated by trained 
surgeons in dedicated centres.[25, 26] It is also possible that STS that have 
attained a large size have done so because they have grown more rapidly and 
therefore have a more aggressive biological behaviour. Some authors have 
suggested that a history of sudden or rapid growth by the STS, or the 
presence of gross tumour necrosis and ulceration within the tumour, may 
imply a more aggressive growth characteristic and warrant increased 
caution.[11] However, these observations have not been validated in clinical 
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trials. A further possibility is that larger tumours have become more 
integrated with the body, with a wider zone of cytokine and humoral 
influence on the surrounding tissues. The significance of the relationship 
established between the tumour and the host tissues, and the role of the 
tumour microenvironment in influencing the potential for tumour recurrence 
after surgery, will be discussed in more detail in a subsequent section of the 
discussion. 
Palpable characteristics: The results of the current study suggest that a 
difference in the mobility of the tumour may help predict the subsequent 
behaviour of the neoplasm. It was shown that STS that feel ‘fixed’ to 
underlying tissues on palpation had significantly increased rates of 
recurrence and reduced survival times compared to those tumours that were 
freely mobile. Other authors have not identified tumour fixation to be 
predictive of outcome,[4] so this finding needs to be validated in a 
prospective setting to see if it can be used to predict prognosis or guide 
resection margins. One reason why a STS that is more fixed to the underlying 
tissue could recur more commonly after surgery may reflect, again, the 
challenges an inexperienced surgeon can face in maintaining a consistent 
dissection boundary about the tumour, particularly if the surrounding tissues 
are more adherent to the tumour than normal. This increased surgical 
difficulty may lead to undocumented compromises in parts of the dissection 
whereby a surgeon may start out with a certain boundary about the mass but 
their surgical margins gradually shrink closer and closer to the tumour 
interface during the surgery as they try and find a comfortable dissection 
plane. This may lead to portions of microscopic tumour being inadvertently 
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left behind in some areas of the wound - potentially leading to recurrence - 
even though the surgeon will have documented that they removed the 
tumour with wide margins. Nevertheless, there are other explanations to 
explain why tumour mobility may impact on risks of tumour recurrence that 
are unrelated to surgical margins. For example, it is possible that STS that 
feel more fixed have a different tumour microenvironment that causes them 
to be more infiltrative or enables greater migration of tumour cells into the 
periphery. Similar effects have been described in human breast cancer, where 
diseased tissue can be 10-times stiffer than normal breast. This increase in 
stiffness is contributed to by increased levels of the enzyme lysyl oxidase 
(LOX) in the stroma. This increase in LOX causes the tumour-associated 
collagen to become linearised through increased cross-linking between the 
molecules. The cross-linked collagen bundles tend to be quite stiff and 
provide an effective highway for tumour cells to migrate along. This 
“highway” can facilitate their migration through the peri-tumoural tissues 
and ultimately into the vasculature and lymphatic circulation.[27] 
Tumour grade, mitotic rate and necrosis: In the current study, the 
histological grade of the STS was found to be significantly associated with 
both local tumour recurrence and survival. Grade 2 and grade 3 STS were 
almost 2 and 6 times, respectively, more likely to cause the death of the dog 
compared to grade 1 tumours. Similar hazard ratios were also reported for 
the risk of local recurrence for both of these higher grade tumours. An 
association of histological grade with patient outcome has been reported by 
other authors, but more commonly due to a higher risk of metastatic disease. 
Rates of metastatic spread for grade 3 STS have been reported to be 22-
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44%,[7, 28] compared to just 7-8% for grade 1 and 2 tumours.[29] It should 
be noted that the precision of these figures is poor due to the inadequacy of 
data collection on metastatic disease in all patients, a factor that will be 
examined in more detail later. An association between tumour grade and 
local recurrence of the tumour following surgery has been less well described. 
Only one study has demonstrated a correlation between the histologic grade 
of the tumour and the risk of recurrence for marginally excised subcutaneous 
STS.[30] In that study, only 7% (3 of 41) of low grade tumours recurred after 
marginal excision compared with 34% (14 of 41) and 75% (3 of 4) for 
intermediate and high grade tumours, respectively. 
Because grade is an aggregated score of several elements of tumour biology, 
including differentiation, mitotic index (MI) and the presence of necrosis, it 
is not surprising that some of these individual measures were also 
significantly associated with disease outcome. In the current study, both a 
high MI (>20 mitoses per 10 high power fields) and a tumour that was more 
than 50% necrotic on histologic examination were associated with a 
significant increase in local recurrence and tumour-related death. The MI is a 
measure of proliferative activity within the tumour, and a high rate of cellular 
turnover is commonly associated with increased (and earlier) rates of tumour 
recurrence, higher rates of metastasis and reduced overall survival for many 
tumour types, including STS.[4] In one study on canine STS, MI was the only 
factor to be significantly prognostic for developing metastatic disease on 
multivariate analysis; in that study, dogs with an MI of >20 were 5 times 
more likely to develop metastasis than dogs with an MI of <20.[7] The role of 
MI in predicting local recurrence has only been reported in one previous 
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study, where almost two-thirds (63%) of tumours with an MI >9 recurred, 
while only a quarter of the STS with an MI of less than 9 recurred,.[10] 
Because MI is a measure of cellular turnover within the STS, it follows that a 
highly proliferative tumour will show more aggressive tendencies, and thus 
may respond to surgery more poorly. It is also possible that the increased 
drive for a sarcoma cell to proliferate reflects an increased concentration of 
growth factors and tumourigenic cytokines around the tumour, which creates 
a microenvironment favourable for tumour progression. 
Although high levels of necrosis within the tumour has been associated with 
reduced survival and shorter disease-free intervals in several studies, this is 
the first veterinary study to show a significant relationship with increased 
local recurrence. An association between the presence of gross necrosis 
within the tumour and poorer patient outcome was first noted in human STS 
in 1984;[31] in that study the authors noted that patients with moderate and 
marked necrosis had a much poorer survival than patients with absent or 
minimal necrosis. In veterinary studies, one study has shown that tumours 
with >10% necrosis were 2.8 times more likely to lead to death of the dog 
than tumours with less than 10% necrosis.[7] It seems counter-intuitive that 
a tumour that appears to be dead on microscopic analysis is actually more 
aggressive than a tumour that does not have these necrotic areas. Reasons 
why this dichotomy could occur are explored in more detail later in this 
thesis, but it may relate to the effects of hypoxia and adaptive evolution by 
the tumour cell.[32] Hypoxia will develop within a growing tumour if it is 
unable to develop the necessary vascular supply to support its continued 
expansion. If a tumour proliferates too quickly, the cells will become 
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increasingly isolated from the existing vasculature, and may extend beyond 
the limits of oxygen diffusion. If the cancer cells are to survive in this hypoxic 
environment, they must either drive angiogenesis to increase the delivery of 
oxygen and nutrients to the growing tumour or adapt their metabolism to 
allow continued survival in the suboptimal conditions. Clonal evolution will 
probably favour cancer cells that are able to upregulate the necessary hypoxia 
response genes and pro-inflammatory genes that will support their survival 
in this challenging environment.[32] 
While an increased proportion of tumour necrosis was found to be 
significantly associated with increased recurrence and reduced survival in the 
current study, it should be recognised that the evaluation of necrosis within a 
STS can be problematic. Necrosis is often not diffusely present within a 
neoplasm so examination of just a portion of a large neoplasm can either 
over- or underestimate the true proportion of necrotic cells within the entire 
tumour. This sampling error is often made worse because histology 
technicians are routinely trained not to trim necrotic areas of neoplasms in 
for histological evaluation.[33]  
Histologic type: All canine STS have traditionally been considered as a single 
group for prognostic purposes.[4] However, evidence from human STS 
suggest that individual STS types will exhibit differences in local 
invasiveness, metastatic potential and recurrence.[34, 35] In canine STS, 
evaluation of differences in outcome between various histologic subtypes has 
been limited by small numbers of STS studied and a lack of consistency in the 
histological classification of STS by veterinary pathologists. In the current 
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study, 2 of 22 (9%) PWT developed local recurrence compared to 21-30% 
recurrence rates for PNST, myxoma and fibrosarcoma. This finding was not 
statistically significant, but this may be due to insufficient numbers of each 
tumour subtype. The possibility that PWTs may be less aggressive than other 
STS subtypes has been suggested by other authors.[4] It should be noted, 
however, that one of the characteristics hallmarks of a STS is the difficulty in 
consistently distinguishing the individual subtypes that make up this group 
using light microscopy alone. The histologic classification of STS subtypes is 
subjective with no clear published guidelines, leading to uncertainty and 
inconsistency between pathologists. The differences in behaviour between 
different STS subtypes in the current study could have been due to the 
pathologist interpreting histological features of aggressive behaviour more 
with some STS subtypes. For example, a neoplasm with greater MI or 
invasiveness may be more likely to be interpreted as a PNST whereas a STS 
that appears histologically benign may be more likely to be interpreted as a 
PWT. Furthermore, while one pathologist may have confidence in their own 
ability to recognise characteristics that can distinguish individual tumour 
subtypes, there is no certainty that a group of pathologists would all agree on 
the same diagnosis. In one study, partial or complete disagreement on 
different diagnostic criteria was reported between two pathologists in over 
50% of cases.[36] Major disagreements in histopathologic diagnosis occurred 
in 19 (37%) cases. In these 19 cases, a second-opinion interpretation 
prompted a change in the recommended staging tests (10 cases), treatment 
plan (19 cases) or prognosis (10 cases). In 21% of cases, a third-opinion 
provided yet another interpretation of the tissue sections, in disagreement 
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with the first two. Nevertheless, if the variance in behaviour of different 
subtypes evident in the current study could be validated and confirmed, this 
would suggest the current single surgical rule for the treatment of all STS 
may not be optimal. It may be that different surgical strategies for different 
STS subtypes could be more appropriate.  
Local tumour recurrence was the most common cause of tumour-related 
death in this study. This is similar to previous studies of canine STS.[1, 6, 7, 
10, 11, 15] As canine STS only rarely spread to other sites in the body systemic 
illness due to the cancer is generally uncommon and the death of most dogs 
with STS is by euthanasia due to the effects of the mass on mobility or other 
impacts on quality of life. Euthanasia may be chosen by clients because the 
costs of surgical management of a STS may exceed the owner’s financial 
limits, or a dog may have concurrent conditions that limit its ability to 
tolerate surgery. Therefore, if recurrence of the tumour occurs after surgery, 
the owners may choose not to proceed with any further treatment. In the 
current study, referring veterinarians were only asked to classify the cause of 
the death in a binary manner, i.e. was the STS a cause of death or not. In 
reality, a decision to perform euthanasia may be influenced by a combination 
of factors, including the presence of concurrent disease conditions. In a 
retrospective study such as this, it can be difficult to truly determine the 
precise cause of death, as the individual characteristics of the decision are not 
evident.   
In the current study, it is worth noting that tumour recurrence did not always 
lead to death, with around a half of dogs with tumour recurrence dying due to 
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non-neoplastic causes. The reasons why some dogs had tumour recurrence 
but did not die of their tumour is difficult to determine because the necessary 
information was not requested in the questionnaire. For example, these dogs 
could have died due to other causes while the tumour was re-growing or the 
tumour may have been kept under control by repeated palliative excision, 
with this fact not being reported by the veterinarian in the questionnaire. 
Cavanaugh and others (2007) reported that repeated marginal (or intra-
lesional) surgery can be effective in maintaining control of recurrent STS,[2] 
and this can be an effective palliative strategy in maintaining control in 
affected dogs. Although the results of the current study suggest that canine 
STS may not result in death even after tumour recurrence, further study is 
required to determine the precise reasons for this. 
There are several limitations to retrospective analyses and long-term follow-
up studies such as this. These limitations include: i) the accuracy and 
reliability of the data collected by questionnaire; ii) the impact of missing or 
absent data; and iii) the deficiencies of margin analysis by histology. 
All of the clinical data used in the current study was obtained by 
questionnaire, with veterinarians asked to provide answers to questions 
many years after the original surgery. These questions included specific 
comment about the characteristics of a tumour, as well as the clinical 
investigations performed and the surgical strategy. In many cases, the 
questionnaire may have been completed by a veterinarian who did not 
perform the original surgery. It is likely that recollections about a patient 
would have required a reliance on clinical notes taken at the time of the 
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original procedure, which may not have contained all of the information in 
the detail requested in the questionnaire. There is also a potential for 
reporting bias, particularly with the description of surgical margin as some 
veterinarians may not want to admit that they had removed tumours with 
surgical margins that were less than those recommended by conventions of 
the time. It is therefore difficult to determine the veracity of the data 
obtained. This means that some of the observations relating to tumour 
characteristics (e.g. size, palpable findings) and the precise surgical margins 
employed may not be accurate.  
For some sections of the questionnaire, veterinarians were unable provide a 
specific response, probably because this information was lacking in the 
clinical records. For that reason, information on tumour size and palpable 
characteristics was unknown for about a third of the cases in the current 
study. The extent of surgical margin used was also unknown in 16% of cases.  
The inclusion criteria for the current study ensured that data on patient 
survival and tumour recurrence was more complete, with no unknown 
observations. For survival analysis, more than 80% of the dogs were known 
to have died during the study period, with a date of death provided from the 
clinical notes. For the remaining animals, it was presumed they were still 
alive, with the censor date for analysis determined to be the last date the dog 
was seen by their veterinarian. However, it is possible these dogs may have 
died at home with their death not reported to their veterinarian, or they had 
been presented to another veterinarian after this period with tumour 
recurrence. This lack of information could have impacted the final analyses. 
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As discussed above, the influence of local tumour recurrence as an actual 
cause of death is also open to question. Owners may make an end-of-life 
decision for their dog for a variety of reasons but may choose to blame the 
recurrence of the cancer even if it was not actually influencing the dog’s 
lifestyle or quality of life directly at that time. 
Because this was a retrospectively performed study, there was no standard 
protocol for the diagnostic examinations performed prior to surgery, and also 
no procedure for consistent follow-up of the patient after surgery. The impact 
of this limitation is mostly influential on the interpretation of metastatic 
disease, both at the time of the original surgery and also as a possible cause of 
death. In the current study, very few dogs had any form of imaging to assess 
the potential for metastatic disease prior to surgery being performed. It is 
likely the significance of this omission on the overall conclusions will be 
minimal, as it is recognised that the incidence of detectable metastasis at the 
time of original diagnosis and surgery of a STS is actually very low. In one 
study, metastatic lesions in the lung were found in less than 7% of grade 1 
and grade 2 STS at the time of presentation for surgery.[37] 
Metastases were identified in 28 dogs in the current study, with a further 12 
dogs having both local recurrence and distant metastatic disease. Metastasis 
was considered to be the cause of death in 24 (60%) of these 40 dogs. The 
accuracy of this figure is questionable, as not every dog in the study was 
subjected to the same degree of post-operative examination. It is possible 
that the incidence of metastasis has been underestimated, because not all 
veterinarians evaluated dogs for metastatic disease following surgery or when 
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euthanasia was performed. Conversely, there is also a chance the incidence of 
metastasis has been overestimated. This is because a full post-mortem 
examination or histologic confirmation of the metastatic lesion was 
performed in less than 10% of cases where metastasis was suspected. In the 
21 of 40 cases where apparent metastatic lesions were discovered on imaging 
studies, the veterinarians completing the questionnaire perhaps made an 
assumption that the prior STS was the primary source. In a small number of 
cases, a presumption of metastatic disease was made simply because the dog 
had developed acute neurological signs and spread of the STS to the brain 
was suspected. Of course, in an elderly patient, there are many potential sites 
of primary neoplasia that may be occult to physical examination, so the 
previous STS may not have been a contributing factor in the newly discovered 
metastatic disease at all. However, when such a patient presents to a 
veterinarian with an acute deterioration in their quality of life, and an end-of-
life decision is being discussed with the owners, it can often be comforting to 
provide an explanation for the sudden demise of their loved pet. The possible 
spread of a cancer that was known to be malignant is well-understood by pet 
owners, enabling them to accept a decision for euthanasia. 
Another important limitation of the current study was the inability to 
complete a histological review of surgical margins. This was often because the 
veterinarian had only submitted a portion of the mass, or the orientation of 
all sections of the tumour processed by the laboratory was not available. This 
lack of evidence may be critical as it is generally recognised that the discovery 
of neoplastic cells extending to tissue margins on histology is an important 
predictor for tumour recurrence.[1, 3, 4, 22, 38-41] In one study, dogs with 
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incomplete margins were more than ten times more likely to experience 
tumour recurrence than dogs where histological margins showed no evidence 
of residual tumour. However, the true impact is actually difficult to quantify. 
In a previous study,[3] incomplete margins were recorded in a third of cases, 
and this finding was associated with significantly shorter disease-free 
intervals (P=0.02). However, in that study, 19 of 34 (56%) of dogs with an 
incomplete histological margin did not develop a recurrence during a median 
follow-up of 2011 days (range 258-3486 days).[Chase D, unpublished data] 
Similar findings have also been reported for human STS. In one large series 
of 2084 patients, 72% of patients with positive margins exhibited no 
recurrence with a median follow up of 50 months.[42]  
Although recognised as a limitation, the lack of standardisation of diagnostic 
and treatment protocols for patients in the current study actually provides a 
valuable insight into the strategies of first opinion veterinarians when dealing 
with a mass on a dog. It is concerning that more dogs had pre-operative 
blood tests performed for anaesthetic purposes than had any investigations 
directly related to understanding identity of the mass about to be operated 
upon. In only 20% of dogs was any attempt made to interrogate the mass 
using fine needle aspiration, and in many of these cases the veterinarians 
acknowledged this test was performed to rule out common tumours such as 
lipoma or mast cell tumour, rather than to identify a potential sarcoma. Less 
than 5% of dogs had a definite diagnosis of sarcoma before surgery. These 
findings are of interest and could be used to assist with the development of 
new treatment recommendations for STS following on from this study. 
Historically, there has been a tendency to encourage veterinarians to pursue 
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aggressive surgical margins for all soft tissue sarcomas in the belief that this 
would translate to improvements in survival and curative outcome. However, 
the results of the current study suggest that it is not the extent of resection 
that is the principle determinant of outcome, with aspects of STS biology (e.g. 
grade, % necrosis etc.) playing a more important role in influencing the 
potential for an individual tumour to recur. It is interesting to note that when 
a STS was suspected from pre-operative biopsy or cytology in the current 
study, there was a tendency for a wider surgical excision to be performed, 
including more dogs undergoing amputation procedures. However, outcomes 
for these patients were no different than the remainder of the population, 
with similar rates of local recurrence. The reason for this is not clear, but it 
does support the notion that some patients can be overtreated for their 
tumour. 
One discovery that was evident from the current study was that many 
veterinarians choose to operate on a mass without any determination of 
whether or not the mass is neoplastic. Surgery was therefore performed 
without any consideration of whether the chosen surgical plan would be 
appropriate for the mass, or whether this plan could actually influence the 
success or failure of the surgery. In humans, such an ‘unplanned’ excision of a 
mass has been shown to detrimentally affect the long-term outcome for that 
patient if it is subsequently found to be a STS on histology. In one study, 
overall disease-free intervals and survival times were reduced for patients 
after an unplanned excision, even when that patient subsequently received 
appropriate curative intent surgery, radiation therapy and chemotherapy for 
their tumour.[39] Comparable veterinary studies are not available; one 
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author reported recurrence rates of 15% after re-excision of an inadequate 
resection of soft tissue sarcoma,[23] but no control population was available 
in this study so the actual benefits of this second intervention are unknown. 
However, reoperation is not always an option for every patient or their 
owner, which emphasises the importance of pre-surgical planning when 
dealing with a potentially malignant mass.  
An explanation for why veterinarians may have an apparent blasé attitude to 
the importance of preoperative interrogation of a mass is that the surgical 
recommendations for many common malignant skin tumours such as STS 
and mast cell tumours are broadly similar.[43-45] Anecdotal observation 
suggests that many veterinary surgeons who do not have a special interest in 
cancer surgery will simply remove a mass along with an unmeasured 
boundary of skin and subcutaneous tissue. The extent of this tissue boundary 
will be influenced by their surgical confidence, and the anatomical limitations 
of the body part involved. This failure by veterinarians in first opinion 
practice to implement surgical guidelines that have been published in 
multiple textbooks is supported by the results of the current study where the 
majority of resection margins were described as marginal or local only. It is 
possible this complacency towards surgical planning is reinforced by the 
types of cases being managed in first opinion practice. Because the majority 
of STS are low-grade, the current study suggests that veterinarians working 
in first opinion practice actually achieve good long-term control in more than 
80% of their patients. This low frequency of treatment failure may thus be 
insufficient to cause a veterinarian to reconsider their normal surgical 
strategy.  
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Importantly, although the results of the current study suggest that the extent 
of resection performed about a STS does not influence the disease-free 
interval or overall survival, this does not imply that surgical margins should 
be reduced in all cases or that wide margins are unnecessary. Because of the 
selection bias that is present it is unsurprising that surgical outcomes are 
better for first opinion veterinarians when they tend to operate on a higher 
proportion of low grade tumours. Current evidence suggests there is a 
spectrum of biologic behaviour of soft tissue sarcomas, with some responding 
favourably to narrow resection margins, whereas others will have a tendency 
to recur, almost in spite of the surgical margins employed. If this were true, 
this would suggest that an interrogation of the STS prior to surgical excision 
could be useful to help identify potential indicators of behaviour and 
therefore the most appropriate surgical margin to use.  
Unfortunately, there is no current consensus on how to determine the best 
margin for each individual tumour. As discussed in the literature review, an 
identical debate on the surgical margins that are required to achieve adequate 
control of STS has occurred in the human literature, without a consensus 
being established.[46-49] One study analysed outcomes for 1261 patients 
with extremity STS over a 20 year period, and concluded that the prognosis 
for patients had not improved at all, indicating that current surgical 
strategies had reached the limits of efficacy.[50] For the human STS surgeon, 
the question of “how much margin is required” has largely been resolved by 
the incorporation of radiotherapy into most standard treatment protocols, as 
evidence demonstrated that the combination of surgery with adjuvant or 
neoadjuvant radiotherapy allowed surgical margins to be safely reduced 
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without compromising tumour control.[51] In veterinary oncology, the 
routine incorporation of radiotherapy is unlikely to become commonplace 
due to the combination of cost, limited access and other logistical reasons. 
Surgery will therefore remain the predominant weapon in the control of 
localised cancer. It will therefore be important to try and develop the ability 
to predict which STS have a higher tendency to recur after surgical excision, 
as this information would greatly help treatment planning. 
In conclusion, the results of the current study pose an important question: 
why does outcome not always improve with an increasing resection margin? 
Some authors have questioned the limitations and reliability of margin 
interpretation in tumour histopathology and it is certainly possible these 
factors do play a significant role in confounding this issue [33, 52]; these 
topics were reviewed in the literature review. However, another important 
consideration is the structure of the pseudocapsule and the tumour 
microenvironment which will influence tumour biology and the potential for 
recurrence after surgery.[53, 54] 
As discussed in the literature review, the pseudocapsule of a STS is a 
renowned feature of this tumour type.[49] While the pseudocapsule may 
appear to be a distinctive fibrous boundary between the tumour and the 
body, it is generally not considered to be an effective barrier to tumour cell 
migration into the surrounding tissues. However, in some tumours the 
fibrous pseudocapsule may actually provide an effective barrier against 
tumour growth and infiltration but this probably holds true for a proportion 
of (mostly) low grade lesions only.[49, 55, 56] In those instances, successful 
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local control could indeed be achieved with excision of the mass including a 
narrow rim of normal tissue; the results of the current study support this 
possibility. However, in higher grade tumours, there is an ill-defined area 
surrounding the pseudocapsule that contains diffusely spread clusters of 
neoplastic cells and a permissive stromal microenvironment. Tumour 
recurrence may be more likely to occur if the plane of surgical excision passes 
through this area. In light of these findings, it was decided that the next 
phase in this thesis would be investigate potential biomarkers that provide 
surrogate evidence of tumours that have a higher tendency to recur after 
surgery. 
3.5 Conclusion 
There were three broad aims for this study. Firstly, to determine the outcome 
for a large cohort of dogs diagnosed with STS that were managed exclusively 
in first opinion practice. The results of this study suggest that outcomes for 
dogs treated with STS in first opinion practice have improved since Bostock 
and Dye published the initial study on this tumour type over 30 years 
ago.[10] While this is likely to be primarily due to the inclusion of dogs from 
primary, rather than referral, veterinary practice it is also possible that 
factors such as earlier patient presentation, better patient selection and a bias 
in reporting patient populations may also have contributed to the better 
prognosis for canine STS observed in the current study. 
The second aim was to evaluate the clinical and histological features of the 
STS to determine if any of these features was correlated with differences in 
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survival times. Results from the current study suggests that important factors 
in predicting prognosis included the age of the patient, tumour size, the 
palpable characteristics of the tumour, grade and the histologic type. These 
features were all found to have prognostic significance for either patient 
survival, tumour recurrence or both.   
The third and final aim was to establish an archive of histological tissue from 
these patients which could be used for novel biomarker discovery as 
described in later chapters of this thesis. This was achieved and these cases 
were used in the following chapters to try and identify more accurate 
biomarkers to help prevent recurrence of a canine STS.  
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Chapter 4: 
Prognostic markers in soft tissue sarcoma: an 
immunohistochemical study 
4.1 Introduction 
he results of the previous chapter generated an important 
question: why does the outcome for dogs with soft tissue 
sarcoma (STS) not always improve with an increasing 
resection margin? It would seem reasonable that the more 
tissue removed around the tumour the less likely it should be for that tumour 
to recur. However, the previous study did not identify a statistical correlation 
between the extent of the resection margin and local recurrence (p=0.8), 
suggesting that factors other than the surgical margin may have an influence 
on the outcome. 
While the evidence from the previous chapter suggests that some STS could 
be safely resected with smaller margins without increasing the risk of 
recurrence, the data also suggested that wider surgical margins may still be 
required to obtain adequate local control for other tumours. It is likely that 
the appropriate resection margin is variable between different STS, with 
certain aspects of tumour biology influencing the potential for recurrence 
after surgery.[1, 2] Given this variance, it would be helpful to identify features 
within a STS that could enable a surgeon to determine if an individual 
T 
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tumour requires narrower or wider surgical margins to prevent recurrence 
after surgery. 
For a microscopic cluster of cancer cells to progress in size to a clinically 
relevant neoplasm, it must have established a relationship with the host.[3, 
4] One of the most important interactions that must occur between an 
emerging tumour and the body includes the development of a supporting 
network of blood vessels, a process known as angiogenesis.[5] Sustained 
angiogenesis is recognised as one of the hallmarks of cancer,[3] and is known 
to play an important role in tumour progression and the development of 
metastasis.[5] A variety of pro-angiogenic factors such as vascular endothelial 
growth factor (VEGF), fibroblast growth factor (FGF), platelet derived growth 
factor (PDGF), placental growth factor, transforming growth factor-β (TGF-
β) and others have been shown to not only mediate the migration of 
microvascular endothelial cells, but to encourage their proliferation and 
formation into microvessels about the tumour.[6] 
For the current study, two important angiogenic molecules – VEGF and 
decorin - were selected for investigation as possible prognostic markers in 
canine STS. 
Vascular endothelial growth factor is considered to be a major driver of 
tumour angiogenesis [8]. Increased VEGF expression is reported to be a 
negative prognostic factor for a wide range of tumour types in humans, 
including breast cancer,[7] colorectal cancer,[8] ovarian carcinoma,[7] renal 
and bladder carcinoma,[9, 10] gastric carcinoma,[11, 12] osteosarcoma,[13] 
soft tissue sarcoma[14-17] and malignant effusions.[18, 19] In humans with 
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STS, higher serum concentrations of VEGF have also been correlated with an 
increased development of local recurrence and metastasis.[20] In the dog, 
VEGF has been studied in several canine tumours, including nasal 
tumours,[21] mast cell tumours,[22, 23] thyroid tumours,[24] 
haemangiosarcoma,[25, 26] central nervous system tumours,[27] mammary 
tumours,[28, 29] and soft tissue sarcoma.[30-33] For canine STS, positive 
VEGF immunostaining was identified in about 65% of tumours,[32] but a 
correlation with survival data has not been performed. In another canine 
study, the serum concentration of VEGF was shown to reduce following 
excision of the STS, suggesting the tumour was contributing directly to the 
increased VEGF production.[33] 
Decorin is an important extracellular matrix protein belonging to the small 
leucine rich proteoglycan family.[34-36] Decorin interacts with several 
growth factors including members of the TGF-b family, FGF, tumour necrosis 
factor-alpha (TNF-a) and PDGF.[35] Decorin prevents angiogenesis in a 
variety of tumour cell lines,[37] and tissue levels have been shown to 
correlate inversely with the extent of vascularisation in human vascular 
tumours.[38] Decorin is primarily synthesised by fibroblasts located in the 
stroma, and production of decorin by a neoplastic cell appears to be 
extremely rare.[39] However, tumour cells have been shown to produce 
soluble factors that can actively suppress the production of decorin by 
stromal myofibroblasts.[40] Down-regulation of decorin expression in 
tumours has been demonstrated in several human cancers including breast, 
endometrial, ovarian and lung.[35, 36, 41-44] Epigenetic regulation of 
decorin gene expression has also been demonstrated in colon cancer.[42] For 
Chapter 4:  Immunohistochemical study – page 118 
humans with STS, lower decorin concentrations within the tumour are 
associated with a shorter disease-free (p<0.05) and overall-survival rates 
(p<0.05).[45] There have been no published studies on the influence of 
decorin and cancer in the dog.  
The aim of the current study was to use immunohistochemistry to identify 
whether these two stromal proteins – VEGF and decorin - are present within 
canine STS that have been previously resected. Analysis was then performed 
to determine if immunostaining characteristics were associated with different 
rates of tumour recurrence and/or patient death. It was hypothesised that 
increased immunostaining for VEGF within the tumour would reduce patient 
survival times and increase the rate of tumour recurrence following surgical 
resection. Conversely, high levels of decorin within the tumour was 
hypothesised to improve survival times and reduce recurrence rates of STS 
after surgery. 
4.2 Materials and Method 
4.2.1 Patient selection 
This immunohistochemical study was performed using 100 cases selected 
from the tissue archive of 350 formalin-fixed paraffin-embedded (FFPE) 
specimens that had been established in the previous chapter. Cases were 
excluded from selection if the grade of the tumour or status of local 
recurrence was unknown. Because the archived population was known to be 
heavily biased towards grade 1 tumours, stratified random sampling was used 
to ensure that the cohort of 100 patients selected for immunohistochemical 
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study would contain a proportion of grades roughly equivalent to the cases 
where local tumour recurrence developed within the parent population. This 
was achieved by firstly determining the proportion of local recurrence that 
occurred for grade 1, grade 2 and grade 3 STS within the parent population, 
after the excluded cases were removed. This calculation was then used to 
decide the number of cases from each grade that should be selected from the 
parent population to create a total cohort of 100 dogs. The random function 
within R (R v 3.2.3, R Development Core Team) was used to select patients 
from each grade, based on these previously calculated proportions. 
Clinical details about each STS had been determined by questionnaire, as 
detailed in the previous chapter. Follow-up information available for each 
tumour included the size, location and palpable characteristics (fixed or 
mobile), as well as the current status of the dog including the period in days 
until the development of local recurrence, metastasis, or death. Surgical 
resection margins were defined as marginal (neoplastic cells were visible 
adjacent to the margins), local (less than 3cm), wide (3cm or more) or 
amputation. If this information was not available in the clinical records, the 
resection margin was defined as unknown. The histological diagnosis and 
grading characteristics, including information on the degree of 
differentiation, percentage necrosis and mitotic rate of each STS, had been 
previously reviewed by a single pathologist according to published 
guidelines.[32] 
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4.2.2 Immunohistochemistry 
Tissue sections (5µm) were obtained from each tumour and mounted onto 
positively charged glass slides. Sections were dewaxed in xylene and 
rehydrated in a graded alcohol series and equilibrated in phosphate buffered 
saline. Antigen retrieval was performed in a decloaker (Biocare Medical, 
Pacheco, CA) at 100℃ for either 20 mins (VEGF) or 2 mins (decorin) in a 
buffer solution (EnVision™ FLEX Target Retrieval Solution (high pH), Dako 
Australia Pty. Ltd). Immunohistochemistry was then performed using a 
Sequenza Immunostaining Center (Thermo Fisher Scientific, UK). 
Endogenous peroxidase activity was blocked using Peroxidase-Blocking 
Reagent (EnVision™ FLEX, Dako Australia Pty. Ltd) for 15 mins. Tissue 
sections were incubated overnight with a 1:300 dilution of mouse antihuman 
VEGF polyclonal antibody [0.33µg /ml] (VEGF (A-20) sc-152: Santa Cruz 
Biotechnology Inc, Dallas, TX) or a 1:400 dilution of mouse antihuman 
decorin polyclonal antibody [0.25µg/ml] (Anti-DCN, Sigma-Aldrich Co, St 
Louis, MI). The specificity of these antibodies for the canine proteins has 
been previously reported so validation of these antibodies was not 
required.[46-49] Antibody detection was performed using diaminobenzidine 
(DAB) (Dako Australia Pty). Positive and negative controls were used for 
each batch of slides. Positive control tissues for VEGF were FFPE sections of 
canine haemangiosarcoma; for decorin, sections of skeletal muscle were 
used. For negative control tissues, the primary antibody was omitted. 
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4.2.3 Evaluation of immunostaining 
Each slide was assessed by light microscopy and immunostaining of either 
VEGF or decorin was determined. Immunostaining was only evaluated in 
areas of well-preserved tissue morphology and away from areas of necrosis, 
tissue edges and other artifacts. Two investigators reviewed all slides 
independently and were blinded to other features of the tumour. Where 
disagreement was present, consensus was achieved by joint review. 
Immunostaining using anti-VEGF antibodies was scored using a modification 
of a previously reported method (Figure 4.1) [14] Briefly, tumours were 
scored based on the proportion of cells showing evidence of VEGF  
Figure 4.1: 
Grading scale of immunostaining for vascular endothelial growth factor (VEGF). A 
low VEGF score was assigned if less than 75% of cells were immunostained. For a 
high VEGF tumour, more than 75% of the cells showed positive immunostaining.  
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immunostaining across 5 non-adjacent and non-overlapping fields. A tumour 
was classified as having “low VEGF” if less than 75% of cells were 
immunostained, whereas a tumour in which more than 75% of cells showed 
immunostaining was classified as having “high VEGF”. Where distribution 
was not homogenous across the tumour fields, the highest score observed 
was assigned. 
The presence of decorin was determined by evaluating the distribution of 
immunostaining within the tumour (Figure 4.2). A “type 1” pattern was 
assigned when decorin immunostaining was confined to the peritumoural  
Figure 4.2: 
Grading scale for decorin immunostaining. A type 1 pattern was assigned when 
decorin immunostaining was confined to the peri-tumoural margins only and no 
staining was visible within the tumour itself. A type 2 pattern was applied to cases 
where isolated islands of immunostained stromal tissue penetrated the tumour at 
various locations. For a type 3 pattern, decorin-labelled stroma saturated the entire 
tumour and intertwined closely about individual cells. 
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margins. A “type 3” pattern indicated that decorin-labelled stroma saturated 
the entire tumour and intertwined closely about individual cells while a “type 
2” pattern was applied to cases where isolated islands of immunostained 
stromal tissue penetrated the tumour at various locations. When a STS 
showed little to no immunostaining within the tumour, the presence of 
intense immunostaining in the peri-tumoural tissues provided a good 
positive internal control.  
4.2.4 Statistical evaluation 
All statistical analyses were performed using SPSS Statistics (SPSS, version 
26, IBM corporation). Local recurrence and death due to the effects of the 
tumour were defined endpoints of the study. Survival time was defined as a 
dog dying or being euthanased due to either local recurrence or metastasis. 
The disease-free interval was defined as the number of days from surgery 
until local recurrence was identified by the veterinarian. Any cases with an 
unknown finding within the category being analysed were not included in the 
statistical evaluation of that characteristic.  
Chi-square analysis using Fisher’s Exact test was performed to evaluate 
variations in immunostaining according to age, sex, tumour size, location, 
palpable characteristics, surgical excision margins, tumour grade, presence of 
necrosis and mitotic index.  
The Kaplan-Meier method was used to compare survival times to assess the 
significance of association between the immunostaining characteristics of a 
tumour with VEGF and decorin with the outcome measures of local 
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recurrence and tumour-related death. Univariate Cox proportional hazard 
analysis was used to assess the association between immunostaining 
characteristics and other clinically relevant variables described above against 
both survival time and disease-free interval. Hazard ratios (HR), 95% 
confidence intervals (CI) and their corresponding p-values were calculated. A 
value of p<0.05 was considered significant.  
Immunostaining using both antibodies were also used to classify the tumours 
into six groups by combining prognostic scores from the most unfavourable 
to the most favourable, as follows: VEGF-high & decorin type 1; VEGF-high & 
decorin type 2; VEGF-high & decorin type 3; VEGF-low & decorin type 1; 
VEGF-low & decorin type 2; and VEGF-low & decorin type 3. Statistical 
analyses were repeated as above to determine differences between these six 
groups of immunostaining characteristics.  
4.3 Results 
4.3.1 Patient selection and demographics 
From the original patient archive of 350 patients, 17 were excluded as local 
recurrence was unknown. A further 2 patients were excluded as tumour 
grade was undetermined. This left a population of 331 dogs. Within this 
remaining population, local recurrence occurred in 72 (22%) patients, 
comprising 42 (58%) in grade 1, 24 (33%) in grade 2 and 6 (8%) in grade 3. 
Using these proportions, 22 (22%) patients were selected from the parent 
population where local recurrence was recorded, comprising 12 (55%) grade 
1, 7 (32%) grade 2 and 3 (13%) grade 3 STS. A further 78 (78%) patients were 
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then selected from the parent population where local recurrence did not 
occur, comprising 45 (58%) grade 1, 26 (33%) grade 2 and 7 (9%) grade 3 
STS, creating a total cohort of 100 patients.  
4.3.2 Determination of Immunostaining characteristics 
Immunostaining for VEGF was interpretable in 82 dogs with STS. In the 
remaining 18 cases, artefactual defects or the lack of positive internal controls 
prevented interpretation. Details of the tumours included in this group are 
outlined in Table 4.1. Within this cohort, tumour size (p=0.04), palpable 
characteristics of the tumour p=0.004) and the development of local 
recurrence (p<0.0001) all had a significant influence on survival on Kaplan-
Meier analysis. However, tumour grade and the histological diagnosis of the 
tumour were not influential on survival outcome. Only the palpable 
characteristics of the tumour were influential on the disease-free interval (p= 
0.03). 
The resection margins obtained about the tumour were not found to 
significantly influence either survival (p= 0.2) or local tumour recurrence (!2 
= 7.0, p= 0.07) Because amputation could bias the potential for local 
recurrence, cases managed by amputation were removed from this analysis. 
In this remaining cohort, local tumour recurrence occurred in 12 of 26 (46%) 
of cases managed by marginal excision, 10 of 41 (24%) of cases managed with 
local excision, and 1 of 4 (25%) of cases managed by wide excision. However, 
resection margins were still not significantly associated with local recurrence 
(!2 = 3.5, p= 0.17). Of the 82 tumours where immunostaining could be  
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Table 4.1: 
Results from chi-square analysis for different tumour characteristics and VEGF 
immunostaining  
 VEGF (n=82) 
 Low High  
n (%) N = 43 N=39 P value 
Sex    0.65 
Female 49 (60%) 27 22  
Male 33 (40%) 16 17  
Neutered    0.13 
No 45 (55%) 20 25  
Yes 37 (45%) 23 14  
Tumour location    0.75 
Head 4 (5%) 2 2  
Trunk 27 (33%) 16 11  
Limb 51 (62%) 25 26  
Size    0.31 
<1cm 2 (2%) 1 1  
1-5cm 45 (55%) 26 19  
>5cm 21 (26%) 8 13  
unknown 14 (17%) 8 6  
Palpable    0.15 
Discrete 32 (39%) 21 11  
Firmly adherent 45 (55%) 20 25  
Unknown 5 (6%) 2 3  
Grade    0.53 
1 46 (56%) 25 21  
2 27 (33%) 12 15  
3 9 (11%) 6 3  
Degree of resection    0.0003 
Marginal 26 (32%) 5 21  
Local 41 (50%) 30 11  
Wide 4 (5%) 3 1  
Amputation 7 (8%) 4 3  
Unknown 4 (5%) 1 3  
Diagnosis    0.11 
Fibrosarcoma 20 (24%) 7 13  
Myxoma 1 (1%) 0 1  
Peripheral nerve sheath 
tumour 
52 (63%) 29 23  
Perivascular wall tumour 9 (11%) 7 2  
 
Tumour cause of death    0.0001 
No 55 (67%) 37 18  
Yes 27 (33%) 6 21  
Local recurrence    0.0001 
No 56 (68%) 39 17  
Yes 26 (32%) 4 22  
 
Survival Time  days days days  
Minimum 117 117 168  
Maximum 2114 2114 1983  
Mean 907 961 847  
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interpreted, 43 (52%) tumours were graded as low VEGF and 39 (48%) were 
high VEGF. There was a statistically significant association between VEGF 
immunostaining and resection margins, with 21 of 26 STS that had a 
marginal excision being classified as high VEGF (p<0.0001). All 5 of the STS 
that had more than 50% necrosis (score 3) had high immunostaining for 
VEGF. This compares with 12 of 23 (52%) and 22 of 54 (42%) STSs that had 
up to 50% necrosis (score 2) and no necrosis (score 1) respectively.  
There was no association between VEGF immunostaining and the following 
characteristics: the sex (p=0.7) or neuter status of the dog (p=0.1), tumour 
location (p=0.7), tumour size (p=0.3), palpable characteristics (p=0.1), 
tumour histologic type (p=0.4), grade (p=0.5) or mitotic index (p=0.2). 
Having a low VEGF immunostaining pattern was significantly associated 
with a longer overall survival time (c2 = 13.0, p = 0.0003) (Figure 4.3). The  
Figure 4.3: 
Kaplan Meier graph of survival time for 82 patients with soft tissue sarcoma based 
on VEGF immunostaining (low and high). 
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median survival time for patients with a low VEGF could not be calculated as 
more than 50% of the dogs remained alive at the close of the study. Overall, 
85% of patients with low VEGF remained alive more than 2 years after 
surgery, with 80% surviving 5 years or more. This contrasts with patients 
with high VEGF, where the proportion surviving at 2, 3 and 5-year intervals 
was 75%, 50% and 7% respectively. The median survival time for patients 
with a high VEGF was 1294 days (95% CI 774 – 1813 days). Having a high 
VEGF tumour increased the risk of death from the STS by a factor of more 
than four (HR 4.6 (95% CI 1.8-11.5, p = 0.001). On multivariate analysis, only 
high VEGF (HR 8.6, p<0.0001, 95%CI =2.8-26.4) was found to be associated 
with survival. 
A STS with high immunostaining for VEGF was also significantly more likely 
to recur after surgery; (56% vs. 9%, p <0.001) (Figure 4.4). High VEGF 
immunostaining tumours were 7.3 times (95% CI 2.5 – 21.4, p < 0.001) more 
likely to recur than tumours with low VEGF. More than 90% of patients with 
a low VEGF STS remained disease-free at 2-, 3- and 5-yrs, compared to 
51%,25% and 3% respectively of dogs with high VEGF STS. 
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Figure 4.4: 
Kaplan Meier graph of disease-free interval for 82 patients with soft tissue sarcoma 
based on VEGF immunostaining (low and high). 
 
4.3.3 Decorin 
Decorin immunostaining could be evaluated in 83 cases. In the remaining 17 
cases, artefactual defects or the lack of positive internal controls prevented 
interpretation. Demographic details of the tumours included in this group are 
outlined in Table 4.2. From Kaplan-Meier analysis, tumour size (p=0.05), 
palpable characteristics of the tumour (p=0.003) and the development of 
local recurrence (p<0.0001) all had a significant influence on survival within 
this cohort. However, tumour grade and the histological diagnosis of the 
tumour were not influential on survival outcome. There was no association 
between resection margins and survival or local tumour recurrence. 
Of the 83 STS, 27 (32%) had a type I pattern, 24 (29%) a type 2 pattern, and 
32 (39%) a type 3 pattern. Twenty-five of the 50 STS that were less than 5cm  
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Table 4.2: 
Results from chi-square analysis for different tumour characteristics and decorin 
immunostaining  







n (%) n n n P value 
Sex     0.07 
Female 47 (57%) 21 13 13  
Male 36 (43%) 6 11 19  
Neutered     0.9 
No 40 (48%) 11 12 17  
Yes 43 (52%) 16 12 15  
Tumour location     0.02 
Head 5 (6%) 1 1 3  
Trunk 28 (33%) 16 3 9  
Limb 51 (61%) 11 20 20  
Size     0.03 
<1cm 0 0 0 0  
1-5cm 50 (60%) 13 12 25  
>5cm 21 (25%) 8 10 3  
unknown 12 (16%) 6 2 4  
Palpable     0.6 
Discrete 31 (37%) 6 8 17  
Firmly adherent 45 (54%) 18 13 14  
Unknown 7 (8%) 3 3 1  
Grade     <0.0001 
1 46 (55%) 6 11 28  
2 28 (34%) 13 12 3  
3 9 (11%) 8 1 1  
Degree of resection     0.3 
Local 68 (82%) 21 20 27  
Wide 8 (10%) 3 4 1  
Amputation 7 (8%) 3 0 4  
Diagnosis     0.06 
Fibrosarcoma 22 (26%) 11 2 9  
Myxoma 1 (1%) 0 0 1  
Peripheral nerve sheath 
tumour 
52 (63%) 16 19 17  
Perivascular wall tumour 8 (10%) 0 3 5  
 
Tumour cause of death     0.02 
No 61 (73% 15 18 28  
Yes 22 (27%) 12 6 4  
Local recurrence     0.55 
No 62 (76%) 19 17 26  
Yes 21 (24%) 8 7 6  
 
Survival Time   days days days  
Minimum 117 126 163 117  
Maximum 1983 1993 1983 1900  
Mean 884 928 877 882  
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in diameter had a type 3 decorin pattern and this pattern was significantly 
more frequent in these smaller tumours than in STS that were greater than 
5cm in diameter (3 of 21 (14%); p=0.02). Additionally, there was a significant 
association between the decorin immunostaining pattern and the extent of 
necrosis within the STS. Twenty-seven of 45 (60%) tumours that had low 
levels of necrosis displayed a type 3 pattern whereas in tumours that had 
>50% necrosis, all 5 displayed a type 1 pattern suggesting negligible decorin 
presence within the tumour.  
The distribution of decorin immunostaining patterns was significantly 
different depending on the location of the STS (p = 0.03). For tumours of the 
trunk, 16 of 28 (57%) had a type 1 immunostaining pattern, compared to 1 of 
5 (20%) and 11 of 51 (22%) of tumours of the head and limb respectively.  
None of the PWT had a type 1 immunostaining pattern, compared to 10 of 20 
(50%) fibrosarcoma and 17 of 53 (32%) PNST. This difference was 
statistically significant (p = 0.05). 
There were no significant associations between the decorin immunostaining 
pattern and the sex of the dog (p=0.07), the neuter status of the dog (p=0.9), 
the palpable characteristics of the STS (p=0.6), the resection margins (p=0.3) 
or the mitotic index within the STS (p=0.1).  
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Figure 4.5: 
Kaplan Meier graph of survival time for 83 patients with soft tissue sarcoma based 
on decorin immunostaining pattern (types 1 and 2 and 3) 
 
For STS with a type 1 pattern of decorin immunostaining, 12 of 27 (44%) dogs 
died due to their STS, compared to 6 of 24 (25%) and 4 of 32 (12.5%) with 
type 2 or 3 patterns, respectively, a finding that was statistically significant. 
(!2 = 7.7, p=0.02) (Figure 4.5). 
Local recurrence of the STS occurred in 8 of 21 (38%) with a type 1 pattern of 
decorin immunostaining, 7 of 21 (33%) and 6 of 21 (29%) with type 2 or 3 
patterns, respectively. This was not statistically significant (p=0.5) (Figure 
4.6). 
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Figure 4.6: 
Kaplan Meier graph of disease-free interval for 83 patients with soft tissue sarcoma 
based on decorin immunostaining pattern (types 1, 2 and 3). 
 
The decorin immunostaining pattern was significantly correlated with the 
histological grade of the STS with low-grade tumours more likely to have a 
type 3 pattern and high-grade tumours more frequently having a type 1 
pattern (p <0.001) (Figures 4.7). 
Figure 4.7: 
Distribution of decorin immunostaining pattern according to tumour grade. Low 
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4.3.4 Combined VEGF and Decorin 
There were 71 cases for which both VEGF and decorin immunostaining could 
be interpreted (Table 4.3). Decorin and VEGF immunostaining were not 
correlated (p=0.9) (Figure 4.8). When the favourable and unfavourable 
extremes of the combined scores were compared, a STS with both a high 
VEGF and type 1 decorin distribution had a significantly lower MST than a 
dog with a STS with a favourable prognostic combination (i.e. low VEGF and 
type 3 decorin distribution) (1031 days vs. 1924 days, p <0.001). No tumour-
related deaths occurred in 18 dogs with a low VEGF / type 3 decorin 
combination, compared to 6/12 (50%) deaths in STS with a high VEGF / type 
1 decorin combination (log rank 16.7, p = 0.005). Similarly, only 1/17 (6%) 
STS with a low VEGF / type 3 decorin combination recurred, compared to 
6/12 (50%) with a high VEGF / type 1 combination (log rank 22.3, p <0.001; 
Figure 4.9). 
Figure 4.8: 





















Univariate cox-regression analysis for survival and local recurrence for patients based on VEGF, decorin and combined 
immunostaining groups. 
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Figure 4.9: 
Kaplan Meier graph of survival time for 73 patients with soft tissue sarcoma based on 6 
groups of combined VEGF and decorin immunostaining levels. The extreme prognostic 
groups (H1 and L3) are highlighted; survival times between these two groups are 
significantly different (1031 days vs. 1924 days, p <0.001) 
 
4.4 Discussion 
In the current study, a significant association was identified between high 
levels of VEGF within the tumour and higher rates of local recurrence of the 
STS after surgery. Additionally, high VEGF immunostaining within the STS 
was also associated with a four times higher risk of death from the tumour. 
This is the first study to demonstrate an association between VEGF levels and 
prognosis in canine STS. Only one other study investigating VEGF and canine 
STS has been performed.[32] In that study, VEGF immunostaining was 
observed in about 65% of STS, but the presence of VEGF was not investigated 
as a possible prognostic marker. In human STS, two studies have reported a 
positive correlation between increased VEGF expression and higher tumour 
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grade, but were unable to confirm an association with clinical outcome due to 
insufficient data.[50, 51] However, increased VEGF expression has been 
shown to be a negative prognostic factor for a range of other tumour types in 
both dogs and humans.[12, 18, 21, 23, 48, 50, 52-57] 
The current study also revealed that reduced decorin within a canine STS was 
significantly associated with an increased chance that the dog will 
subsequently die due to the STS. While no statistical association was found 
between decorin pattern and local recurrence, this may have been due to the 
small patient numbers in this study. Decorin has not previously been 
investigated in canine tumours. There are also limited prognostic studies to 
evaluate the role of decorin in humans with STS, although the ability for 
decorin to influence the behavior of human cancer has been reported in 
several in vitro and in vivo studies.[37, 39, 43, 44, 58] In one study on 
human STS, decorin was assessed in 85 different tumours by real-time 
quantitative PCR and immunohistochemistry.[45]  In that study, decorin 
expression was shown to vary according to histologic type; benign tumours 
such as lipoma and neurofibroma expressed higher quantities of decorin than 
more malignant types (liposarcoma and peripheral nerve sheath tumour). 
Low levels of decorin within the tumour were also associated with reduced 
disease-free (p<0.05) and overall-survival rates (p<0.05). In addition, 
decorin expression in recurrent or metastatic STS was lower than in the 
primary lesions, supporting a hypothesis that these secondary tumours have 
a more aggressive phenotype than the original primary tumour.[45] 
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In the current study, the prognostic potential of combining the 
immunostaining results of both VEGF and decorin was also evaluated. When 
VEGF and decorin immunostaining classifications were combined, the ability 
to identify subsets of tumours with very favourable or very unfavourable 
outcomes was improved. Thus, a STS with a combination of poor prognostic 
scores (i.e. high VEGF and type 1 decorin distribution) was more likely to 
recur or cause death of the dog compared to a STS with the most favourable 
combination of prognostic scores (i.e. low VEGF and type 3 decorin 
distribution). This finding supports a strategy where a suite of different 
prognostic markers could be used to better predict individual tumour 
behavior than relying on one single attribute alone.  
The findings of the current study suggest that both VEGF and decorin can 
profoundly influence the behaviour of a STS. Both VEGF and decorin are 
extracellular matrix [ECM] proteins and these, and other ECM proteins, have 
been shown to be under- or over-produced in a number of different cancer 
types,[59-61] with varying influence on the progression of the tumour. To the 
author’s knowledge, this is the first time that the presence of these proteins 
has been evaluated for their role as potential biomarkers in canine STS.  
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor and 
has been described as an essential growth factor for vascular endothelial 
cells.[62] VEGF, along with a variety of other angiogenic factors such FGF, 
PDFG, placental growth factor, TGF-β and others, mediates the migration of 
microvascular endothelial cells, but also encourages their proliferation and 
formation into microvessels.[6] While the growth of a new vascular system is 
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fundamental for embryonal development and growth,[62] formation of new 
blood vessels is unusual in the normal adult animal. In an adult, angiogenesis 
will occur in the female reproductive system during ovulation, menstruation, 
and the formation of the placenta, but otherwise will only occur during 
wound healing or organ regeneration. However, angiogenesis is a vital 
process in the evolution of a tumour: if a neoplastic growth is to proceed 
beyond a 2mm cellular mass, it must develop its own vascular supply. This 
requires cooperation from the body’s own resources.[5] As early as 1971, it 
was proposed that a tumour could be maintained in a dormant state simply 
by inhibiting angiogenesis.[5] However, it took another 25 years before the 
mechanisms that enabled this ‘angiogenic switch’ to occur were 
described,[63] with identification of the molecules involved in this process 
reported in 1997.[64] 
In the current study, a significant association between the extent of necrosis 
within the STS and both increased VEGF and reduced decorin 
immunostaining was found. Soft tissue sarcoma with high levels of necrosis 
were found to have a less decorin immunostaining while tumours with low 
levels of necrosis were more likely to show type 3 decorin immunostaining. 
Smaller tumours were also more likely to have type 3 decorin 
immunostaining than larger tumours. Because necrosis is an indicator of a 
tumour that is poorly viable and larger tumours are more likely to have 
grown beyond the capacity of their innate blood supply, it seems reasonable 
to presume that the impact of hypoxia and its influence on angiogenic 
mechanisms is a probable explanation for these changes. The two ECM 
proteins examined in the current study - VEGF and decorin - were chosen 
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due to their known influence on angiogenesis.[36, 37, 62] Angiogenesis is 
controlled by a complex balance between stimulatory and inhibitory signals 
for blood vessel growth.[65] The influence that these two proteins have on 
angiogenesis are described in more detail below. 
Stimulatory: Vascular endothelial growth factor is implicated as one of the 
major stimulatory factors in tumour angiogenesis.[62, 65] Increased 
expression of VEGF by tumour cells is influenced principally by hypoxia, but 
a number of other growth factors (e.g. TNF-a, TGF-b, epidermal growth 
factor (EGF) and PDGF, COX-enzymes) and oncoproteins (including ras, 
HER2, EGF and bcr-abl) are also involved in inducing VEGF expression. A 
tumour may also develop autonomous secretion of VEGF by epigenetic or 
DNA mutational change.  
Inhibitory: Decorin is considered to inhibit angiogenesis by suppressing the 
production of endogenous VEGF by the tumour cell. Decorin is known to 
bind strongly with several growth factors within the ECM, including the TGF-
b family, FGF, TNF-a and PDGF, amongst others.[35] Normal tissue levels of 
decorin allow the ECM to act like a sponge for these vital signaling molecules, 
creating a concentration gradient and providing some regulation to their 
availability for cell-signalling.[66] It follows that less decorin in the tissues 
will lead to higher concentrations of VEGF, TGF-b, FGF and PDGF being 
available in the extracellular environment, allowing for increased interactions 
with cellular receptors.[45] One study evaluated the difference in decorin 
expression between benign (i.e. haemangioma) and malignant vascular 
tumours (i.e. Kaposi's sarcoma and angiosarcoma).[38] In malignant 
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tumours, no decorin mRNA expression or immunoreactivity was detected 
while it was abundantly present in the benign tumours, particularly in the 
connective tissue stroma surrounding the clusters of intratumoural blood 
vessels. There were also fewer blood vessels present in the benign tumours. 
These results support the conclusion that decorin possesses a suppressive 
effect on tumour angiogenesis. 
A reason why varying levels of these ECM proteins may influence the 
potential for local tumour recurrence may be explained by their potential 
influence on the tumour microenvironment. Detection of these proteins may 
identify a tumour where the influences of the tumour microenvironment have 
enabled a tighter assimilation with the local tissues than others, with this 
integration enabling some tumour cells to persist or survive within the 
residual tumour bed after surgery. Reasons to explain why variable levels of 
VEGF and/or decorin could contribute to the different rates of recurrence or 
patient survival observed in the current study are discussed below. These 
include 1) the wider diffusion of tumour cells beyond the gross boundary of 
the STS and 2) the development of cellular dormancy.  
Wider infiltration of tumour cells: One reason to explain why a tumour 
may recur after resection of the grossly visible mass is that tumour cells have 
migrated into the peripheral tissues and escape surgical extirpation. The 
persistence of microscopic clusters of tumour cells within the wound bed is a 
commonly recognised cause for tumour recurrence. In human STS, 
microscopic tumour nodules have been identified between 1 cm and 4 cm 
from the main mass in 30% of cases, with recurrence almost 7-times more 
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common when these microscopic tumour foci were observed.[67] Similar 
findings have been reported for other types of tumour.[1, 67-69] In dogs, 
satellite lesions have been observed in 6% of low-grade STS, with tumour 
cells extending between 2-17mm from the tumour boundary.[70] 
The impact of varying levels of VEGF and decorin identified in STS in the 
current study may reflect their influence on tumour cells being able to 
infiltrate beyond the main tumour mass. Studies of human STS have shown 
that high expression of VEGF receptor-3 (VEGFR-3) is an independent 
prognostic indicator of reduced disease-free survival in human patients with 
STS, even when the tumour has been widely resected with clean histologic 
margins.[57] Because the VEGFR-3 pathway is principally associated with 
increased lymphangiogenesis rather than angiogenesis,[57] it is possible that 
tumours with high VEGFR-3 have increased development of lymphatic 
pathways that enable the increased distribution of cells beyond the local 
tumour site. In addition, abundant expression of decorin is thought to lead to 
a more organised ECM, with the strong stromal matrix creating a physical 
barrier against tumour cell metastasis.[34] Conversely, low levels of decorin 
in a tumour are thought to create a more fragile matrix structure that 
facilitates cell migration, which would enable increased local invasion and 
metastasis.[36] This evidence raises the possibility that the increased rates of 
recurrence and reduced survival observed in STS with high VEGF and low 
decorin levels in the current study could be due to a wider distribution of 
satellite cells radiating beyond the immediate circumference of the tumour. If 
there is an increased proportion of microscopic satellite lesions persisting in 
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the wound bed after surgery, this may contribute to an increased rate of 
recurrence or metastasis after surgery. 
Persistence of dormant tumour cells: Dormancy is an innate ability 
within all living cells that enables survival in the face of unfavourable 
environmental conditions, particularly hypoxia. Diffusion of oxygen from the 
blood supply is limited to a distance of between 100 to 200µm; therefore, as a 
tumour increases in size the expanding cluster of cells will become more and 
more isolated from the innate blood supply. For a cancer cell to survive in 
this increasingly hypoxic environment, it must either drive angiogenesis to 
increase the delivery of oxygen and nutrients to the growing tumour, or adapt 
its metabolism to allow continued survival in the suboptimal conditions.[71] 
One of the most potent stimulators for VEGF activity in the tissues is local 
hypoxia.[62, 64] In Chapter 3, it was shown that larger STS, and tumours 
with higher levels of necrosis were associated with shorter disease-free 
intervals and survival times. It is therefore possible that the high VEGF 
detected in STS in the current study is simply a surrogate indicator for a 
tumour that has been more hypoxic during its development. As discussed in 
Chapter 3, hypoxia will develop within a growing tumour if it is unable to 
develop the necessary vascular supply to support its continued expansion. 
Across the entire tumour mass, there will be heterogeneity with some areas 
attaining adequate vascularisation, and other areas where oxygen and 
nutrient delivery remains poor. In a hypoxic environment, generation of 
hypoxia inducible factor (HIF-1a) within the affected cell will drive 
metabolism towards anaerobic glycolysis, with increased production of lactic 
acid.[72, 73] It has been shown that cells derived from a persistently acidic 
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environment are often in a dormant state, with cell proliferation held in G0 
phase by reduced CDK-1 activity. Such dormant cells are known to be more 
immune to destruction by chemotherapy and radiation therapy. Thus, while a 
persistently hypoxic tumour microenvironment will undoubtedly lead to a 
high percentage of cellular death and tumour necrosis in sections of the 
tumour, it will also favour a genotype that is more resistant to immune 
destruction and more capable of surviving in a dormant state. This evidence 
suggests that the increased rate of recurrence in tumours with high VEGF 
may be because these STS harbour a higher concentration of dormant cells 
within the peri-tumoural environment. These dormant cells may survive 
within the tumour bed following surgical resection, becoming reactivated to 
grow once environmental conditions improve following resection and tissue 
healing.[74, 75] 
There are several limitations to the presently reported study. One important 
limitation is that the immunostaining was only interpreted by two people. 
For a prognostic scheme to be successful in the general population, the 
assessment criteria for a tumour has to be well-enough defined to minimise 
inter-pathologist variability. While the immunostaining in the current study 
appeared easy to assess, additional studies using a larger number of 
pathologists in different settings is required to ensure consistency in 
interpretation. Variations in the interpretation of immunostaining intensity 
may occur as a result of differences in tissue fixation, the 
immunohistochemical protocol and from intra- and/or inter-observer 
variability.[76] However, in the current study the assessment criteria relied 
more on the proportion of positive staining cells, or the distribution within 
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the tumour. The inter-observer reliability of this more quantitative estimate 
is considered good, with one study suggesting that pathologists can estimate 
differences in proportions of objects in an image even if the difference is as 
little as 5%.[77] 
Immunohistochemical investigation of VEGF has previously been performed 
in a variety of canine and human tumour types.[8, 14, 21, 23, 24, 26, 27, 50, 
78-81] Two studies have evaluated VEGF immunostaining in soft tissue 
sarcoma and fibrosarcoma;[30, 32] while these latter studies did not 
correlate staining patterns with prognosis or other tumour characteristics, 
they provide some validation of the immunohistochemical protocol and 
staining patterns for canine mesenchymal tumour cells. In all previous 
studies, immunostaining of VEGF has demonstrated a cytoplasmic or 
perinuclear localisation of the protein, consistent with the observations in the 
current study. One canine study has described variations in the cytoplasmic 
distribution and granule size between benign and malignant canine 
mammary tumours,[81] but this variation has not been reported by other 
authors.[27, 30, 32, 48]  
An additional limitation of the current study was the potential for uncertainty 
in the quality of follow-up information obtained for all patients, given that 
this information was obtained retrospectively. The extent of resection 
performed by the surgeon was based on recall from medical notes written on 
a surgery performed many years previously. Evidence for tumour recurrence 
was dependent on the owners returning to their veterinarian; the cause of 
death was also open to interpretation as almost all dogs were euthanased, 
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with no postmortem. Also, because this archive set was derived from cases 
managed in first opinion practice, there was a higher proportion of low-grade 
STS. The combination of these features may introduce several confounding 
factors to the results. Validation of this study using multiple pathologists 
assessing a wider population of STS would be of value. Finally, the number of 
cases examined in this study was small. Due to selection bias, these results 
may not be a generalizable to a larger population, so require further 
validation. The small number of patients also led to some erroneous findings 
in subgroup analysis. As an example, this study found that almost all STS 
resected by marginal excision had a high VEGF. This would appear to be a 
random finding, as there is no valid explanation for why VEGF 
immunostaining should be influenced by the resection margin. There was no 
apparent statistical association found between resection margins and 
outcome of local recurrence or survival in this study. Nevertheless, the 
influence of this apparent selection bias on the overall results of the study are 
difficult to predict. 
4.5 Conclusion 
In conclusion, the results of this study suggest that evaluation of VEGF and 
decorin levels within a STS may provide information about the biologic 
behavior of the tumour and allow identification of a tumour that has a higher 
risk of local recurrence after surgery, and/or to cause the death of the dog 
due to metastasis. Validation of these results using a wider population of 
pathologists and patients will be important.  
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In order to better understand the relationship between VEGF and STS 
growth, determination of the mRNA expression of VEGF using polymerase 
chain reaction (PCR) assay was undertaken in the next chapter. The PCR 
allows a more detailed analysis of gene expression. To the authors 
knowledge, there have been no studies demonstrating the concordance 
between IHC and PCR for VEGF in canine STS. 
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Chapter 5 
Development of a PCR assay to investigate the expression 
of splice variants of vascular endothelial growth factor in 
soft tissue sarcomas 
5.1 Introduction 
n the previous chapter, different patterns of vascular endothelial 
growth factor (VEGF) and decorin immunostaining were associated 
with varied rates of local tumour recurrence and overall survival 
following surgical removal of a soft tissue sarcoma (STS). The 
conclusion from that study was that identification of these biomarkers in STS 
would more accurately predict prognosis and could be used to guide clinical 
decisions. For example, these biomarkers could potentially be used to 
identify dogs that are more likely to benefit from active monitoring or 
adjuvant therapy to help detect or prevent recurrence after surgery.  
In the previous study, quantification of these proteins was performed using 
immunohistochemistry (IHC). While IHC is recognised as an economical and 
rapid method for examining tumour tissue for the status of a biomarker.[1, 2] 
the results can be difficult to interpret with often quite significant variability 
between pathologists and between laboratories.[2] Additionally, there can be 
variation in the intensity of protein immunostaining in different sections of 
the tumour due to heterogeneity within the tissues. This may lead to further 
I 
Chapter 5: PCR analysis of splice variants of VEGF in STS – page 156 
variability in the interpretation of the IHC result, particularly if one section of 
the tumour contains more intense immunostaining than other sections from 
the same neoplasm.[2] An alternative method for evaluating biomarkers in 
tissues is to quantify the expression of the DNA for the biomarker. This can 
be done by measuring mRNA using the reverse transcriptase polymerase 
chain reaction (RT-PCR).[3] In contrast to IHC, RT-PCR is mostly an 
automated method that produces an objective value. Therefore RT-PCR will 
not be influenced by the inter-observation variation that is unavoidable with 
subjective assessment of immunostaining.  
Another important distinction between IHC and RT-PCR is that IHC simply 
detects the presence of a certain protein within the tumour.[1] By 
comparison, RT-PCR is able to measure the quantity of RNA within the 
tissue.[3] This distinction is important because the quantity of RNA does not 
always correlate with the quantity of protein that is produced.[4] The 
development of this difference between the amount of gene expression and 
the quantity of protein produced by a cell can be a significant process in the 
neoplastic transformation of a cell. Differences can occur as a result of post-
transcriptional or post-translational defects leading to low protein 
production despite large quantities of mRNA being produced. Alternatively, if 
there is lower gene expression than normal, as well as reduced quantities of 
the relevant protein within a cell, this may suggest that gene expression has 
been silenced by mutation or through methylation of the gene promotor. 
Furthermore, the presence of large quantities of protein but little RNA 
suggests the presence of large quantities of altered protein that cannot be 
broken down by the neoplastic cell.  
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One of the mechanisms that may result in a discrepancy between gene 
expression and protein production is alternative RNA splicing.[5] Splicing is 
a precisely regulated process that occurs after gene transcription, but before 
mRNA translation. Splicing occurs as a result of deletion or re-arrangement 
of different portions of the pre-mRNA molecule, with ‘cut and paste’ 
reactions between different intron and exon boundaries being catalysed by a 
small spliceosome enzyme. Rearrangement of the pre-mRNA molecule leads 
to the production of a variety of different mature mRNAs from a single gene; 
this process provides some explanation for the complexity and diversity of 
protein morphology that occurs in mammals.[5] Different splice variants can 
have different physiological activities due to loss or addition of functional 
domains. For example, it has been reported that some splice variants may 
actually block the normal function of a protein, perhaps providing some 
feedback control of ligand activity. Some splice events can also transform 
membrane-bound proteins into soluble proteins, allowing them to have a 
wider influence within the tissues.  
The impact of alternative splicing on the VEGF molecule has been described 
in humans,[6] and the dog.[7] The VEGF gene typically consists of eight 
exons,[8] and all of the VEGF isoforms share a highly preserved VEGF 
homology domain, encoded by exons 1 to 5. Exons 6 and 7 encode for two 
distinct heparin-binding domains, and the expression of these varies between 
different isoforms. In people, at least 9 different isoforms have been 
described: these have been termed VEGF206, 189, 183, 165, 148, 121 and 
111.[6] Each isoform shows variability both in their localisation within the 
tissues as well as their physiological activity, as described below: 
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• VEGF206, 189, 183, 162 and 145 tend to be tightly bound to heparin-
containing proteoglycans in the extracellular matrix (ECM), such as 
decorin. The bioavailability of these forms is dependent on release by 
heparinase or other proteolytic enzymes, and their activity is less 
potent. The ECM largely acts a repository for these isoforms, where 
they can exert their effect over a longer period of time. 
• VEGF121 and 111 are highly soluble isoforms and have potent 
angiogenic properties. They are freely diffusible within the tissues. 
• VEGF165 has angiogenic properties that are intermediate to the 
isoforms described above. It retains heparin-binding ability within the 
ECM, but about 50% of the protein remains cell-associated.  
Mutations within a neoplastic cell can disrupt alternative splicing, resulting 
in increased or decreased production of specific protein isoforms.[5] Some 
authors suggest that this altered production of protein isoforms can influence 
the initiation or progression of the cancer.[9] In humans, VEGF121 
expression has been shown to be increased relative to VEGF165 in colorectal, 
prostate and breast cancer, and this increase correlates with enhanced 
angiogenesis within the tumour.[9-12] In human osteosarcomas, VEGF165 
expression was significantly correlated with the development of metastases 
(P = 0.005); in one study, patients with an osteosarcoma that did not express 
the VEGF165 isoform had a significantly improved overall survival compared 
to patients with osteosarcomas that did express this isoform.[13] Other 
studies of human cancers have shown that not only do different tumour types 
express varying isoform profiles, but other angiogenic factors or modulators 
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within the tumour environment influence whether the soluble or membrane-
bound VEGF isoforms are more likely to have a dominant role.[14]  
In the dog, five VEGF isoforms have been described.[7, 15] These isoforms 
are almost identical in structure to the human molecules apart from a single 
glutamic acid residue which is missing at position 5 of the canine VEGF 
protein. This deletion has also been noted in VEGF from other mammalian 
species and is not thought to influence the biological activity of the 
protein.[7] Due to the missing glutamic acid the canine isoforms are 
designated VEGF188, 182, 164, 144 and 120. It is presumed that the 
physiologic activity and tissue binding properties of the canine isoforms are 
similar to those described for human isoforms, with VEGF120 being the most 
soluble form, and VEGF188, 182 and 144 being tightly bound to proteins in 
the ECM. 
To date, there have been few investigations into the expression of the 
different VEGF isoforms in canine cancer and no study has evaluated 
whether or not different isoforms have prognostic significance.[7] One study 
investigated the expression of three VEGF isoforms (VEGF120, VEGF164, 
VEGF188) in canine primary central nervous system tumours.[15] All three 
isoforms were detected in all of the tumour types examined, with VEGF164 
being the predominant isoform in grade 3 oligodendrogliomas. However, no 
attempt was made to correlate prognosis with variations in VEGF mRNA 
expression in that study. 
To the author’s knowledge, there have been no studies comparing VEGF 
immunostaining and VEGF expression in canine STS. Additionally, the 
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presence of different VEGF isoforms within a STS has never been evaluated 
and no studies in veterinary medicine have associated the VEGF isoforms in a 
neoplasm to the subsequent clinical behaviour of that neoplasm. Therefore, 
the aim of this study was to measure the expression of VEGF isoforms within 
a series of canine STS with known VEGF immunostaining and known 
recurrence and survival times. The hypothesis of this study was that there 
would be an overall increase in VEGF expression in tumours with increased 
rates of local recurrence or reduced survival time, in concordance with the 
results of the IHC study. Additionally, tumours with increased rates of local 
recurrence or reduced survival time would show a different ratio of 
expression of individual VEGF isoforms than tumours where no recurrence 
or tumour-related death occurred after surgery. 
5.2 Materials and method 
5.2.1 Sample selection 
Samples included those in the tissue archive of 350 STS that had been 
established in Chapter 3. Clinical details about each STS had been 
determined by questionnaire, as detailed previously.  
For the current study, cases were excluded if the status of any of the following 
criteria was recorded as unknown: tumour recurrence, tumour as a cause of 
death, tumour grade, tumour size, location, palpable characteristics, and the 
degree of resection. Cases were also excluded if the STS had been removed by 
amputation. This left a total of 136 cases. A total of 71 samples were randomly 
selected from this final cohort using the CRAN package “sampling” in R (R 
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version 3.5.1, R Foundation for Statistical Computing, Vienna, Austria). 
Stratification was performed to provide an equal allocation of histological 
grades across the main outcome measure of local tumour recurrence. 
To maximize the chance of having sufficient tissue for RNA extraction, 
formalin-fixed paraffin-embedded (FFPE) blocks were examined from each 
dog included in the study. For inclusion, tissue blocks had to contain a large 
piece of tissue in which the tumour occupied over 50% of the tissue. If no 
suitable FFPE blocks were available for an individual dog, then another case 
was randomly selected from the total population pool. This new dog had to 
have a STS of the same grade and tumour recurrence status as the excluded 
dog. 
5.2.2 Cloning positive controls 
Positive controls for VEGF were developed by cloning DNA fragments 
designed from the three VEGF splice variants (NM_001003175.2, 
NM_001110501.1, NM_001110502.1, known as VEGF splice variant 1, 2 & 3 
respectively) that have been categorised on the National Center for 
Biotechnology Information database 
(https://www.ncbi.nlm.nih.gov/nuccore/?term=Canis+lupus+familiaris+VE
GFA). Sequence-verified, double-stranded DNA Gene Fragments (gBlocks) 
were obtained from Integrated DNA Technologies (Coralville, IA, USA). A 
further positive control for the housekeeper gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) used in this study was cloned from 
genomic DNA extracted previously. Primers used to produce the GAPDH 
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PCR product were based on those published previously.[16] A PCR was 
performed to amplify the GAPDH fragment as follows: 1x FIREPol master 
mix (Solis Biodyne, Estonia), 250nM of each primer, 50ng of template DNA, 
and then made up to a total volume of 20µl with nuclease free water. Thermal 
cycling conditions were: 95°C for 15 min, followed by 40 cycles of 95°C for 30 
sec, 52°C for 30 sec, 72°C for 30 sec, with a final extension at 72°C for 7 
minutes. PCR products were separated via electrophoresis (1% w/v agarose 
(Bioline, UK) in 0.5x TBE), products of the appropriate size were excised and 
eluted overnight at 4°C in elution buffer (10mM Tris-HCl). The PCR product 
from the gBlocks and GAPDH were cloned into E. coli using the Invitrogen 
TOPO TA Cloning Kit with One Shot TOP 10 cells following the 
manufacturer’s instructions. (K45750, ThermoFisher Scientific, USA). 
Plasmids containing the cloned gBlocks and GAPDH were then extracted 
from the bacterial colonies using Invitrogen PureLink Quick Plasmid 
Miniprep extraction kit following the manufacturer’s instructions (K210011, 
ThermoFisher Scientific, USA). The plasmid DNA was stored at −20°C until 
used in further experimental methods. 
Confirmation of successful cloning was performed using M13 insert flanking 
primers to amplify all clones.[17] The PCR to amplify the clones was 
performed as follows: 1x FIREPol master mix (Solis Biodyne, Estonia), 
250nM of each primer, 50ng of template DNA, and then made up to a total 
volume of 20µl with nuclease free water. Thermal cycling conditions were: 
95°C for 15 min, followed by 40 cycles of 95°C for 30 sec, 52°C for 30 sec, 
72°C for 30 sec, with a final extension at 72°C for 7 minutes. PCR products 
were separated via electrophoresis (1% w/v agarose (Bioline, UK) in 0.5x 
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TBE). Products of the appropriate size were excised and eluted overnight at 
4°C in elution buffer (10mM Tris-HCl). Eluted PCR product was sent to 
Massey Genome Service (Massey University, New Zealand) for bi-directional 
Sanger sequencing. Results were compared to the target sequences using 
Geneious (v. R8.1) (https://www.geneious.com, Biomatters, Ltd., Auckland, 
New Zealand). 
5.2.3 Designing and testing primers 
Primers to amplify three of the currently recognised splice variants of canine 
VEGF were designed using the Geneious software (version R8.1) 
(https://www.geneious.com, Biomatters, Ltd., Auckland, New Zealand). This 
included VEGF188 (AF133250.1), VEGF182 (AF133249.1), and VEGF164 
(AF133248.1). Primers were also developed to amplify the mRNA specific for 
the homologous region of VEGF. Three different primers for this portion of 
the VEGF gene were developed to try and create a shorter PCR amplicon 
product which would reduce the time of the program. Primers were designed 
to amplify a 75-200bp product with a GC content that was 50-60%, with G 
and C repeats that were no longer than 3 bases. Regions with long repeats of 
single bases (>4) were avoided. Details of the primers selected are shown in 
Table 5.1. 
All primers were tested using the cloned VEGF spliced variants as templates, 
initially via endpoint PCR. Endpoint PCR was performed as follows: 1x 
FIREPol master mix (Solis Biodyne, Estonia), 250nM of each primer, 50ng of 
template DNA, and then made up to a total volume of 20µl with nuclease free  
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Table 5.1 
Details of the primers designed to amplify the individual VEGF splice variants, the 
homologous region of total VEGF and the housekeeping gene GAPDH  
Locus Primer details Forward primer (5’ – 3’) 
Reverse primer 








Splice variant 1: 
VEGF 188 
GTA TAA ACC 
CTG GAG CGT 
TC 
TTT AAC TCA 
AGC TGC CTC 
GC 
58°C N/A 
Splice variant 2: 
VEGF 182 
GAA AGC GCA 
AGA AAT CCC 
GTC 
TTT AAC TCA 
AGC TGC CTC 
GC 
58°C N/A 
Splice variant 3: 
VEGF 164 
GAT AGA GCA 
AGG CAA GAA 
AAT C 
TTT AAC TCA 




CAA CAT CAC 
CAT GCA GAT 
TAT G 
ACA CGT CTG 




CAT AGC AAA 
TGT GAA TGC 
AGA C 
ACA CGT CTG 




CAA CAT CAC 
CAT GCA GAT 
TAT G 
GTA CAA GAT 




GGA GAA AGC 
TGC CAA ATA 
TG 
ACC AGG AAA 




water. Thermal cycling conditions were: 95°C for 15 min, followed by 40 
cycles of 95°C for 30 sec, annealing for 30 sec, 72°C for 30 sec, with a final 
extension at 72°C for 7 minutes. Annealing temperatures varied by primers 
and ranged between 50°C to 60°C. The PCR products were separated via 
electrophoresis and sent for Sanger sequencing when necessary, using the 
same protocol as described previously. 
5.2.4 Primer Validation 
The primers designed to amplify the splice variants were amplified via 
quantitative PCR (qPCR) under the following conditions: 1x KAPA SYBR 
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FAST qPCR Master Mix (MS, USA), 0.2µM of each primer, 2µL of template 
plasmid DNA and nuclease free water to create a total volume of 20µL. All 
RT-qPCR reactions were performed in a Qiagen RotorGene Thermal cycler 
(Hilden, Germany) under the following conditions; 95°C for 3min, 45 repeats 
of 95°C for 10sec and 60°C for 30sec and 72°C for 30 secs, with melt analysis 
from 72°C to 95°C in 0.2°C/sec increments. 
5.2.5 Extraction of RNA from soft tissue sarcoma samples 
Total RNA was extracted from the FFPE samples selected previously using 
the High Pure FFPE RNA Isolation Kit (Roche Applied Science, Mannheim, 
Germany) according to the manufacturer’s instructions. Briefly, tissue 
sections were cut at a thickness of 10µm and deparaffinised in xylene and 
then graded ethanol (absolute and 70%). A stepwise tissue lysis step using 
proteinase K was performed until no particulate matter remained. This was 
followed by RNA isolation on a filter column through a series of wash buffer 
rinses. The RNA was finally eluted into a collection tube using elution buffer.  
Samples were stored at -80°C until required. RT-qPCR was then performed 
on each sample, using the protocol as described in subsequent sections. 
5.2.6 Reverse Transcriptase Quantitative PCR assays 
Reverse transcriptase quantitative PCR of the VEGF and GAPDH primer set 
was performed on all extracted RNA in triplicate. Included in each PCR run 
was a serial dilution of the appropriate plasmid ranging from 0.2 - 
0.0000002 ng/µl (100pg – 0.1 fg/µl). All RT-qPCR were performed using the 
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KAPA SYBR FAST One-Step qRT-PCR Kit according to the manufacturer’s 
specification. Briefly, into each 0.2mL thin-walled PCR tube on ice was added 
1x KAPA SYBR FAST qPCR Master Mix (MS, USA), 0.2µM of each primer, 
2µL of template mRNA, 1X KAPA RT Mix and 7.2µL nuclease free water to 
create a total volume of 20µL. All RT-qPCR reactions were performed in a 
Qiagen RotorGene Thermal cycler (Hilden, Germany) under the following 
conditions; 42°C for 10 min, 95°C for 3min, 45 repeats of 95°C for 10sec and 
60°C for 30sec and 72°C for 30 secs, with melt analysis from 72°C to 95°C in 
0.2°C/sec increments. A negative control containing nuclease free water was 
used in all assays. Melt curve predictions were determined using uMel;[18] 
the expected melt temperature was predicted as 88.5°C for the VEGF primer 
set and 92.5°C for the GAPDH primer set. 
5.3 Results 
5.3.1 Primer validation 
Primers for splice variants 1 and 2 were both successfully amplified and 
sequenced. However, efforts to amplify splice variant 3 proved problematic, 
despite modifications to conditions. After repeated efforts, the results from 
agarose gel electrophoresis indicated that the combination of forward primer 
for splice variants 1, 2 and 3 with the reverse primer for Total VEGF-ver3 
produced the most consistent results. These primers were then tested using 
quantitative RT-qPCR. 
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5.3.2 Reverse Transcriptase and Quantitative PCR of the splice variants 
Even though there were significant differences in genetic sequences between 
the three splice variants, by coincidence all melt temperatures were identical 
to each other (Figure 5.1). Despite modifications to the qPCR parameters and 
primer concentrations, it was not possible to quantify individual splice 
variants with this protocol. The study was continued but instead of trying to 
examine individual VEGF isoforms, only total VEGF was evaluated. 
Figure 5.1: 
Amplification and melt curves from RT-qPCR of each strain variant. 
 




Splice variant 3: VEGF 164 
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5.3.3 Primer validation: Standard curve for VEGF and GAPDH 
The results of amplifications using primer Total VEGF-ver3 and 
housekeeping gene GADPH at serial dilutions are shown in Table 5.2. For 
VEGF, amplification had a correlation coefficient (R2) of R2 = 0.97066. The 
melt curve showed a single inflection point, suggesting a pure amplicon 
product was produced (Figure 5.2a). For the GAPDH reference gene, the 
amplification standard curve showing the Ct at reducing concentrations of 
starting product had an R2 of 0.99924. Melt curve temperatures had a single 
inflection point, confirming a pure amplicon product (Figure 5.2b). 
Table 5.2:  




VEGF  GAPDH 
Name Given Conc (ng/ul) Ct 
Melt Temp 
(℃) 
 Name Given Conc (ng/ul) Ct 
Melt Temp 
(℃) 
100pg 0.2 9.79 84  100pg 0.2 9.79 84 
10pg 0.02 13.52 84  10pg 0.02 13.52 84 
1pg 0.002 18.07 84  1pg 0.002 18.07 84 
100fg 0.0002 22.87 84  100fg 0.0002 22.87 84 
10fg 0.00002 26.13 84  10fg 0.00002 26.13 84 
1fg 0.000002 29.11 84  1fg 0.000002 29.11 84 
0.1fg 0.0000002 29.67 84  0.1fg 0.0000002 29.67 84 
0.01 fg 0.00000002 33.4 84  0.01 fg 0.00000002 33.4 84 
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Figure 5.2a and 5.2b 
Amplification curves (left) and melt curves (right) arising from serial dilutions of total 
VEGF and GAPDH. 
Figure 5.2a: Vascular endothelial growth factor (VEGF) 
 
Figure 5.2b: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
 
5.3.4 Measurement of RNA extraction from FFPE blocks:  
RNA concentration was measured using a Nanodrop ND-1000 
spectrophotometer on twelve samples only. RNA concentration in these 
samples was considered good, ranging from 17.4 – 1059 ng/µL (Table 5.3). 
These results provided confidence in the sample extraction methodology. 
Due to time constraints, measurement of RNA concentration in the 
remaining samples was not performed. 
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Table 5.3: 
RNA concentrations from the subset of soft tissue sarcoma samples, as measured 
by Nanodrop ND-1000 spectrophotometer 














5.3.5 Reverse Transcriptase and Quantitative PCR (RT-qPCR): VEGF 
expression in STS samples 
Reverse transcriptase and quantitative PCR was performed in triplicate on 27 
individual STS cases, so a total of 81 reactions were performed. The R2 value 
of the standard curve for the VEGF template in each individual RT-qPCR run 
had values ranging from 0.98486 to 0.99755 confirming successful 
amplification conditions.  
By comparison, Ct values for the STS samples were poor. In 18 of 81 RT-
qPCR reactions, no amplicon product was detected. In the remaining 63 
reactions, the Ct ranged from 30.27 to 43.78. However, in these cases, 
multiple melt temperatures were observed suggesting a heterogenous PCR 
product was present. In both cases, a single inflection peak was observed for 
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the VEGF template, suggesting the PCR conditions were appropriate (Figure 
5.3a and 5.3b). 
Figure 5.3a and 5.3b 
Examples of melt curves from the RT-qPCR assays performed on two different 
cohorts of STS samples. Multiple melt temperatures are observed for most sample 
reactions. A single inflection peak was observed for the VEGF template, suggesting 
good PCR conditions were present. 
 
 
5.3.6 Reverse Transcriptase and Quantitative PCR (RT-qPCR): GAPDH 
expression in STS samples 
Reverse transcriptase and quantitative PCR for the house-keeping gene 
GAPDH was performed in triplicate on 18 individual STS cases, giving a total 
of 54 reactions. The R2 value of the standard curve for the GAPDH template 
in each individual RT-qPCR run had values ranging from 0.98486 to 0.99755 
confirming successful amplification conditions.  
By comparison, Ct values for the STS samples were poor. No amplicon 
product was detected in 13 of 54 reactions. In the remaining 41 reactions, the 
Ct ranged from 28.5 to 44.12. Once again, multiple melt curve temperatures 
were observed (Figure 5.4a and 5.4b). 
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Figure 5.4a and 5.4b 
Examples of melt curves from the RT-qPCR assays performed on two different 
cohorts of STS samples. Multiple melt temperatures are observed for most sample 
reactions. A single inflection peak was observed for the GAPDH template, 
suggesting good PCR conditions were present. 
 
 
5.3.7 Further analysis abandoned 
Because of the poor performance of the PCR assay with both the VEGF and 
GAPDH reference gene primers, the study was paused to allow for further 
validation. However, due to inadequate quantities of necessary reagents, no 
further RNA could be extracted from the FFPE blocks to support additional 
investigations. The study therefore had to be abandoned at this point.  
5.4 Discussion 
Polymerase chain reaction is a relatively routine technique, so it is frustrating 
when it does not work as planned. However, there are many components 
which can disrupt the amplification process. In the current study, two major 
problems occurred that prevented successful achievement of the research 
goals. Firstly, there was inconsistent amplification when using both the VEGF 
and GAPDH primers on mRNA extracted from the soft tissue sarcoma 
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samples. Secondly, the PCR reaction could not be validated to allow 
quantification of the RNA for each of the VEGF splice variants.  
The inability to amplify VEGF or GAPDH from any STS sample in the study 
was considered most likely to be due to an inadequate quantity of amplifiable 
RNA within the sample. This interpretation was based on the amplification 
and melt curves derived in the study. The amplification curves from the RT-
qPCR revealed that either no or inadequate amounts of RNA was being 
amplified from the mRNA extracted from the STS samples. The amplification 
curve provides a visualisation of the gene products being produced in the 
PCR assay, by measuring the magnitude of fluorescence within the 
amplicon.[3, 19] In the current study, the PCR assay made use of a 
fluorescent dye, SYBR green. SYBR green will bind avidly to double-stranded 
DNA (dsDNA), with binding causing the magnitude of its fluorescence to 
increase.[3] The cycle threshold (Ct) is defined as the number of cycles 
required before the fluorescence emanating from dsDNA exceeds the 
threshold of background noise. Measurement of Ct therefore gives a real-time 
indicator of the quantity of nucleic acid that has developed within the sample. 
The RT-PCR protocol used in this study underwent 45 cycles of amplification. 
Under ideal conditions, the RT-PCR reaction should have amplified the 
initial quantity of target RNA for fluorescence to be detectable within 29 
cycles, giving a Ct of ≤29.[19] This reading is indicative of a strong positive 
reaction and suggests there should be abundant target nucleic acid in the 
sample. A Ct of between 29-38 would be considered weakly positive, 
suggesting there were only moderate amounts of nucleic acid present in the 
PCR vial. Readings over this level are considered only weakly positive and are 
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likely unreliable for analysis. In the current study, the Ct was unmeasurable 
in 18 out of 81 reactions with the VEGF primer, and in 6 out of 47 reactions 
with the GAPDH primer. When PCR product was detected in the remaining 
reactions, the Ct for VEGF ranged from 30 to 43 (mean Ct = 37.3) and 28.5 to 
44 (mean Ct = 36.7) for GAPDH. In each PCR assay, the Ct for the positive 
control templates for both VEGF and GAPDH increased predictably in 
accordance with the serial dilution of the starting product. The R2 of the 
standard curve from each PCR experiment was consistently greater than 
0.99, providing confidence that the cycling conditions and all reaction 
solutions that were used for the qPCR were stable and correct.[19] 
The positive Ct readings generated from some of the samples in the current 
study may suggest that copies of the target gene had been amplified, raising 
the prospect for an interpretable result in these cases. However, analysis of 
the melt curve suggested the PCR product in these cases was probably a 
heterogenous nucleic acid population, rather than a pure clone of VEGF or 
GAPDH RNA being amplified.[3, 20] Melt curve analysis is an important 
diagnostic measure to verify the specificity of the PCR assay, and to 
determine that the amplicon present at the end of the amplification phase is 
indeed the target gene.[21] The assumption behind the melting curve is that 
the amplicon will be homogenous and will therefore degenerate 
spontaneously at identical conditions. If the amplicon is a single gene 
product, a single large melting peak will be observed in the melt curve when 
50% of the dsDNA has degenerated. However, if amplification has resulted in 
multiple gene fragments, then multiple melt peaks will be obtained. In the 
current study, melt curves from reactions using the VEGF and GAPDH 
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primers with the STS samples were composed of multiple distinct peaks. This 
suggests that non-specific amplification had resulted in non-target RNA 
being amplified. The melt curves from each of the PCR assays did have 
distinct single inflection peaks that related to degeneration of the amplicon 
generated from the positive control VEGF template. The presence of these 
peaks confirmed that amplification of the positive control template had 
performed as expected.  
The interpretation of these findings is that no significant quantities of VEGF 
or GAPDH RNA was being amplified from the majority of STS samples 
during RT-PCR. In the few samples from which RNA was amplified, this 
appeared to be multiple gene sequences, suggesting that very little total RNA 
had been extracted from the STS samples.  
In the current study, the concentration of extracted RNA was only measured 
in 12 of the 27 samples due to time-constraints, with a focus on generating 
reportable data from the experiment. The decision to not measure extracted 
RNA in all samples was influenced by the detection of adequate 
concentrations of RNA extracted from the 12 STS samples where analysis was 
performed. Ideally, determination of RNA concentration should have been 
performed on all samples to provide confidence that adequate RNA was 
available for amplification in every case.  
Nevertheless, even if the concentration of RNA was adequate, another 
potential problem in the current study is the quality of the RNA was not 
determined. While RNA is a relatively stable biological protein, it is prone to 
denature when exposed to unfavourable conditions.[22, 23] There are a 
Chapter 5: PCR analysis of splice variants of VEGF in STS – page 176 
number of factors that could have reduced the quality of the RNA in this 
study as the sections of STS used in this study were initially fixed in formalin 
following surgery and then stored as FFPE blocks for more than 13 years. 
Processing conditions for the samples were directed more towards the 
establishment of a histological diagnosis for clinical reasons, rather than the 
precise preservation of the tissue for molecular research. For this reason, the 
processing and storage conditions that the tissues were exposed to will have 
created a number of unfavourable factors that could have influenced the 
integrity of the RNA within the sample.  
Two of the major factors known to affect the quality of the RNA within FFPE 
samples is the time spent in fixative solution prior to processing and the age 
of the block.[23, 24] Fixation in formaldehyde for periods of between 48 
hours and 7 days, or longer, has been shown to have a detrimental effect on 
the amplification efficiency of RT-PCR.[22, 23] In the current study, it was 
impossible to know the time the samples would have spent in formaldehyde 
prior to being processed and embedded into paraffin. The samples had been 
obtained from a commercial laboratory that serves the veterinary community 
in the UK. Under most instances, it could be presumed that the STS 
specimens will only have been stored in formaldehyde for the time taken to 
be transported by a postal or courier service from the clinic to the laboratory, 
a period that would likely range from 24-48 hours for samples sent on a 
weekday. However, this duration could increase to 72 hours or more for 
samples where transportation to the laboratory was disrupted by weekends, 
holiday periods or other logistical delays.  
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The size of the tissue samples being fixed will also impact on the quality of 
the RNA extracted;[22] if a tissue section is thicker than 2 cm, penetration of 
formaldehyde into the deeper portions of the tissue will be delayed. Cells 
deep within the tissue may start to autolyse and degenerate due to the lack of 
oxygen and nutrients. In the current study, 40% of the tumours were 
described as being more than 5cm in diameter. This would result in a surgical 
specimen that was at least 7-8 cm and up to 11-12 cm if a circumferential 
surgical margin of between 1-3 cm was obtained. It is therefore possible that 
some tissues will have arrived at the laboratory being inadequately fixed, with 
subsequent autolytic changes affecting the integrity of the tissue. While these 
failings may not have had a profound impact on the ability to provide a 
reliable histological interpretation, there will be potential consequences on 
the integrity of the nucleic acid required for the RT-PCR analysis in the 
current study. 
Another factor that will influence RNA quality was the storage conditions of 
the FFPE blocks since their creation.[22, 23] It has been shown that after 1-
year storage at 4℃, ribosomal RNA extracted from tissue will usually still be 
of acceptable quality.[22] However, other authors have shown that after 4 
years of storage at ambient temperatures, RNA quality will deteriorate 
significantly.[23, 24] In the current study, the FFPE blocks had been stored 
for almost 13 years prior to being sectioned for the RT-PCR study. During 
this time, their storage conditions were less than optimal, having been 
transported half-way around the world, and kept at room temperature with 
wide fluctuations in range depending on the season. The possibility that 
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significant RNA degeneration was responsible for the poor RT-PCR results in 
the current study was therefore high.  
Because of the age and poor storage conditions of the FFPE blocks used in 
the current study, efforts to analyse the quality of RNA extracted from the 
tissue sections should have been performed, particularly when it became 
evident that RT-PCR analysis was not working as expected. The most obvious 
evidence that the quantity or quality of RNA extracted from the samples was 
inadequate was the consistent failure of the RT-PCR for the house keeping 
gene GAPDH, which is expected to be consistently expressed in all tissues.  
The quality of RNA in a sample is a measure of the degree of degradation due 
to the effects of various nucleases on the molecular structure.[22] Gradual 
degradation of RNA will be reflected by a progressive shift towards shorter 
fragment sizes. Thus, although the total RNA concentration may be 
acceptable, the RNA strands have become increasingly fragmented which 
may interfere with amplification during a RT-PCR assay. There are several 
alternative methods that could have been used to evaluate the quality of the 
RNA. These include the RNA integrity number (RIN),[25] the paraffin-
embedded RNA metric (PERM),[26] and the fragment analysis metric 
(DV200).[27] One study has suggested there is considerable variation in the 
usefulness of these different RNA quality measures for FFPE blocks that have 
been stored for periods ranging from <2yrs under ideal conditions, to >21 
years at room temperature.[28] However, in most instances, fragment 
analysis (DV) outperformed PERM and RIN in determining sequencing 
quality for gene detection. None of these techniques were employed in the 
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current study as there was no access to an Agilent bioanalyser required to 
generate the necessary data for calculation of each metric.  
The other problem encountered in the current study was the inability to 
generate individual PCR amplicons for the VEGF splice variants of interest. 
Each of the primers were designed using Geneious software (version R8.1) 
(https://www.geneious.com, Biomatters, Ltd., Auckland, New Zealand), with 
the intent that each primer would be specific for each splice variant. 
However, melt curve analysis from the PCR amplicons proved challenging as, 
by coincidence, all three splice variants had the same melt temperature. 
Normally, the melt temperature would be used to confirm that the nucleic 
acid product being generated was consistent with the target gene of interest. 
Because this was not the case for the VEGF splice variant primers used in the 
current study, it would only have been possible to determine if the amplicon 
generated was unique to the primer of interest by performing sequencing 
analysis.  
In the current study, primer design was difficult as there was a lack of 
significant sequence variation between the different splice variants. This 
caused a potential overlap between the primers, which could have led to 
amplification of an incorrect product. To understand this finding, each 
primer sequence was entered into the nucleotide Basic Local Alignment 
Search Tool [(BLASTn), National Centre for Biotechnology Information 
(NCBI), Bethesda, MD, USA] to determine the apparent specificity of the 
primers to the canine genome. This search showed that the primers designed 
for VEGF strain variant 1 and VEGF strain variant 2 had good homology with 
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the mRNA for VEGF188 and VEGF182, respectively. However, the primer for 
VEGF strain variant 3 showed evidence of alignment with VEGF188, 
VEGF182 and VEG164. Analysis of the exon structure of the known canine 
splice variants shows the close similarity between the isoforms chosen for 
study in this chapter with the only difference between variations in 
expression of exons 6a and 6b. It is possible that the primer design that was 
performed at the time was inaccurate. It may also have been preferable to try 
and study some of the other isoforms such as VEGF 144 or VEGF 120, which 
may have had a greater variation in sequence structure. At the time this study 
was being designed, there were limited publications investigating splice 
variants of VEGF in the dog. In hindsight, using primers published from the 
previous study on canine VEGF isoforms may have yielded a better result.[15] 
The failure of this study to generate interpretable results was frustrating, as it 
limits our further understanding of the importance of VEGF and, by 
extension, decorin on the prognosis of STS. At the start of this Chapter, it was 
hypothesised that there would be different ratios of expression of individual 
VEGF isoforms between STS that have a higher tendency to recur or cause 
the death of a dog compared to tumours that have a good prognosis after 
surgery. One of the goals of this chapter was to try and obtain more insight on 
the possible interactions between VEGF and other molecules within the 
tumour microenvironment, such as decorin. In the previous chapter, it was 
determined that both decorin and VEGF had an influence on STS prognosis. 
It is hypothesised that decorin may act as a tumour suppressor by 
sequestering a number of important ligands and growth factors within the 
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matrix, thereby influencing ligand-receptor interactions and attenuating 
down-stream signaling pathways.[29, 30] Therefore, a loss of decorin within 
the microenvironment of a STS, which was shown in the previous Chapter to 
be associated with reduced disease-free survival, will increase the availability 
of these ligands and growth factors, which may help drive tumour 
progression. Because there is a variable degree of binding affinity by VEGF 
splice variants to matrix proteoglycans such as decorin, it would be important 
to understand whether the increase in VEGF observed in some STS is due to 
an increase in the expression in one or all VEGF isoforms, or whether the loss 
of decorin simply increases the bioavailability of VEGF isoforms that would 
normally be sequestered in the matrix, without an overall increase in 
expression.  
In the current study, the processing and storage conditions that the tissues 
were exposed to were presumed to have created a number of unfavourable 
factors that influenced the integrity of the RNA within the sample. Because 
utilisation of FFPE samples provides a valuable resource for biomarker and 
molecular research in oncology, the impact of storage is increasingly 
recognised.[24] There is a potential for PCR analysis to generate spurious 
results that are more a reflection of biospecimen handling rather than those 
of disease state, and false interpretation of these results could therefore 
confound patient diagnosis. It is generally recommended that any biomarker 
discovery from FFPE tissue should be validated against fresh frozen tissue to 
ensure any disparity detected in nucleic acid levels is a true reflection of the 
disease condition.[22] 
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The failure of this study means additional investigation will need to be 
performed to determine if analysis of VEGF could become a reliable 
prognosis test for STS. If a prognostic test is to be of clinical use, it would 
need to be simple to perform, reliable and cost-effective to perform. The 
result should also influence clinical decision making. In addition to the 
differences between PCR and IHC discussed in the introduction to this 
Chapter, PCR has the advantage of being able to be performed on very small 
cellular samples. There are existing analyses currently used in a veterinary 
clinic for other disease conditions that can be performed on cellular samples 
obtained by fine needle aspirate. If validated for STS, such a test would lend 
itself favourably to quantification of the VEGF expression within the tumour. 
If this test was performed pre-operatively, it could potentially help a clinician 
decide the optimal resection margins prior to surgery being performed. By 
comparison, IHC typically requires histological sections of tissue for reliable 
immunostaining. This tissue would need to be obtained by biopsy and 
necessitate exposure of the cells to formaldehyde, which is known to have a 
negative influence on RNA quality. Furthermore, because there is 
heterogeneity in VEGF expression between different sections of a STS, 
multiple sections of a tumour would need to be examined to provide a 
reasonable overview of the tumour, necessitating multiple sections of tumour 
to be obtained. By comparison, it would be a simple matter for a clinician to 
obtain multiple fine needle aspirate samples from a variety of sites in the 
tumour, with these samples being pooled for PCR analysis. Further study will 
be required to correlate VEGF immunostaining with VEGF expression in 
canine STS if such a prognostic test was to be developed in the future. 
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5.5 Conclusion  
In conclusion, the aims of this study were not achieved due to technical 
challenges and failings within the experimental design. It is likely the age and 
storage conditions of the FFPE blocks required a more sensitive approach to 
analysis than was originally anticipated. It is possible with more time and 
resources, viable results could have been obtained. 
Nevertheless, there is sufficient evidence from previous studies to suggest 
that evaluation of VEGF and decorin levels within a STS could allow 
identification of a tumour that has a higher risk of local recurrence after 
surgery, and/or to cause the death of the dog due to metastasis. The findings 
from Chapter 4 suggested that a combination of immunostaining results 
provided an enhanced ability to identify a small subset of tumours with a 
reduced risk of recurrence or tumour-related death after surgery. This 
finding supports a strategy where a suite of different prognostic markers 
could be used to better predict individual tumour behavior, rather than 
relying on one single attribute alone. To investigate this possibility further, 
the next chapter will explore the development of a clinical formula that uses a 
number of individual tumour characteristics to provide the clinician with an 
improved ability to predict patient outcome after surgery.  
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Chapter 6: 
Development of a nomogram to predict the outcome for 
patients with soft tissue sarcoma 
6.1 Introduction 
n the previous chapters, variations in vascular endothelial growth 
factor (VEGF) and decorin were found to be associated with both 
recurrence of the tumour and with patient survival after surgery. 
These results suggest that evaluation of these proteins could be used 
to help predict patient outcome after surgical resection of a soft tissue 
sarcoma (STS). The ability to predict whether an individual STS has a higher 
or lower potential to recur after surgery would greatly assist patient 
management. This ability could allow a clinician to decide whether an 
individual patient is likely to benefit from adjuvant chemotherapy or 
radiotherapy, or whether additional surgery should be performed to remove 
residual tumour from the wound bed. Having confidence that an individual 
patient is safe from recurrence would also provide considerable reassurance 
to pet owners.  
Various methods have been developed over the years to help clinicians 
predict the prognosis for a patient with cancer.[1] Historically, the gold 
standard for prognostication in human oncology is considered to be the 
tumour, node, metastasis (TNM) system.[2, 3] This system has been 
I 
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described for most forms of human cancer since 1953,[3] and was first 
applied to veterinary oncology in 1980.[4] The TNM system allows 
categorisation of patients with a different extent of local and distant disease, 
and offers an ability to stratify the outcome for a patient based on the 
presenting characteristics of their tumour. Despite the widespread 
acceptance of the TNM system by the oncology community as an effective 
method to distinguish patients with different burdens of disease, there are 
several limitations to the TNM system.[2] This is, in part, because it is 
founded on the basis that prognosis is directly related to overall tumour 
burden and an orderly anatomical progression of disease.[5] It is now 
increasingly understood that many elements of individual tumour biology 
such as mitotic rate, genetic and histologic characteristics play an 
increasingly important role in overall prognosis,[1] and these are not always 
accounted for in the TNM system. 
A TNM system has been described for canine STS, but this has not been 
validated in a clinical setting.[6] Even without this validity, there are notable 
deficiencies to the classification system that limit its reliability as a predictive 
tool. For example, within the “T” (tumour) profile, tumour size is the only 
characteristic used to distinguish different patient subsets. While size does 
play an influencing role in the prognosis of canine STS,[7, 8] there are several 
other criteria that are also known to be influential on recurrence including 
tumour grade, mitotic index, and the percentage of tumour necrosis.[9, 10] 
Another major limitation of the existing TNM system for canine STS is that it 
presumes prognosis is determined by the presence of nodal or distant 
metastasis, which is at odds with the clinical reality of this disease. While 
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metastatic spread will occur in a proportion of dogs with STS, it is recognised 
that the majority of dogs that die from STS will be euthanased because of the 
local impact of their disease rather than the development of metastasis.[11]  
In Chapter 4, combining the results of both VEGF and decorin 
immunostaining classifications appeared to improve the ability to identify the 
subsets of tumours with either highly favourable or highly unfavourable 
outcomes. This lends support for a strategy where a combination of different 
tumour characteristics or prognostic markers could help predict individual 
tumour behaviour. This conclusion is consistent with developments 
occurring in the management of human cancer, where a variety of different 
techniques are being explored to try and improve the accuracy of prognostic 
predication.[12, 13] Amongst these techniques has been the re-emergence of 
the nomogram.[14, 15] 
A nomogram (also called a nomograph, alignment chart or abaque) is a 
calculating device that allows the approximate graphical computation of a 
mathematical function.[5] The field of nomography was invented in 1884 by 
the French engineer Philbert Maurice d’Ocagne. In an age before pocket 
calculators and computers, the nomogram became a vital tool for many 
industries because it allowed quick and accurate computations of complex 
formulae. The pictorial element of the nomogram allowed a user to derive a 
reliable solution without having to understand the complex mathematical 
formulae behind the interface. For more than 75 years, the nomogram was a 
vital tool for a variety of industries, in particular the railways, astronomy, 
aeronautics and the military. In more recent years, the nomogram has re-
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emerged within the medical field as a potential tool to help patients and 
doctors utilise complex statistical equations to derive an accurate individual 
risk assessment for patients with a variety of conditions, including 
cancer.[14]  
The owner of a dog with cancer typically wants to know what their prognosis 
will be as a result of treatment. Traditionally, a clinician will use their 
knowledge of the oncology literature, combined with their own experiences, 
to help determine the potential prospects for an individual patient with 
cancer. There are a virtually endless supply of clinical studies that have 
sought to identify different features that help differentiate a cancer patient 
with a “good prognosis” from a “bad prognosis”. The statistical methods used 
in these papers utilise various forms of logistic regression equations to 
determine the probability that a certain tumour characteristic, or 
combination of characteristics, will influence a particular outcome, for 
example death or tumour recurrence, for an individual patient. These 
probabilities are published as odds or hazard ratios (HR), with a figure 
greater than 1.0 indicating there is a higher likelihood for that outcome to 
occur in a patient with a given tumour characteristic. Conversely, an HR less 
than 1.0 indicates a lower likelihood for that outcome to occur. An 
experienced veterinarian familiar with the literature will know that the HR 
for recurrence of a STS larger than 5cm is 1.8, almost doubling the risk for 
recurrence when compared to a 1cm tumour.[1] They will also be aware that a 
grade 3 STS has a HR of 5.8 for recurrence compared to a grade 1 STS. 
However, HRs have been published for a range of tumour characteristics, 
including the results of histologic, immunohistochemical or molecular 
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analysis of the tumour. Because an individual patient with cancer will present 
with a unique combination of tumour characteristics it is challenging, if not 
impossible, for a clinician to perform the complicated multi-parameter 
logistical regression calculations necessary to assimilate the combined 
influence of each independent tumour variable into an expected outcome. 
Against this clinical background, the nomogram has emerged as a potential 
tool to allow a clinician to utilise complex statistical equations to predict a 
binary outcome from a combination of risk factors.[14] 
In human oncology, nomograms have been developed for a variety of tumour 
types and clinical situations. For example, nomograms have been developed 
to estimate recurrence,[16] survival outcomes,[17, 18] the benefit of adjuvant 
therapy[19, 20] and also the impact of a particular treatment on quality of 
life.[21, 22] Nomograms have been developed to determine the risk for a 
patient having an incomplete resection if a conservative surgical strategy is 
employed,[23] or for neoplastic cells to be present within draining lymph 
nodes.[24] Nomograms have also been developed to better identify patients 
who may benefit from more extensive surgery.[25] In one study, a predictive 
nomogram was shown to be significantly more reliable at determining the 
risk of cancer progression for an individual patient than the clinical 
judgement of the specialist clinician alone.[26]   
To date, nomograms have not been utilised in veterinary medicine to support 
clinical decisions. Therefore, the aim of the present study was to determine if 
a nomogram could be used to predict whether an individual STS was likely to 
recur after surgical resection. After development of the nomogram, the 
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predictive accuracy was compared with the actual outcome for the patient. 
This was also compared with the accuracy of predicting outcome using the 
HR for individual tumour characteristics alone. The hypothesis was that the 
nomogram would be more accurate at determining patient outcome than the 
prognosis that could predicted from individual tumour characteristics. 
6.2 Materials and Method 
6.2.1 Patient data 
Separate datasets were used to develop the two nomograms created in this 
current study. The first dataset was derived from the population of 350 soft 
tissue sarcoma established in Chapter 3. This dataset was called “Clinical”. 
Because accurate nomogram construction requires no missing or incomplete 
information for the variables used in the analysis, any cases with unknown or 
missing values were excluded. The final Clinical dataset therefore included 
170 cases. The second dataset utilised the clinical cases that were used to 
determine the immunostaining characteristics for VEGF and decorin as 
detailed in Chapter 4. This dataset was termed “IHC”. Once again, any cases 
with unknown or missing values were excluded. The final IHC dataset 
therefore included 82 cases. 
To allow development of well-calibrated and validated nomograms, each 
model is ideally built using a training cohort of data, and then validated 
against an independent validation cohort. To establish these two required 
cohorts, the CRAN package “sampling” in R (R version 3.5.1, R Foundation 
for Statistical Computing, Vienna, Austria) was used to randomly select 68 
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cases from the Clinical dataset. These selected cases were used to create the 
validation cohort, called “Clinical_validate”. The cases remaining now 
created the larger training cohort which consisted of 102 cases; this dataset 
was renamed as “Clinical_train”.  
Because of the small number of cases in the IHC database, it proved 
impossible to separate the dataset into two and still retain a meaningful 
number of events within each cohort. For this reason, it was not possible to 
create an independent cohort for the IHC nomogram to permit external 
validation. 
6.2.2 Patient demographics and risk analysis of individual variables 
All statistical analyses were performed with SPSS (Version 25, IBM Statistics, 
USA). Local recurrence of the tumour within 3 years was the defined end 
point for the study. The disease-free interval (DFI) was defined as the time 
from surgery to the time when recurrence was identified by the referring vet. 
Patients were censored if they had died prior to the end point of the study 
and no tumour recurrence had been noted at that time, based on clinical 
records of the referring veterinarian. 
The Kaplan Meier method was used to compare DFI according to age, 
palpable characteristics, tumour size, histological characteristics (i.e. 
differentiation, necrosis, mitotic score, grade), and the development of local 
tumour recurrence. Finally, Cox regression analysis was performed to 
identify categories of significance, and their hazard ratios, for patients whose 
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tumours recurred within 3 years of surgery. A value of p<0.05 was 
considered significant. 
6.2.3 Using a ROC curve to evaluate the predictive accuracy of individual 
tumour characteristics  
For each category showing significance with Cox regression analysis, the test 
result was plotted against actual tumour recurrence in a receiver-operating-
characteristic (ROC) curve. The ROC curve provides an ability to determine 
the ability of a diagnostic test to discriminate between affected and non-
affected patients.[27] When the outcome is binary (such as tumour 
recurrence), a diagnostic test may reliably predict whether an event actually 
occurred (true positive (1) or true negative (0)), or wrongly predicts an 
outcome which does not occur (false positive or false negative). An imperfect 
test will produce an equal number of false-positive and false-negative results, 
providing a predictive ability that is no better than chance (i.e. 50:50). If the 
binary predictions of a diagnostic test are presented graphically, a diagonal 
line will be generated between the origin (0,0) and the top right quadrant of 
the graph (1,1). The ROC curve thus provides a visual representation of the 
clinical utility of a particular test. Calculation of the area-under-the-curve 
(AUC) of the ROC curve line also provides an objective measure of reliability 
of the diagnostic test.[27] A perfect test will have an AUC of 1.0 whereas the 
imperfect test will have an AUC of 0.5. The aim for a diagnostic test is to have 
an AUC as close as possible to 1.0. 
Using co-ordinates from the ROC curve, a cut-off value for 3 year local 
recurrence probability was determined by calculating the differential positive 
Chapter 6: Predictive nomogram – page 195	
rate using the following formula: [sensitivity – (1-specificity)].[27] This 
allowed determination of a probability value that provided an optimal 
balance of sensitivity and specificity. This enabled a binary recurrence 
outcome (i.e. yes or no) to be predicted, based on the actual test result. By 
comparing this predicted outcome with the actual outcome in a 2x2 table, it 
was possible to calculate Sensitivity, Specificity, Positive Predictive Value and 
Negative Predictive Values for both the “Clinical_train” and the “IHC” 
nomograms.   
6.2.4 Nomogram construction 
To identify the independent predicators of time-to-event outcome that should 
be used in nomogram construction, multivariable Cox regression analysis 
was performed on all recorded clinical variables in the “Clinical_train” 
dataset, including age, size of tumour, palpable characteristics, location, as 
well as histological characteristics of the tumour including grade, 
differentiation, necrosis, mitoses and mitotic rate. Backward selection of 
variables was performed to obtain the model with the best fit. Due to the 
small size of the dataset, variables were selected for use in the model if their p 
value was <0.15.  
Following selection of the independent variables to be used in the model, 
nomograms were constructed using the ‘rms’ and ‘survival’ packages 
available in R (R version 3.5.1, R Foundation for Statistical Computing, 
Vienna, Austria), as described by Harrell.[28] The code for nomogram 
construction is shown in Table 6.1. 
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These above steps were then repeated using the “IHC” dataset. The variables 
used for development of the multivariable logistic equation included age, size 
of tumour, palpable characteristics, location, the histological characteristics 
of the tumour (i.e. grade, differentiation, necrosis, mitoses and mitotic rate), 
as well as the immunostaining scores for VEGF and decorin. 
Table 6.1 
Example of the R code used to develop the clinical nomogram. This utilised the 
‘rms’ and ‘survival’ packages in R. 
#RMS load data and nomogram construction 
nomo <- read.csv("Clinical_train_random.csv", TRUE) 
library(rms) 
mod.Cox <- cph(Surv(DFI, CENSR) ~Palpnew + Mitoticrate + Necrosis, 
nomo,surv=TRUE) 
ddist <- datadist(nomo) 
options(datadist='ddist') 






#RMS validation of Cox model using validation dataset 
nomo_valid <- read.csv("Clinical_train.csv", TRUE) 
fit_valid <- cph(Surv(DFI,CENSR) ~Palpnew + Mitoticrate + 
Necrosis, nomo_valid,x=TRUE, y=TRUE) 
validate(fit_valid, method="boot", B=40, bw=FALSE, 
rule="aic",type="residual", sls=.05, aics=0, force=NULL, 
estimates=TRUE, pr=FALSE, dxy=TRUE, u, tol=1e-9) 
 
#RMS nomogram of IHC training data 
nomo <- read.csv("IHC_test all.csv", TRUE) 
library(rms) 
mod.Cox <- cph(Surv(DFI, CENSR) ~VEGF + Decorin + Mitoticrate + 
Age, nomo,surv=TRUE) 
ddist <- datadist(nomo) 
options(datadist='ddist') 






#RMS validation of Cox model using IHC_validation dataset 
nomo_valid <- read.csv("IHC_test all.csv", TRUE) 
fit_valid <- cph(Surv(DFI, CENSR) ~VEGF + Decorin + Mitoticrate + 
Age, nomo_valid,x=TRUE, y=TRUE) 
validate(fit_valid, method="boot", B=40, bw=FALSE, rule="aic", 
type="residual", sls=.05, aics=0, force=NULL, estimates=TRUE, 
pr=FALSE, dxy=TRUE, u, tol=1e-9) 
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6.2.5 Statistical validation of the nomograms 
The performance of both the “Clinical_train” and the “IHC” nomogram was 
assessed by determining the concordance index (C-index). The C-index is a 
measure of goodness of fit for binary outcomes in a logistic regression model 
and gives the probability for whether the predicted outcome agrees with the 
observed outcome. The difference between these two measures is Somer’s D 
(Dxy) value. The C-index was calculated from Dxy using the following 
formula: C-index = 0.5 * (Dxy + 1). 
With nomogram development, it is common practice to use resampling 
methods to enable validation of the predictive performance of the Cox model 
used in the nomogram. For this study, the Bootstrap method was employed, 
with the model iteratively applied to 200 randomly created datasets using 
cases selected from the original cohort.[29] The results generated by the ‘rms’ 
validate function in ‘R’ compares the predictive ability of the original data 
with the mean of those derived by bootstrapping. The difference between the 
original C-index and the average derived by bootstrapping is an estimate of 
the overfit, or optimism. 
6.2.6 Validation of the nomograms using an independent dataset 
The performance of the nomogram was next assessed by generating the C-
index using the independent dataset “Clinical_valid”. The bootstrap method 
was again employed, with the model iteratively applied to 200 randomly 
selected samples from the independent cohort. The C-index was calculated 
from Dxy, using the formula as above. 
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6.2.7 Nomogram validation by manual calculation of values 
Following creation of the nomogram, the probability of outcome was 
manually calculated for each case in the original “Clinical” and “IHC” 
datasets. Previously excluded cases from the original population of 350 soft 
tissue sarcoma established in Chapter 3 were included if their “unknown” 
variable was not required in the nomogram calculation. For the Clinical 
dataset, this enabled the addition of another 62 cases where ‘size’ had been 
classified as unknown; the final cohort available for manual validation of the 
Clinical nomogram was now 232 cases. No additional cases were included in 
the IHC dataset for manual validation of the IHC nomogram. 
6.2.8 Sensitivity, Specificity and ROC validation of the nomograms 
The probability score for predicted tumour recurrence derived from the 
nomogram was then plotted against actual tumour recurrence in a Receiver 
Operating Characteristic (ROC) curve.  
Using co-ordinates from the ROC curve, a cut-off value for 3-yr local 
recurrence probability was determined. This cut-off value was then applied to 
the local recurrence probability that had been determined for all patients in 
both the “Clinical” and the “IHC” datasets. This enabled a binary recurrence 
outcome to be predicted. By comparing this predicted outcome with the 
actual outcome in a 2x2 table, Sensitivity, Specificity, Positive Predictive 
Value and Negative Predictive Values could be calculated for both the 
“Clinical” and the “IHC” nomograms.  The area under the curve (AUC) of the 
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ROC curve line was also calculated and compared with the C-index generated 
by the statistical method described above.  
6.3 Results 
6.3.1 Clinical train dataset 
6.3.1.1  Patient Demographics: 
The “Clinical_train” dataset contained a total of 102 patients. During the 
study period, tumour recurrence occurred in 27 patients (27%), with a 
median DFI of 557 days (range 28 – 1068 days). From Kaplan Meier analysis, 
the palpable characteristics of the tumour (fixed vs. mobile) and various 
histological characteristics (necrosis, mitotic rate and grade) were all found 
to have a significant influence on recurrence.  
Calculated hazard ratios for each individual clinical parameter was 
determined by univariate Cox regression analysis. These results suggested 
that a fixed tumour was 4.4 times more likely to recur than a discrete, mobile 
tumour; a high-grade tumour was 2.6 times more likely to recur than a low-
grade tumour; and a tumour with a mitotic index of 3 was 1.9 times more 
likely to recur than a tumour with a mitotic index of 1 (Table 6.2). 
Based on the ROC curves generated for each clinical parameter, the 
predictive ability to determine the actual outcome for patients was 
considered to be poor for tumour size, differentiation, mitotic rate, necrosis 
and age; the AUC for these variables was calculated to be between 0.49 and 
0.60. Only the variables “Palpable characteristics” and “Grade” showed some 
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ability to distinguish patients, with an AUC of 0.68 and 0.67 respectively 
(Table 6.3). 
Table 6.2: 
Demographics – Clinical_train dataset 
 Mean Median Signif. HR  (95% CI) 
Disease free interval 
(days) 764.57 655   
Recurrence 
 Recur = 27 (27%) 
 No recur = 75 (73%) 
    
Differentiation 
 1 = 54 (53%) 
 2 = 38 (37%) 
 3 = 10 (10%) 
  p= 0.7 1.2 (0.7 - 2.2) 
Mitotic rate 
 1 = 80 (78%) 
 2 = 14 (14%) 
 3 = 8 (8%) 
  P = 0.03 1.9 (1.1 - 3.2) 
Necrosis 
 0 = 74 (73%) 
 1 = 23 (23%) 
 2 = 5 (5%) 
  P = <0.001 2.8 (1.6 – 5.0) 
Grade 
 1 = 70 (69%) 
 2 = 24 (24%) 
 3 = 8 (8%) 
  P = <0.001 2.6 (1.6 - 4.3) 
Age 
 3 – 16 years 9.657 9.5  1.0 (0.9 - 1.2) 
Size 
 < 1cm = 6 (6%) 
 1-5cm = 57 (56%) 
 5cm = 39 (38%) 
  P = 0.1 1.0 (0.1 - 6.5) 
Palpable 
 Mobile = 49 (48%) 
 Fixed = 53 (52%) 
  P = 0.001 4.4 (1.8 - 11.05) 
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Table 6.3:  
AUC of ROC curve for individual parameters in the Clinical_train dataset 
Parameter AUC significance 95% confidence interval 
Size 0.581 p = 0.215 0.45 - 0.711 
Palpable characteristics  0.676 p = 0.007 0.561 - 0.79 
Differentiation 0.534 p = 0.606 0.406 - 0.661 
Mitotic rate 0.584 p = 0.197 0.453 - 0.715 
Necrosis 0.604 p = 0.109 0.472 - 0.737 
Grade 0.666 p = 0.011 0.541 - 0.792 
Age 0.488 p = 0.856 0.376 - 0.6 
Mitoses 0.629 p = 0.047 0.501 - 0.757 
 
Using coordinates from the ROC curves, the cut-off values for “palpable 
characteristics” and “grade” was determined to be “fixed, immobile” and 
“grade 2 or grade 3” tumours respectively. When this predicted outcome was 
compared to the actual outcome, the following results were obtained: 
Palpable characteristics: A true positive result was obtained in 21 patients, 
but a further 32 patients were wrongly predicted to experience recurrence 
when they did not (i.e. false positive). Accurate prediction of no recurrence 
was made in 43 patients (i.e. true negative), but tumours recurred in 6 
patients when the test results suggested it would not (i.e. false negative). 
Overall, this gave a sensitivity of 78%, a specificity of 57%, a positive 
predictive value of 40%, and a negative predictive value of 88% 
Grade: A true positive result was obtained in 15 patients, but a further 17 
patients were wrongly predicted to experience recurrence when they did not. 
Accurate prediction of no recurrence was made in 58 patients, but tumours 
recurred in 12 patients when the test results suggested it would not. Overall, 
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this gave a sensitivity of 56%, a specificity of 77%, a positive predictive value 
of 47%, and a negative predictive value of 83%. 
6.3.1.2  Nomogram construction: Clinical 
Using backward selection multi-variable Cox regression analysis, the optimal 
variables for use in the nomogram was determined, as shown in Table 6.4.  
Table 6.4 
Multivariable COX regression analysis on Clinical_train database to identify 
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Based on these results, “Palpable characteristic”, “Mitotic Rate” and 
“Necrosis” were used to generate a nomogram to calculate the probability for 
being tumour free at 3 years (Figure 6.1). 
Figure 6.1: 
Nomogram developed from the Clinical_train dataset 
 
 
6.3.1.3  Statistical validation of the clinical nomogram 
Validation of the Cox model using the training dataset (Clinical_train) 
generated a Dxy value of 0.45, which equated to a C-index of 73%. With 
bootstrapping, the Dxy value was 0.44, which equated to a C-index of 72%. 
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From these values, the optimism-corrected estimate of Dxy was 0.4, giving a 
C-index of 70%. 
When validation of the Cox model was performed using the independent 
dataset (Clinical_valid), the Dxy value was 0.23, which equated to a C-index 
of 61%. With bootstrapping, the Dxy value was 0.14, which equated to a C-
index of 57%. From these values, the optimism-corrected estimate of Dxy was 
0.03, equating to a C-index of 51%. 
6.3.1.4 Manual validation of the clinical nomogram 
Use of the nomogram is relatively simple and involves 3 separate steps, as 
shown in Figure 6.2. Firstly, using the scale for each variable, the ‘Points’ 
scale at the top of the chart is used to determine the individual value for each 
patient. Next, the ‘total score’ of all variables are totalled. Finally, the ‘Total 
points’ scale is used to determine the ‘probability of outcome’, with values 
read from the 3-year DFS (disease free survival) probability scale.  
Using the probability values generated from the nomogram for each case in 
the “Clinical” database, the resulting ROC curve gave an AUC of 0.67 (95% CI 
0.6 – 0.75, p= <0.0001) (Figure 6.3). 
Using coordinates of the ROC curve, the optimal cut-off value of probability 
to provide a binary predictor of tumour recurrence within 3 years was 
determined to be >85%. When this value was applied to all cases in the 
Clinical dataset, the nomogram was found to have correctly identified 41 
patients where recurrence occurred (true positive), but incorrectly predicted 
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Figure 6.2: 
Steps to using a nomogram. 1) determine the POINTS scored for each 
characteristic defined in the nomogram 2) Total these points and identify this value 
on the TOTAL POINTS scale. 3) The 3-year disease free interval is then determined 





recurrence in 110 patients when no recurrence was observed (false positive). 
The nomogram accurately predicted tumour-free survival in 73 patients (true 
negative), but failed to predict recurrence in 9 patients (false negative). 
Overall, the sensitivity, specificity, positive predictive and negative predictive 
values for the Clinical nomogram were 82%, 40%, 27% and 89% respectively.  
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Figure 6.3: 
ROC curve generated from probabilities derived from Clinical nomogram 
 
6.3.2 IHC dataset 
6.3.2.1  Patient Demographics 
The IHC dataset contained a total of 82 patients (Table 6.4). Tumour 
recurrence developed in 26 patients (32%), with a median DFI of 655 days 
(range 28 – 1098 days). From Kaplan Meier analysis, immunostaining of 
VEGF, necrosis and the palpable characteristics for the tumour were all 
found to be influential on recurrence.  
Calculated hazard ratios for each individual clinical parameter, as determined 
by univariate Cox regression analysis, are shown in Table 6.5. These results  
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Table 6.5:   
Demographics - IHC dataset 
 
 Mean Median Range Signif. HR  (95% CI) 
Disease free interval 
(days) 772.51 655 
   
Recurrence 
 Recur = 26 (32%) 
 No recur = 56 (68%) 
     
VEGF score 
 Low = 43 (52%) 
 High = 39 (47%) 
   p= <0.001 8.4 (2.9 - 24.4) 
Decorin score 
 1 = 26 (32%) 
 2 = 22 (27%) 
 3 = 34 (42%) 
   p= 0.7  
Differentiation 
 1 = 31 (38%) 
 2 = 40 (49%) 
 3 = 11 (13%) 
   p= 0.7  
Mitotic rate 
 1 = 61 (74%) 
 2 = 12 (15%) 
 3 = 9 (11%) 
   p= 0.6  
Necrosis 
 0 = 54 (66%) 
 1 = 23 (28%) 
 2 = 5 (6%) 
   p= 0.003 
- 
1.1 (0.4 - 2.7) 
7.2 (1.9 - 26.7) 
Grade 
 1 = 46 (56%) 
 2 = 27 (33%) 
 3 = 9 (11%) 
   p= 0.5  
Age 9.77 10 12   
Size 
 < 1cm = 2 (2%) 
 1-5cm = 45 (55%) 
 >5cm = 21 (26%) 
   p= 0.2  
Palpable 
 Mobile = 32 (39%) 
 Fixed = 45 (55%) 
   p= 0.03 - 2.7 (1.1 - 6.8) 
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suggested that a tumour with diffuse immunostaining for VEGF was 8.4x 
more likely to recur than one with low immunostaining. A tumour with >50% 
necrosis was 7.2x more likely to recur than one with minimal necrosis, and a 
fixed tumour was 2.7x more likely to recur than a mobile one. 
Using the ROC curve, the predictive ability of individual test characteristics 
to reliably determine the actual outcome for patients was considered to be 
poor. For the variables decorin, differentiation, mitotic rate, necrosis, grade, 
age and tumour size, the AUC was calculated to be between 0.49 and 0.64 
(Table 6.5). Only VEGF showed some ability to distinguish patients, with an 
AUC of 0.79 (Figure 6.4). 
Using coordinates from the ROC curves, the cut-off value for VEGF to 
determine a binary decision for recurrence was “1”. When this predicted 
outcome was compared to the actual outcome, true positive results were 
obtained in 22 (27%) patients, but a further 17 (21%) patients were wrongly 
predicted to experience recurrence when they did not (false positive). 
Accurate prediction of no recurrence was made in 39 (48%) patients (true 
negative), but tumours recurred in 4 (5%) patients when the test results 
suggested it would not (false negative). Overall, this gave a sensitivity of 84%, 
a specificity of 70%, a positive predictive value of 56%, and a negative 
predictive value of 90%. 
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Figure 6.4: 




AUC of ROC curve for individual parameters in the IHC dataset 
Parameter AUC significance 95% confidence interval 
VEGF 0.786 p = <0.001 0.677 - 0.895 
Decorin 0.534 p = 0.628 0.398 - 0.669 
Differentiation 0.488 p = 0.863 0.354 - 0.622 
Mitotic rate 0.517 p = 0.804 0.379 - 0.655 
Necrosis 0.54 p = 0.572 0.399 - 0.68 
Grade 0.506 p = 0.936 0.37 - 0.642 
Age 0.626 p = 0.072 0.5 - 0.752 
Size 0.52 p = 0.779 0.374 - 0.665 
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6.3.2.2 Nomogram construction: IHC 
The stepwise determination of optimal variables using backward selection 
multi-variable Cox analysis is shown in Table 6.6. Based on these results, four 
variables - VEGF, decorin and mitotic rate and age - were used to generate a 
nomogram to calculate the probability for being tumour free at 3 years 
(Figure 6.5). 
Table 6.6: 
Stepwise backward selection of variables in the IHC database using Cox regression 
analysis eventually identified four characteristics of appropriate significance to be 
used in the nomogram 
 Clinical characteristic Significance HR 95.0% CI for HR 
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Validation of the Cox model using all of the cases in the IHC dataset 
generated a Dxy value of 0.6. This equated to a C-index of 80%. With 
bootstrapping, the D value was 0.61, which equated to a C-index of 81%. This 
provided an optimism-corrected C-index of 76%. 
Figure 6.5: 
Nomogram developed from the IHC dataset 
 
6.3.2.3 Manual validation of the IHC nomogram 
Using the probability values generated from the nomogram for each case in 
the IHC database, the resulting ROC curve gave an AUC of 0.84 (95% CI 0.76 
– 0.93, p= <0.0001) (Figure 6.6). 
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Figure 6.6: 
ROC curve generated from probabilities derived from IHC nomogram 
 
Using coordinates of this ROC curve, the optimal cut-off value of probability 
to provide a binary predictor of tumour recurrence within 3 years was 
determined to be >90%. When this value was applied to all cases in the IHC 
dataset, the nomogram was found to have correctly identified 25 patients 
where recurrence occurred (true positive), but incorrectly predicted 
recurrence in 31 patients when no recurrence was observed (false positive). 
The nomogram accurately predicted tumour-free survival in 25 patients (true 
negative) but failed to predict recurrence in 1 patient (false negative). Overall, 
the sensitivity, specificity, positive predictive and negative predictive values 
for the IHC nomogram were 96%, 45%, 45% and 96% respectively.  
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6.3.3 Summary of results  
When the predictive abilities of individual tumour characteristics are 
compared with the results of both the clinical and IHC nomogram, the IHC 
nomogram shows clear superiority in providing a reliable prediction of 
outcome with an AUC of 0.84 (Table 6.7). 
Table 6.7: 
Comparison of predictive abilities of individual tumour characteristics are compared 
with the results of both the clinical and IHC nomogram 
 C-index 
AUC of ROC curve 
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Key: C-index = concordance index 
 AUC of ROC curve = area under curve of receiver operating curve 
 Sens = Sensitivity 
 Spec = Specificity 
 PPV = Postive predictive value 
 NPV = Negative predictive value 
 
6.4 Discussion 
The results from this study suggest that a nomogram may be useful to help 
predict the likelihood for a STS to recur after surgery in a dog. Of the two 
nomograms developed in the current study, inclusion of the 
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immunohistochemical staining characteristics developed in Chapter 4 
significantly improved the reliability of the prediction provided by the model. 
While the use of various clinical and histological characteristics of the tumour 
have been used for many years to help predict potential tumour behaviour, 
this is the first time the use of a graphical calculating tool such as a 
nomogram has been described in veterinary medicine.  
The purpose of the nomograms developed in this study was to identify dogs 
whose tumours were more likely to recur after surgery. This endpoint was 
selected as it is known that local recurrence of the tumour is the most 
common cause of tumour-related death.[1] If these dogs could be identified 
earlier, it is possible that their lives could be saved or prolonged by 
performing a wider resection of the tumour scar, or by providing other 
adjuvant therapies such as chemotherapy or radiotherapy to prevent 
progression of their tumour.  
An important attribute of any diagnostic test is its ability to provide an 
accurate prediction of the true disease status of an individual patient. A 
diagnostic test needs to have an optimal balance between sensitivity and 
specificity; this will ensure the animals that the test is intended to identify are 
not overlooked (false-negatives), while animals who do not have the attribute 
are not inadvertently included (false-positives). From the current study, the 
AUC of the ROC curve for individual tumour characteristics such as size, age, 
mitotic rate and necrosis was between 0.5 and 0.6, which suggests their 
ability to predict which individual was likely to have an undesirable outcome 
was not much better than flipping a coin. Only the grade and palpable 
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characteristics of the tumour provided some improved differentiation, but a 
high degree of uncertainty remained in the prediction. Using these criteria 
alone, it would be challenging for a clinician to recommend that a dog 
undergo further treatment when there is up to a 50% chance that the dog has 
been falsely identified as being ‘at-risk’ and recurrence will actually never 
occur. 
When several characteristics of the tumour, including palpable 
characteristics, mitotic rate and necrosis score, were combined into a 
nomogram using statistical modelling, the ability to predict outcome 
improved with a sensitivity of 82%, However, because specificity remained 
poor, there were almost three dogs wrongly suspected of being at risk of 
recurrence for every dog correctly identified. 
It was only when the immunohistochemical characteristics of the tumour 
were included in the model that the predictive abilities of the nomogram 
began to demonstrate some degree of clinical utility. However, even in this 
instance, there was still an almost 40% false positive rate. This would again 
create challenges for a clinician who needs to decide whether to recommend 
additional treatment for an individual patient. 
Although the nomograms developed in this current study may not, in their 
existing form, provide a clinician with the precision required to accurately 
identify patients where recurrence was more likely, the high sensitivity of the 
IHC nomogram does allow a clinician to accurately identify patients where 
recurrence is unlikely to occur. Using the IHC dataset, the nomogram 
accurately predicted tumour-free survival in more than 96% of patients. 
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Within the study population, the risk of recurrence was almost 30%, and 
there was no other ability to distinguish the patients where recurrence was 
likely or unlikely to occur. However, by using the information from the IHC 
nomogram, a clinician could confidently identify the patients where tumour 
recurrence would not occur. For the owners of these dogs, progressing from a 
30% possibility that recurrence could develop after surgery to an almost 
100% certainty that their dog’s tumour was not going to recur can provide a 
tremendous degree of relief. 
Nevertheless, the inability of the nomograms to reliably predict which STS 
will recur is a major weakness, and suggests they lack some vital 
distinguishing characteristic that would improve differentiation. One of the 
obvious deficiencies in the data used to develop the nomograms in the 
current study is the absence of information on the completeness of tumour 
resection, or the histological margin. It is generally accepted that 
demonstration of a resection margin that is clear of tumour cells is 
considered the best predictor for improved local tumour control,[1, 7, 30-36] 
It is therefore likely that if information on the histological completeness of 
the surgical margin were included in the nomogram, this would improve the 
specificity of the nomograms developed in this study. 
Despite this lack of information on the surgical margin, it is interesting that 
the nomograms developed in this study were able to provide a reasonably 
accurate prediction of tumour recurrence. This lends support to the 
hypothesis that the status of the surgical margin is not always a definitive 
guide to a patient’s outcome after surgery, with other aspects of tumour 
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biology influencing the ability for a tumour to regrow after surgery, 
irrespective of whether the surgeon has successfully removed all of the 
neoplastic cells. As discussed in Chapter 2, a STS may recur even when the 
histologic margins have been determined to be complete, and an incomplete 
surgical margin does not mean tumour recurrence is inevitable. In dogs, 
recurrence rates for STS of between 5-22% have been reported when a clean 
resection has been achieved, and no regrowth may occur in up to 83% of 
patients when incomplete or close resection margins have been described.[7, 
37] Similar findings have been reported for human soft tissue sarcoma.[38]   
It is therefore an intriguing prospect that the IHC nomogram developed in 
this study was able to provide a reasonable prediction of tumour outcome 
after surgery, even though the model incorporated no knowledge about the 
surgical margin or whether there was persistence of tumour cells within the 
wound bed. One of the goals of this PhD was to identify predictive markers 
for STS behaviour that could assist the surgeon in identifying when a STS 
could be safely treated with a conservative resection, or when an aggressive 
resection with adjuvant therapy should be considered. The results of the 
current study raise the possibility that a nomogram could be used to predict 
the potential for an individual tumour to recur, even before surgery has been 
performed. Such a strategy could enable a clinician to determine the 
appropriate surgical margins required for effective management for that 
individual tumour. There are currently only a limited number of publications 
in human oncology that describe the development of a nomogram to enable 
prediction of surgical margins.[23, 39, 40] In one paper, a nomogram was 
developed to enable better pre-operative stratification of patients due to 
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undergo breast conserving surgery (BCS) for early-stage breast cancer.[23] 
Breast conserving surgery is a highly effective strategy for the treatment of 
women with localised breast cancer and may be preferred over more radical 
mastectomy procedures due to the reduced morbidity and cosmetic impact of 
surgery. However, if conservative surgery is performed on a tumour that 
proves to be more aggressive than was originally suspected, then the patient 
will need to undergo additional surgery and adjuvant treatment in an effort 
to regain effective control of their tumour. This situation is the current reality 
of surgical planning for many forms of cancer: that is, the information 
necessary to predict the prognosis and best treatment strategy for a patient 
only becomes available to a clinician once the surgery has already been 
performed. Ideally, the planning of cancer surgery should be performed in 
conjunction with appropriate knowledge about the tumour’s innate 
behaviour. This would enable to surgeon to perform an appropriate dose of 
surgery – with dose equating to the extent of surgical margins performed 
about the mass – required to achieve successful control of that individual 
tumour. Evidence from the IHC nomogram developed in the current study 
suggests that such a strategy could be viable, but further development 
validation would be required. In reality, oncologic surgeons would need 
exceedingly good evidence to be convinced that surgical margins could be 
deliberately reduced about a STS, as the consequences of an incomplete 
resection could be detrimental for the affected patient.  
There have been numerous studies on the use of nomograms to predict 
various aspects of the clinical decisions surrounding cancer management,[15-
20, 23, 24, 26, 39-42] but the actual uptake of these in the clinical setting is 
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unknown. Each of the studies described above was performed retrospectively, 
using data from patients who had already undergone surgery. To date, there 
is only one publication that reports a nomogram being used prospectively to 
influence surgical decisions.[40] In that study, a pre-operative nomogram 
was used to decide whether or not intraoperative assessment of the tumour 
margins using frozen sections should be performed. In that study it was 
shown that using the nomogram to influence surgical decisions did not 
significantly increase the re-operation rate due to a positive resection margin 
compared with the control group. By using the nomogram, the surgical time 
of almost 62% of patients was reduced without any detrimental effects. While 
this study lends some support to the concept of using a pre-operative 
nomogram to improve surgical decisions for the benefit of the patient, 
additional studies are required to confirm the results of this single study.  
There are many limitations to the nomograms developed in the current study 
that would limit their immediate application in clinical practice. These 
limitations can be divided into three main components, namely 1) the 
nomogram construction, 2) nomogram interpretation and 3) its clinical 
application. 
The first limitation of the proposed nomograms is in the construction of the 
algorithm that resides behind the pictorial nomogram. The nomograms 
described in the current study were constructed using data from a 
retrospective study that assessed the outcome for dogs with STS that were 
surgically excised in first opinion practice. Ideally, the patient cohort used to 
derive the nomogram should be representative of the diseased population. As 
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was described in Chapter 3, there are significant differences in the surgical 
outcomes of dogs with STS operated in first opinion practice and dogs that 
are referred to a specialist centre. Due to these differences it is likely that a 
nomogram developed from a first opinion population may not be 
transferrable to a case that is being managed in a referral centre. The bias 
towards low grade tumours within this archive population may also impact 
on the transferability of this nomogram to a wider population. This bias may 
also explain why tumour grade was not utilised within any of the nomograms 
developed in the current study, even though grade is one of the most 
consistent and validated tumour characteristics to differentiate likely 
behaviour after surgery.[37]  
It should also be considered that the quality of surgery performed in first 
opinion practice will also have an influence on the rates of tumour recurrence 
on which this data is based. Veterinarians working in first opinion surgery 
will have a range of surgical skills, and very few will have had any particular 
training in oncologic surgery. As has been discussed in previous chapters, the 
ability to maintain an appropriate en bloc resection margin about a STS 
requires considerable confidence and cognisance of anatomical features. 
Inexperienced surgeons may not have the confidence to maintain a consistent 
dissection plane about the entire circumference of a STS, particularly if it is 
large, more firmly fixed to the surrounding tissues, or located close to vital 
structures. As the dissection proceeds deeper into the tissues, there will be a 
desire to find a comfortable cleavage plane that allows the tumour to more 
easily elevate away from the tissues. The pseudocapsule that surrounds a STS 
can provide the inexperienced surgeon with this comfort zone, and allows 
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them to complete the difficult phase of the surgery successfully. However, by 
straying closer to the pseudocapsule and reactive zone of the STS, there is a 
risk that a higher proportion of microscopic tumour cells will have been left 
behind in the wound. Because the nomogram is founded on the hypothesis 
that elements of tumour biology are influential on the risks of tumour 
recurrence, this variance in surgical quality poses the challenge that 
recurrence of a STS in some cases was due to inadequate surgery rather than 
the effects of tumour biology. If this is true, the logistic regression equation 
on which the nomogram is based will be inaccurate, leading to an 
inappropriate estimation of risk. Ideally, the nomogram would need to be 
validated or reconstructed using data derived from a population of dogs 
operated by trained oncologic surgeons, to ensure this risk of bias is 
eliminated.  
Another important limitation of the data quality on which the nomograms 
are constructed is the fact that information on cases within the study was 
collected retrospectively; this may result in recall bias or inaccuracy within 
the responses. Veterinarians completing the survey were reliant on clinical 
notes that had been written many years previously. This raises the possibility 
that some of the clinical information supplied about the tumour may be 
inaccurate. This deficiency could have an impact on the Clinical nomogram, 
which utilised a subjective description about the tumour in its algorithm. For 
example, the distinction of whether a tumour is “fixed” or “mobile” is subject 
to individual interpretation by the clinician. In the IHC nomogram, the 
variables used were less liable to misinterpretation, as it utilised more 
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objective or defined data such as age, mitotic rate and immunostaining 
characteristic of VEGF and decorin. 
An additional deficiency of the current study was the small number of cases 
used to construct the nomogram. The small size of the population cohorts 
used in both the Clinical and the IHC nomogram will have a significant 
impact on the ability to detect statistical differences between the covariates 
selected for inclusion within the nomogram. Large studies that contain many 
hundreds of patients are more likely to detect subtle influencing 
characteristics within a population that may potentially be overlooked in a 
smaller study cohort. Most human studies where nomograms have been 
described and accepted within the clinical community have typically utilised 
sample sizes 10-100 times larger than that used in the current study.  
The small sample size will also reduce the reliability of the regression 
calculations. When an outcome is binary - i.e. did tumour recurrence occur or 
not - then published guidelines for nomogram construction state that the 
number of recurrences should be greater than 10 times the number of 
predictors used in the calculation, to give an expected error rate of less than 
10%.[28, 43] In both of the nomograms developed in this study, the small 
sample size made it impossible to have 10 times the number of events for 
each predictor. For example, in the Clinical_train dataset, three covariates 
were used in the calculation but there were only 27 dogs with tumour 
recurrences. This is less than the 30 events that would be the minimum 
recommended number. Within the IHC dataset, four covariates were used in 
the calculation but only 26 recurrences were present. For the current study, 
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reducing the number of variables within the nomogram was not feasible as it 
resulted in less differentiation between cases, and reduced accuracy. Ideally, 
considering the number of included variables, the nomograms would need to 
be developed using a disease population at least two or three times larger 
than the one used. 
The covariates used in the nomograms were selected using the results of a 
multi-variable Cox proportional hazards model. Because of the small number 
of cases in the cohort, covariates were selected when significance was only 
0.15, rather than a more conventional figure of 0.05. The use of 0.15 means 
that there is a 15% (almost 1 in 6) chance that the selected variable does not 
actually influence the outcome as suspected. In contrast, when using a p 
value of 0.05 this means that there is just a 5% (1 in 20) chance that the effect 
of the variable is simply due to chance. By broadening the inclusion of 
potentially relevant cases into a selected variable in this way, the accuracy of 
the nomogram will suffer. Because the selected variable may now lack 
sufficient distinguishing power, the nomogram may identify cases that are at 
risk of developing tumour recurrence, when they did not. This lack of 
accuracy will increase the number of false-positive results and explains the 
poor specificity of the nomograms developed in this study. The only way of 
overcoming this potential Type 1 error would be to increase the sample size of 
the study population so that there were sufficient cases within each variable. 
This would ensure that the proportion that developed the relevant outcome 
was then sufficient to meet the accepted 5% statistical threshold.  
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Another potential source of error that may limit the reliability of the 
nomogram is if any of the selected variables are likely to exert an influence on 
another. If the variables used in the nomogram are not truly independent of 
each other, then there are no additional benefits from including the 
additional characteristic in the algorithm. This dependence may also bias the 
selection of cases, as a case with one dependent variable is likely to gain an 
additional score on the nomogram from its related variable. In the IHC 
nomogram developed in the current study, the variables decorin, mitotic rate, 
and VEGF were identified by the Cox model as having an independent 
influence on outcome and were selected as characteristics to be used in the 
nomogram. In Chapter 4, we did not identify any obvious correlation between 
VEGF and decorin on Chi square analysis. However, at a physiological level, 
decorin is recognised as an important tumour suppressor.[44] It follows that 
reduced levels of decorin within a tumour will increase the availability of 
VEGF and other sequestered cytokines within the tumour 
microenvironment.[45] Possible variations in the proportions of VEGF 
isoforms within the tumour, the focus of study in Chapter 5, may also impact 
on the bioactivity of this important angiogenic protein within the tumour 
microenvironment. The varied bioavailability of these cytokines within the 
tumour microenvironmnent will likely have diverse consequences on the 
tumour, including influences on cellular metabolism, mitotic activity and the 
production of other, unmeasured molecules that may influence tumour 
progression. It follows that the true independence of VEGF, decorin and 
mitotic index cannot be assured, and it is likely that more sophisticated 
statistical tools would be required to analyse this further. 
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The second component of nomogram construction that requires examination 
is whether the performance of the algorithm is reliable, and relevant to the 
target population. The ultimate goal of a nomogram is to predict the outcome 
for an individual as accurately as possible. Calibration is therefore an 
essential step of nomogram development as it provides an objective measure 
of the ability of the nomogram to reliably discriminate patients based on the 
individual characteristics used in the model. The predictive accuracy of a 
nomogram is defined by the concordance index (C-index), which provides an 
objective measure of the difference between the predicted outcome and the 
actual outcome. By knowing the C-index, together with the 95% confidence 
interval, it is possible to gauge how reliable a particular nomogram will be. A 
C-index of 0.5 suggests the nomogram has no discriminating ability, with the 
prediction no better than a 50:50 chance - similar to a ‘heads’ or ‘tails’ 
outcome from a coin-flip. In the current study, the C-index for the IHC 
nomogram was 0.84, which suggests that the nomogram was able to discern 
a patient that would experience tumour recurrence from a patient that would 
not develop recurrence 84% of the time. However, the 95% confidence 
interval suggests the actual range may actually be between 76% and 93%.  
The gold standard for nomogram calibration is to utilise an independent 
dataset i.e. one that is distinct from the population originally used to develop 
the nomogram.[5] In the current study, external validation was performed 
for the clinical nomogram by splitting the original dataset into two 
populations, with one set used for development and training of the model, 
and the other for external validation. The external validation dataset showed 
a disappointing discrimination ability, with a C-index of only 0.51, compared 
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to 0.71 that was described for the training cohort. This poor performance of 
the external validation raises serious questions about the reliability of the 
nomogram construction and would make it unsuited to use in a clinical 
setting. The reasons for this poor performance of the nomogram with the 
external dataset ultimately reflect the many limitations of the training dataset 
that have discussed in the previous section on nomogram construction. 
It should also be noted that splitting the original population into two, as was 
performed in this current study, does not create a truly independent dataset. 
This is because the population used for the validation has ultimately been 
derived from the same study as the training dataset. The cases in the 
validation dataset are thus influenced by the same biases and limitations that 
affected the training dataset; these biases and limitations were outlined in the 
previous section. Ideally, external validation should be performed with a truly 
separate population. Although the author did have data from a previous 
study that had been derived from the population of dogs operated in first 
opinion practice,[30] the histological descriptions for each of these tumours 
was limited and a precise mitotic index and necrosis score was not available. 
Immunohistochemical staining of these cases had also not been performed. 
None of this data was therefore appropriate for use with the existing 
nomogram.  
External validation of the IHC nomogram developed in the current study was 
not possible due to the small size of the original population cohort. Attempts 
to divide the database into a training and a validation cohort failed as there 
were insufficient events in each group to allow for adequate statistical 
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modelling. In this instance, validation relied completely on a statistical 
methodology called bootstrapping. Using this method, a validation dataset is 
created by randomly sampling cases from the original cohort. Due to random 
selection, it is possible that Patient A from the original cohort may be 
represented 3 times, whereas Patient B will not be represented at all. The 
nomogram is then applied to this bootstrap cohort, and the C-index 
calculated. This process is then repeated again and again - for the current 
study the number of repetitions was 200 – and the mean of the C-index of all 
200 bootstrap samples derived. For the IHC nomogram, there was good 
agreement between the C-index of the original dataset and the mean C-index 
by internal validation, but because this is achieved by resampling of cases 
from the original dataset, such good agreement should not be unduly 
surprising. Therefore, confidence in the performance of the IHC nomogram 
will only be achieved when it has been validated against an external 
population.  
The final component of nomogram development that requires scrutiny is 
whether it is ultimately suited for use in a clinical setting. The ultimate 
purpose of a nomogram is to provide a patient or clinician with a better 
prediction of outcome or optimal treatment choices compared to clinical 
judgment alone. Because there will always be limitations and possible errors 
with any predictive tool, it is important that users of the nomogram 
understand the potential deficiencies of the method. One important criterion 
that a successful nomogram must meet is whether it can outperform clinical 
judgement; if an experienced clinician can provide a prognosis for the patient 
with a reliability that is equivalent or better than the nomogram, then there is 
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little to be gained by using this tool. There have been several studies in 
human medicine that have attempted to address this question. In one study 
evaluating patients with prostate cancer, the performance of 22 different 
nomograms was compared to clinical judgment alone. Only 13 (59%) of the 
nomograms showed a predictive ability better than a human expert.[46] In a 
further experiment, clinicians were provided with concise summaries of the 
patient, and asked to predict both the 5-year recurrence-free probabilities for 
each patient, and also the potential for the disease to have spread beyond the 
prostate. The clinician’s predictions were then compared with the outcome 
provided by the nomograms. This study showed that nomogram predictions 
of organ-confined disease were comparable to those provided by a clinician, 
with a C-index of 0.79 and 0.78. However, other studies have suggested that 
nomograms can significantly outperform human experts,[26] and may 
provide a patient with the necessary objectivity to support a particular 
treatment decision.[42] However, it is also important to recognise that there 
are no current methodologies that can predict patient outcome with perfect 
accuracy. Furthermore, while a well-constructed and validated nomogram 
may be considered an accurate and discriminating tool for predicting a 
particular outcome for a patient with cancer, it must be recognised this is 
simply an objective prediction that may be isolated from other clinical 
considerations that may be relevant to that patient. A nomogram cannot 
make treatment recommendations based on other patient characteristics or 
co-morbidities, or act as a surrogate for interactions between the veterinarian 
and the pet owner or client. They also do not provide definitive information 
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on symptomatic disease progression or the potential for complications 
associated with treatment.[42] 
6.5 Conclusion 
In conclusion, the results for this current study provides the first evidence in 
veterinary oncology to support a role for the nomogram to assist with 
predicting the outcome for patients after surgery for STS. From the 
evaluations performed, a nomogram that incorporates data from IHC 
interrogation of the tumour is more reliable than a nomogram that does not. 
However, while it is evident that nomograms may have the power to become 
an important component of decision making for the cancer patient, they will 
need to demonstrate robust reliability and accuracy if they are to completely 
supplant the insight and judgement of a clinical expert. 
Evidence from this study suggests a nomogram could play an important role 
in helping to identify patients who either have no risk of recurrence after 
surgery, or who are liable to experience recurrence at some time in the future. 
These latter patients may choose to undergo additional therapy – either a 
wider surgical resection, radiation therapy or chemotherapy – to help reduce 
this risk of recurrence. It is also of interest that the nomograms developed in 
this study were able to predict this recurrence risk by using a combination of 
clinical and biological information derived from the patient and tumour 
details only, and were not reliant on information that would become revealed 
once a surgery has been performed, such as the extent of histologic margins. 
This supports the conclusions from previous chapters that suggest it may be 
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elements of tumour biology and not the surgical strategy that are influential 
in the prognosis of STS. This discovery lends support for using a nomogram, 
or other predictive tools to help determine the actual surgical margins 
required for an individual tumour, using information gained from a pre-
operative interrogation of the tumour. Additional study will be required to 
ensure such a tool could be reliably and confidently incorporated into routine 
surgical planning. 
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Chapter 7:  
Targeting vascular endothelial growth factor as an adjuvant 
treatment for soft tissue sarcoma 
7.1 Introduction 
n previous chapters, it was shown that increased levels of vascular 
endothelial growth factor (VEGF) within a soft tissue sarcoma (STS) 
influenced tumour progression. Using immunohistochemistry, a STS 
with diffuse VEGF immunostaining was more likely to recur or cause 
death of the dog; this influence was independent of the surgical margins 
performed. 
The reason why increased immunostaining of VEGF within a STS should be 
associated with an higher rate of tumour recurrence is unknown. In Chapter 
4, it was speculated that detection of high VEGF may be a surrogate indicator 
for a STS that has a more permeable pseudocapsule that enables a wider 
migration of neoplastic cells into the surrounding tissues.[1] Alternatively, 
the high VEGF level may indicate that the tumour has evolved from a more 
hypoxic microenvironment.[2] Such a tumour may harbour a higher 
proportion of dormant tumour cells that are able to regenerate when 
favourable conditions return to the wound bed after healing is complete.[3] A 
further possibility is the extracellular matrix (ECM) surrounding a tumour 
that had diffuse VEGF immunostaining will also be rich in VEGF and other 
I 
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angiogenic molecules. This residual tumour microenvironment within the 
wound bed may be more enabling of further oncogenesis than the residual 
wound of a tumour with low VEGF. Either or all of these possibilities may 
allow an individual tumour to be more able to re-grow following surgical 
resection.[4, 5] 
If high VEGF promotes tumour recurrence and is associated with poorer 
survival, it follows that suppression of VEGF production could potentially 
slow tumour recurrence and progression. To test this hypothesis, thalidomide 
was used to suppress VEGF production within splenic haemangiosarcomas 
(HSA) in a series of dogs. Thalidomide was used as this has been shown to be 
a potent suppressor of angiogenesis through its effects on the expression of 
several genes influential on angiogenesis, particularly VEGF.[6] 
Dogs with HSA were selected for this study rather than STS to allow the 
hypothesis to be tested in a timely and cost-effective manner. Soft tissue 
sarcoma can be slow to recur, and recurrence may not develop until up to 2 
years after surgery in the majority of patients. Furthermore, local recurrence 
may occur in only 20% of patients. Therefore, to determine whether or not 
thalidomide could significantly reduce the incidence of local recurrence of 
STS by 50%, almost 500 patients would be required in each treatment group. 
Recruiting enough dogs into such a study would be difficult and would take 
many years to complete. Furthermore, due to the high numbers of dogs 
required, such a study would be very costly to perform. In contrast, virtually 
all dogs with splenic HSA will die due to tumour recurrence and almost 50% 
of patients will develop metastatic disease after splenectomy within 2-3 
Chapter 7: Targeting VEGF with thalidomide - page 237	
months.[7-11] This high rate of rapid recurrence greatly reduces the time 
required to complete the study. A power analysis suggested that as few as 10 
dogs would be required if thalidomide increased the survival time from 60 
days to 300 days. An additional benefit of using HSA as a model is that these 
neoplasms are common in dogs, representing between 12 to 21% of all 
mesenchymal malignancies, with an estimated incidence rate of 24/100,000 
dogs per year.[8, 12-14]. While HSA do have some differences to STS, both 
neoplasms are mesenchymal in origin and have been shown to share some 
common molecular characteristics.[15, 16] This suggests that an effect of 
thalidomide on the progression of HSA could translate to a similar result 
being expected for STS. 
The aim of the study described in this chapter was to compare survival times 
of dogs that received thalidomide to dogs that did not receive thalidomide 
after they had undergone splenectomy due to splenic HSA. The hypothesis 
was that thalidomide would significantly increase the survival time in treated 
patients. 
7.2 Materials and methods 
7.2.1 Patient inclusion: Treatment group 
The inclusion criteria for dogs recruited to the treatment arm of this study 
included recovery after splenectomy, and a histological diagnosis of HSA. 
There were no exclusion criteria. Sections from all tumours were confirmed 
to be splenic HSA by a specialist veterinary pathologist using a combination 
of histology and immunohistochemistry (IHC). The criteria that enabled 
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positive identification of a HSA were positive immunostaining for CD31 
and/or Factor VIII-related antigen. Immunostaining was performed at a 
commercial laboratory using previously validated techniques,[17, 18] as 
described below. The patient signalment was recorded, as well as body weight 
and the date of surgery. 
Complete tumour staging was performed in all dogs at the commencement of 
the study.[11] (Table 7.1) This was achieved with computed tomographic 
imaging (CT) of the abdomen and thorax, with 1.5mm sections. No contrast 
agent was used. All dogs were sedated for the scan with medotomidine 
(0.005 mg/kg) and torbugesic (0.1mg/kg), administrated intravenously. The 
presence and location of any possible metastatic lesions was noted, but fine 
needle aspiration or biopsies were not performed. Sedation was reversed 
using atipamazole 0.001mg/kg, subcutaneously. After recovery from 
sedation, the dogs were discharged to their owners.  
Table 7.1:  
Stage Classification for canine HSA (from Wood et al, Prognosis for dogs with stage 
I or II splenic HSA treated by splenectomy alone: 32 cases (1991-1993). J Am Anim 
Hosp Assoc. 1998;34(5):417-21)[11] 
Stage I Primary tumour only 
Stage II Primary tumour with splenic rupture or lymph node involvement 
Stage III Primary tumour with splenic rupture or lymph node involvement and evidence of distance metastasis 
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Owners were required to contact the principle investigator every month in 
order to receive further thalidomide medication for their dogs. On each 
occasion, the owners provided information on their dog’s current status 
including activity levels, and the presence of any possible side effects. 
A full clinical examination, and repeat evaluations of the abdomen and 
thorax using a CT scan was repeated 3 months after commencing treatment, 
using the same sedation protocol outlined above.  
In the event of the dog’s death or euthanasia, the primary care veterinarian 
was asked to confirm the cause of death. A cosmetic post-mortem of both 
chest and abdominal cavities was performed, and samples of any secondary 
lesions were collected for histopathology if they were present. 
7.2.2 Patient inclusion: Control group 
Control cases were recruited using records from two commercial laboratory 
services in New Zealand: Gribbles Laboratory and New Zealand Veterinary 
Pathology (NZVP). Databases from each laboratory were searched to identify 
dogs with histologically confirmed splenic HSA diagnosed during the same 
time period as the treatment arm of the study (2012-2014). Histology 
sections from identified tumours were reviewed by a specialist veterinary 
pathologist to confirm the diagnosis of splenic HSA, using a combination of 
histology and immunohistochemistry for CD31 and FVIII, as described 
below.  
The veterinarians who submitted the samples were sent a standardised 
questionnaire requesting signalment information about the dog, as well as 
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details about the history, clinical examination and methods of tumour stage 
determination at the time of surgery. The current status of the dog at the time 
of questionnaire was also determined. In the event of the dog’s death or 
euthanasia, the veterinarians were asked for information relating to the cause 
of death, in particular if this was considered due to the HSA. Dogs were 
included in the control group if the following criteria were met: complete 
splenectomy was performed, no adjuvant treatment had been provided for 
the HSA, adequate clinical notes were available for review, and the current 
status of the dog, including cause of death, was known. 
7.2.3 Immunohistochemistry 
Immunohistochemistry was performed on 4µm sections of formalin fixed 
paraffin embedded tissue sections that were cut onto positively charged slides 
for each neoplasm. Each slide was deparaffinised and rinsed onboard a 
Benchmark Ultra staining platform (Ventana Medical Systems) and 
processed as follows for CD31 (PECAM-1) and von Willebrands factor (FVIII) 
immunohistochemical staining. 
CD31: The slide was heated to 100°C and incubated with cell conditioner 1 for 
32 minutes to retrieve epitopes. The slide was then rinsed and taken to 36°C; 
a peroxidase inhibitor was applied and incubated for 4 minutes. Next, 100µL 
of 1:200 dilution of mouse antihuman CD31 monoclonal antibody (CD31 
(JC70A): Dako Australia Pty. Ltd), diluted in antibody diluent (Ventana), was 
applied and incubated at 36°C for 8 minutes. Visualisation was achieved via 
the Ventana Optiview Detection Kit. Secondary antibody was applied and 
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incubated for 8 minutes, then hydrogen peroxide and DAB for 8 minutes. 
Copper was applied for 4 minutes to stop the reaction.  
von Willebrand Factor (FVIII): The slide was heated to 36°C, a peroxidase 
inhibitor was applied and incubated for 4 minutes. Next, 100µL of Protease 1 
(Ventana) was applied and incubated for 8 minutes to retrieve epitopes. Next, 
100µL of a 1:400 dilution of rabbit anti-human von Willebrand Factor (FVIII 
(P0226), Dako Australia Pty. Ltd), diluted in antibody diluent (Ventana), was 
applied and incubated for 16 minutes at 35°C. Visualisation was achieved via 
the Ventana Ultraview Detection Kit. Secondary antibody was applied and 
incubated for 8 minutes, then hydrogen peroxide and DAB for 8 minutes. 
Copper was then applied for 4 minutes to stop the reaction. 
All sections were counterstained with Gills Haematoxylin (Surgipath). 
Internal canine control tissues (vascular endothelium) were present on all 
slides 
7.2.4 Thalidomide preparation 
Thalidomide (α-N- [phthalimido] glutarimide, C13H10N2O4), was prepared at 
Massey University using a two-step process as previously described.[19] 
Briefly, glutamine was reacted with N-carbethoxyphthalimide in water in the 
presence of sodium carbonate (99% Riedel de Hahn, water free) at room 
temperature. Then, the product of this reaction (N-phthaloyl-L-glutamine) 
was reacted at reflux with 1,1’-carbonyldiimidazole in the presence of a 
catalytic amount of N,N-dimethylaminopyridine in tetrahydrofuran. The two 
procedures were followed exactly as previously described,[19] with the only 
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alteration being that the first step was based on 100 grams of N-
carbethoxyphthalimide and the second step was based on 100 grams of 
carbonyldiimidazole. All yields and analytical data were consistent with those 
previously reported, giving confidence for drug purity.[19] Confirmation of 
99.7% synthesis purity was performed by nuclear magnetic resonance 
(600MHz) analysis, with a sample of pharmaceutical-grade thalidomide used 
as a reference material.[20] 
The dog owners were asked to read and sign a consent form indicating they 
understood the potential human health implications of thalidomide 
exposure, and women of child-bearing age were advised not to handle the 
drug. Non-sterile latex gloves were supplied to the owners to be worn at the 
time of drug administration, with recommendations for hand washing after 
handling thalidomide. Each client was provided with a lockable box for 
storage of the thalidomide, to ensure the drug could not be accidentally 
handled by other people. 
Following the initial evaluation, all patients in the treatment arm of this 
study received thalidomide with treatment commencing on the evening after 
CT examination. Owners were encouraged to give the thalidomide to their 
dogs in the evening, due to the known somnolence effects of this drug.[6]  
All dog owners were provided with a 30-day supply of thalidomide at a time; 
this restricted supply was utilised to minimise the potential wastage of drug 
supply should the dog die, and also to ensure that monthly updates about the 
dog’s general health were received from the owners. All dogs received daily 
administration of the drug from the time of their initial examination until 
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their death. Thalidomide was dispensed into individual gel capsules at a 
previously recommended dose of 8.5mg/kg per os once daily.[21] Each 30-
day batch of capsules was prepared from the bulk supply of thalidomide, 
which was cool-stored in a sealed container. Capsules were individually 
weighed during preparation, with a 10% tolerance for the actual dispensed 
weight of the capsule compared to the desired dose.  
7.2.5 Statistical Analysis 
Analyses were performed with statistical software (SPSS Statistics v24.0.0, 
IBM, New York, NY). Death or euthanasia due to the HSA was the primary 
end point for the study. Survival times (ST) were calculated from the date of 
surgery until the date of death. For survival calculations, dogs that died 
because of their tumour were considered completed events. Dogs that were 
still alive at the time of the study were censored at the close of the study. 
Survival time was calculated from the date of splenectomy (T0) to death or 
censor date. The interval from when splenectomy was performed to the start 
of thalidomide therapy was defined as the treatment gap. 
The Kaplan-Meier method was used to analyse ST according to age, sex, 
neuter status, tumour stage. Cox regression analysis was performed to assess 
the impact of treatment gap on outcome. P <0.05 was considered significant.  
The study was approved by the Massey University Animal Ethics Committee 
(application MU 11/56). 
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7.2.6 Historical population 
A literature search was performed in PubMed (NCBI, Bethesda, USA) to 
identify all previous published studies for dogs where splenectomy had been 
performed to manage splenic haemangiosarcoma. Data retrieved from each 
article included: the number of animals in each treatment group; tumour 
stage at the time of treatment (if known); the details of any adjuvant 
treatments used; overall median survival time and range. This data was 
tabulated. 
7.3 Results 
7.3.1 Patient characteristics 
Patient and tumour characteristics of both cohorts are summarised in Table 
7.2. From August 2012 to December 2014, fifteen dogs were recruited into 
the thalidomide treatment group. The age of the dogs ranged from 7 to 14 
years, with a median age of 10 years. Eight dogs were male, and 7 were 
female. A variety of breeds were represented including German shepherd (4), 
Labrador retriever (3), heeler, boxer, dachshund, elkhound, border collie, 
huntaway, miniature schnauzer, and a Welsh corgi. Sixteen dogs were 
included in the control group. The age of the dogs ranged from 6 to 15 years, 
with a median age of 10 years. Eleven dogs were male and 5 were female. Dog 
breeds represented included border collie (3), German shepherd (3), golden 
retriever (2), Labrador retriever (2), beagle, great Dane, Jack Russell terrier, 
miniature schnauzer, Staffordshire bull terrier and a Tibetan spaniel. 
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There were no significant differences in the age or sex of dogs between 
treatment and control groups.  
Table 7.2 
Patient and tumour characteristics of treatment and control cohorts 
Characteristic Treatment (n=15) Control (n=16) 
Age 7-14 (median 10 years) 
6-15 










Tumour presentation all haemoperitoneum all haemoperitoneum 
Stage 
 Stage 1 
 Stage 2 













7.3.2 Neoplasm staging  
In the treatment group, 5 dogs were classified as stage 3 due to the presence 
of cystic lesions within the liver on CT scan. No concurrent thoracic or 
cardiac lesions were identified in any dog. The suspected metastatic lesions 
ranged in size from isolated clusters of 4mm radiolucent cysts to a large 4cm 
multi-loculated cystic mass within the left lateral lobe. A fifth dog was 
classified as stage 3 due to a histological diagnosis of metastatic lesions 
within the omentum. The remaining 10 dogs were classified as stage 2, as no 
evidence of metastatic lesions was identified in any abdominal or thoracic 
organ.  
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Within the control dogs, there was more variability in the methods used to 
stage the HSA. In 5 dogs, thoracic radiographs and abdominal ultrasound 
were performed prior to surgery while in 8 dogs, thoracic radiographs were 
performed prior to surgery, and the liver and other abdominal organs were 
visually inspected at the time of surgery. In the remaining 3 dogs, no thoracic 
or abdominal imaging was performed prior to surgery, but the abdominal 
organs were visually inspected at the time of surgery. Based on the 
information provided by the referring veterinarians from these 
investigations, four dogs in the control group were classified as stage 3 due to 
the presence of metastatic lesions within the liver (3 dogs) or omentum (1 
dog). A further 9 dogs were classified as stage 2. The stage at the time of 
surgery could not be reliably defined in 3 dogs as thoracic radiographs had 
not been obtained prior to surgery. 
7.3.3 Patient outcomes 
The follow-up period ranged from 6-660 days (median 90 days). Results are 
summarised in Table 7.3. 
Thirty of the 31 dogs enrolled in the study died during the study period. This 
included 14 of the 15 dogs in the treatment group and all 16 control group 
dogs. A diagnosis of haemoabdomen due to bleeding from one or multiple 
metastatic lesions in the abdomen was confirmed at necropsy in 13 dogs in 
the treatment group. In another dog in the treatment group, extensive 
bleeding isolated to the retroperitoneum was identified at post-mortem, with 
histologic evidence of HSA in the adjacent kidney. One other dog in the 
treatment group was euthanatised 628 days after surgery due to progressive 
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senile behaviour and separation anxiety. No evidence of neoplasm recurrence 
had been observed in a CT of the chest and abdomen on the day of 
euthanasia; no necropsy was performed. One dog remained alive at the end 
of study period, 594 days after surgery. All dogs in the control group died or 
were euthanased due to acute weakness or collapse. Specific details about the 
clinical findings at the time of euthanasia were not consistently provided by 
veterinarians, and was only available for 9 of the 16 dogs. For these 9 dogs, 
anaemia was recorded in 7 cases, with recurrence of a haemoabdomen 
confirmed by abdominocentesis in 5 cases. 
Table 7.3: 
Statistical analysis of outcomes for treatment and control groups 
Treatment Group Stage 2 Stage 3 Overall p value 
Thalidomide 
n= 
Mean survival time 















Mean survival time 
Median survival time 
9 
87 days 
49 days (0-98) 
4 
20 days 
13 days (0-36) 
16 
67 days 




 p=0.001 p=0.001 p=0.01  
 
7.3.4 Median survival times 
7.3.4.1 Effect of tumour stage: all dogs 
For all 28 dogs enrolled in the study for which tumour stage could be 
determined, tumour stage was found to significantly influence survival. Dogs 
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with stage 2 tumours had a MST of 172 days compared to 34 days for dogs 
with stage 3 HSAs (p = 0.0003) (Figure 7.1). 
Figure 7.1:  
Kaplan Meier survival curve showing differences in survival based on tumour stage 
for all dogs enrolled in this study 
 
  
7.3.5 Effect of thalidomide treatment 
Dogs receiving thalidomide survived between 31 and 660 days and had a 
median survival time (MST) of 172 days (95% CI 93-250 days). In 
comparison, dogs in the control group survived between 6 and 225 days, with 
a MST of 32 days (95% CI 26-37 days). The use of thalidomide significantly 
increased the survival times for dogs receiving treatment (p=0.001) (Figure 
7.2). 
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Figure 7.2: 
Kaplan Meier survival curve showing differences in survival based on tumour stage 
for dogs receiving thalidomide compared to the control population 
 
 
For dogs with stage 2 disease, thalidomide treatment improved the MST over 
the control group from 49 days to 303 days, giving a hazard ratio (HR) for 
death in the treatment group of 0.2 (95% CI, 0.08 to 0.63; P=0.005; Figure 
7.3a). For stage 3 disease, a significant difference in survival was also noted, 
but the survival advantage was less pronounced (13 days vs 40 days, p=0.01; 
Figure 7.3b). The HR for death in stage 3 dogs receiving thalidomide was 
0.09 (95% CI, 0.01 to 0.85; P=0.04). 
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Figure 7.3a and 7.3b:  
Kaplan Meier survival curve showing differences in survival based on tumour stage 
for dogs receiving thalidomide compared to the control population  
 
 
When the effect of tumour stage for dogs within each treatment group were 
considered separately, significant differences in survival times were also 
observed. Treated dogs with stage 2 tumours had a MST of 303 days (95% CI 
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0-744 days) which was significantly longer than the 40 days (95% CI 31-48) 
seen in dogs with grade 3 tumours (Log Rank 15.7, p<0.0001). Untreated 
dogs with stage 2 tumours had a MST of 49 days compared to just 13 days 
(95% CI 0-36) for stage 3 dogs (Log Rank 4.6, p=0.03). 
7.3.6 Effect of treatment delay 
The median time to start thalidomide treatment was 11 days after surgery. 
This delay was primarily due to the time taken to obtain histologic 
confirmation and subsequent examination for staging. Two dogs did not start 
treatment until more than 30 days after surgery, and one dog did not start 
until 62 days. However, there was no significant influence of this treatment 
delay on outcome (HR 1.010, 95% CI 0.97 - 1.049, p=0.59). 
7.3.7 Medication compliance and side-effects 
All dogs were reported to receive their daily dose of thalidomide continuously 
until their death once treatment was started. There were no disruptions due 
to logistical problems with delivery of medications or adjustment to the dose 
or dosing interval due to side-effects. 
All owners commented on some sedation within 30 minutes after drug 
administration, but in no dog was this of sufficient concern to warrant a 
change in the administered dose. One dog, the lightest in the study at 6.5kg, 
was reportedly mildly stuporous for the first few days after medication 
commenced, but these effects resolved by the end of the first week with no 
change in treatment dose. One working police dog and one working Guide 
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Dog remained in full work while on thalidomide, with no apparent change in 
their concentration abilities or working routines. 
No other side-effects were reported while dogs were receiving thalidomide 
medication. 
7.3.8 Historical population 
There were 19 previous studies published that described the outcome of dogs 
after treatment for splenic HSA by splenectomy. In 14 of these studies, some 
form of adjuvant therapy was provided following surgery. The average 
median survival time for dogs that underwent splenectomy only was 52 days 
(range 19-86 days). The average median survival time for dogs that also 





Statistical analysis of outcomes for all dogs receiving thalidomide compared to previously published studies and a contemporaneous control 
population 
Study Adjuvant treatments Group (n=) Median Survival Time (days) 
Thalidomide + Thalidomide 15 172 (31-744) 
Contemporaneous 
control (this study) Surgery only 16 32 (6 – 225) 
Johnson et al 1989 
Brown et al 1985 
Wood et al 1998 
Prymak et al 1988 
















Brown et al, 1985 
Brown et al, 1985 
Dervisis et al, 2011 
Finotello et al, 2015 
Finotello et al, 2015 
Gardner et al 2015 
Hammer et al 
Johnson et al, 1989 
Kahn et al, 2013 
Sorenmo et al 
Vail et al, 1995 
Vail et al, 1995 
Kim et al, 2007 
+ Mixed Bacterial Vaccine 





































144 (74 -2717) 
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7.4 Discussion 
The present study showed that thalidomide may prolong survival of dogs 
with splenic HSA. To the author’s knowledge, this was the first prospective 
study to assess the effect of adjuvant thalidomide on patient outcome after 
splenectomy for HSA. Previously published studies had suggested that good 
patient response was possible with this drug,[9, 21] but these trials were 
stopped as thalidomide became unaffordable later in the studies. The results 
of the present study confirm the potential of thalidomide as a useful adjuvant 
therapy for canine splenic HSA. It also provides evidence to support the 
investigation of thalidomide as an adjuvant treatment for other mesenchymal 
neoplasms including STS, which were the focus of this thesis. 
In this study, the overall survival times of dogs receiving thalidomide after 
splenectomy were improved when compared to dogs treated by splenectomy 
alone. The most beneficial effects of thalidomide were observed in dogs with 
stage 2 HSA. Within this stage group, thalidomide treatment improved the 
MST over the control group from 49 days to 303 days. Although there was a 
significant survival advantage noted between the thalidomide and control 
dogs with stage 3 HSA, the survival benefit was smaller with the MST only 
increasing from 13 days to 40 days. The key difference between these stages 
is the metastatic lesions in stage 2 HSA are not grossly discernible using 
existing imaging modalities and may range in size from individual cells to a 
small nodule <1-2mm in size. In stage 3 dogs, the metastatic lesions may 
range from just a few millimeters to masses many centimetres in size; these 
larger lesions tend to be very fragile and prone to rupture. The reduced 
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survival time for stage 3 dogs is therefore understandable, because the gross 
metastatic lesions present in these animals will be more susceptible to 
spontaneous rupture leading to internal haemorrhage. Thalidomide 
treatment did appear to remain effective in this group; the HR for death in 
the treatment group was 0.1, which suggests that stage 3 dogs receiving 
treatment had a 90% lesser chance of dying from their HSA for every day 
they received thalidomide when compared to dogs of an equivalent tumour 
stage who were not receiving the drug. However, the confidence interval of 
this HR was wide, meaning the survival benefit could have been anything 
between 15% and 99%. The small number of dogs in this group makes further 
analysis of the possible benefit of thalidomide in this treatment stage 
difficult. 
It is well documented that the prognosis for dogs with splenic HSA is 
consistently poor.[22] While surgery is the standard therapy for HSA,[23] 
this is considered palliative as metastasis has usually occurred by the time of 
surgery.[9] As a consequence, almost all dogs will die from secondary 
tumours within 1 year of surgery unless additional treatment is given.[9, 11] 
In the current study, five of the dogs that received thalidomide – representing 
almost one-third of the study population – survived more than one year after 
surgery. The results of this study provide sufficient evidence to support 
further investigation comparing thalidomide alongside other adjuvant 
chemotherapy strategies suggested for canine HSA.  
The ability of adjuvant chemotherapy to increase the survival times of dogs 
with splenic HSA has been previously demonstrated, but despite the use of 
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various treatment combinations the duration of remission with most 
protocols remains short.[9, 13, 23-27] Current adjuvant chemotherapeutic 
protocols have utilised doxorubicin alone, doxorubicin with 
cyclophosphamide, vincristine with cyclophosphamide and doxorubicin, 
dacarbazine and vincristine; no individual protocol has been shown to be 
superior. When doxorubicin-based protocols are used, studies have reported 
median survival times of 125-180 days.[24, 25, 28-31] By comparison, 
thalidomide resulted in an equivalent median survival time of 172 days. 
While these results suggest that thalidomide could be as effective as 
conventional cytotoxic medications, it is disappointing that the overall 
survival for HSA was not improved beyond our current expectations. 
The results from the current study suggests that the targeting of angiogenesis 
alone may actually be insufficient to prevent tumour progression.[32, 33]. 
Almost all dogs in the treatment group died as a consequence of 
haemorrhage from a ruptured secondary tumour, which suggests that 
thalidomide was unable to prevent the development of metastatic disease. It 
may be possible that combining an anti-angiogenic treatment like 
thalidomide with conventional cytotoxic drugs could provide some 
synergistic benefits. Using this strategy, conventional cytotoxic drugs would 
act to kill residual HSA by directly targeting the cancer cells, whilst 
thalidomide would be used to disrupt crucial angiogenic pathways, and 
inhibit the reactivation of dormant tumour clones and other resistant 
populations. Other authors have examined the outcomes when conventional 
cytotoxic medications are combined with anti-angiogenic or tumour 
environmental modulators. In one study, dogs with HSA were initially 
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treated with conventional chemotherapy using a doxorubicin-based 
protocol.[29] After completion of this treatment course, a subset of dogs then 
received continuous treatment with a small molecule inhibitor (Toceranib 
phosphate, [Palladia®]) that has activity against VEGF and PDGF. None of 
dogs treated with the small molecule inhibitor therapy showed any 
improvement in disease-free interval or overall survival. However, the 
apparent lack of response to toceranib may have been due its delayed 
administration, which was not started until a full-course doxorubicin 
chemotherapy was completed, or due to a more limited angiogenic effect of 
Palladia compared to other drugs like thalidomide. It would be useful to 
repeat this study, but using a combination of conventional cytotoxic 
chemotherapy in conjunction with thalidomide to determine if there is any 
possible synergistic effect. 
In recent studies, thalidomide has also been combined with other anti-
angiogenic protocols, including metronomic chemotherapy (MTC).[34] 
Metronomic chemotherapy, also called continuous low-dose chemotherapy, 
uses a combination of cyclophosphamide and a cox-2 selective non-steroidal 
anti-inflammatory drug (NSAID). Metronomic chemotherapy is considered 
to disrupt tumour progression via two key mechanisms: firstly, by disrupting 
host endothelial cells from dividing and forming new vasculature and 
secondly, by restoring the innate anti-tumour immune response by depleting 
regulatory T cells (Treg) and restoring the natural killer (NK) and T cell 
functions within the tumour microenvironment.[35-37] Metronomic 
chemotherapy alone has been reported to achieve comparable outcomes to 
historical survival times for dogs treated with conventional cytotoxic 
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chemotherapy.[35] A synergy between cyclophosphamide and thalidomide 
has been demonstrated in a mouse model,[38] so it is reasonable to assume 
that combining these drugs could lead to further improvements in tumour 
control. A recent study has reported results when thalidomide was included 
with a MTC protocol.[34] Unfortunately, this was a multi-institutional 
retrospective study, so the chemotherapy protocols were not consistent for all 
dogs. This study was also limited to the treatment of dogs with stage 3 HSA 
only. Nevertheless, 87% of the dogs that received MTC also received 
thalidomide at a dose of 2-4mg/kg per os once daily. Sadly, the apparent 
benefits of MTC plus thalidomide in this study were disappointing with the 
survival time for dogs receiving conventional chemotherapy being 140 days, 
which was significantly better than the survival times for dogs that were 
receiving MTC plus thalidomide (58 days). Because this study was limited to 
dogs with stage 3 HSA, the potential synergy that may be gained from 
combining thalidomide and MTC for all dogs with HSA remains unknown. 
However, the results of this study do suggest that anti-angiogenic treatment 
may provide only a limited survival benefit for dogs with gross metastatic 
lesions, which is consistent with the results of the current study. It is possible 
that anti-angiogenic treatment alone may be less effective on macroscopic 
tumours, perhaps because the angiogenic switch becomes self-sustaining 
beyond a certain point in tumourigenesis. It may be that the antiangiogenic 
and immunomodulatory effects of drugs such as thalidomide and 
cyclophosphamide can no longer disrupt the progression of a tumour once it 
has established in its own microenvironment. 
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Thalidomide was chosen for the current study due to its reported effects on 
suppression of VEGF. The previous studies documented in this thesis had 
determined that STS with an increased immunostaining of VEGF were 
associated with higher rates of local recurrence and reduced survival; it was 
therefore reasoned that VEGF could be an appropriate therapeutic target. 
However, the potential benefits of thalidomide are not limited to VEGF alone, 
and this drug is known to have a range of diverse effects on the regulation of 
angiogenesis, as well as immunoregulatory and inflammatory pathways.[6, 
39-47] For example, thalidomide has been shown to induce the down-
regulation of several inflammatory cytokines including TGF-β	and NF-
kB;[40] increased expression of these pathways has been shown to be 
significant indicators for reduced disease-free survival in human STS.[16] 
Thalidomide is also known to stimulate primary T lymphocytes to increase 
their anticancer activity. In canine STS, levels of regulatory CD4+Foxp3+ 
regulatory T cells (Treg) are increased,[48] which can cause inhibition of 
innate anti-tumour immune responses. Recent studies have shown that 
thalidomide and cyclophosphamide can act to eliminate these suppressive 
Treg cells,[48, 49] thus restoring the normal immune response to the 
tumour. In further studies, it would be helpful to evaluate the status of these 
other treatment pathways, to determine if there is a critical tumour size at 
which point tumour growth can no longer be impeded by anti-angiogenic 
treatments such as thalidomide.  
Despite the positive results reported in the current study, the cost of 
thalidomide may limit the potential for this drug becoming accepted for 
routine use into veterinary treatment. Even for humans, the cost of 
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thalidomide for patients has become increasingly controversial as the clinical 
indications for its use have expanded.[50] Thalidomide is a drug with a 
terribly legacy and these historical issues continue to impact on its 
availability.[51] For humans, access to the drug remains rigidly controlled 
and prescription is only possible if the patient agrees to comply with a System 
for Thalidomide Education and Prescribing Safety (STEPS). The conditions 
required under this program include limiting prescription and dispensing 
rights to authorised prescribers and pharmacies, keeping a registry of all 
patients prescribed thalidomide, providing extensive patient education about 
the risks associated with the drug, and providing periodic pregnancy tests for 
women who take the drug.[52] Under normal circumstances thalidomide 
would now be off-patent, and cheaper generic derivatives of this drug would 
be available. However, because of the rigidly enforced legislation that 
surrounds thalidomide there is still only one manufacturer with the licence to 
bring the drug to the market. By citing the restrictive legislative agreements, 
this company has reportedly actively inhibited the development of generic 
alternatives.[53] However, since 2000, the price of thalidomide has increased 
by almost 1000%.[50] This price inflation has impacted on veterinary use of 
this drug; initial clinical trials that started in the late 1990s were abandoned 
due to the rising cost of the drug.[9, 21] Based on 2019 prices for thalidomide 
from veterinary suppliers in the UK, the monthly cost of thalidomide for a 
30kg dog would be more than £1200. Given that thalidomide needs to be 
given continuously for the remainder of a dog’s life, this could equate to an 
annual cost of almost £15,000. This cost would exceed the ability for many 
pet owners to afford therapy. This is unfortunate as, based on the results of 
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the current study, thalidomide may prove to be an important drug in the 
management of canine HSA and potentially other mesenchymal tumours.  
The optimal therapeutic dose of thalidomide has not been well-established in 
the dog. Aside from a specific toxicity study, where doses ranging from 43-
1000mg/kg/day were used, various clinical reports have used doses ranging 
from 2-3mg/kg q24h or q48h,[34] to 20mg/kg/day.[54] The dose used in the 
current study was based on recommendations from the authors of a 
discontinued trial of thalidomide in canine HSA, where some beneficial 
effects had been noted.[21] Further study may be required to help determine 
the optimal therapeutic dose in the dog. One recent publication has described 
a gradually reducing dose strategy when thalidomide was used to treat 
malignant cancer affecting the mammary gland of dogs. In that study, 
thalidomide was initially given at 20 mg/kg once daily for 3 months, after 
which time the dose was reduced to 10 mg/kg once daily until the patient’s 
death from the tumour. This study reported improved survival times for dogs 
with advanced stage disease compared to those receiving conventional 
chemotherapy only.[54] Treatment was apparently well-tolerated, although 
excessive somnolence was reported at the 20mg/kg dose in some patients. It 
is likely the cost of thalidomide may lead a drive to determine efficacy at the 
lowest possible dose in the dog. Even in humans, the optimal dosing schedule 
for thalidomide is unclear, with doses of between 200 – 800 mg/day used in 
most cancer trials.[55] For people, the dose is usually titrated to the highest 
dose tolerated by the patient with the minimum of side effects. It is not clear 
if there is a dose-response relationship, or if smaller doses are equally 
effective with lesser side effects.  
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Apart from drowsiness and the well-known teratogenic effects, chronic use of 
thalidomide tends to be well tolerated.[56] For that reason, monitoring for 
haematologic or biochemical toxicities was not performed in this study. 
Human patients have experienced peripheral neurological disturbances such 
as hypo- and hyperalgesia, impaired temperature sensitivity, and 
polyneuritis, but these effects have not been observed in the dog.[57] Other 
less commonly reported side effects include constipation, deep vein 
thrombosis and a mild skin rash.[56] In toxicity studies performed in dogs, 
no evidence for systemic toxicity was reported with thalidomide doses 
ranging from 10 - 1000 mg/kg/day.[54, 57]  
A major limitation of this study was there was no placebo or alternative 
treatment arm included in the clinical trial design. No placebo treatment was 
included in this study because it is already well-established that the outcome 
for dogs with HSA treated with surgery alone is poor; median survival times 
of just a few months have remained unchanged in publications over the last 
thirty years. The outcome for patients receiving thalidomide was therefore 
compared with a second population of dogs with HSA that had been treated 
by surgery alone during the same time period. While this provided a 
contemporaneous control population with which to compare outcomes, this 
decision resulted in a different quality of staging investigation for the HSAs 
between the treatment and the control groups. All of the dogs receiving 
thalidomide had a CT scan of the chest and abdomen at the start of the study, 
and again after 3 months of treatment. By comparison, none of the dogs in 
the control population underwent CT staging, and only 5 of 16 dogs had an 
ultrasound evaluation of the liver, which was the most common site for 
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metastasis in the thalidomide group. It is likely that the plain thoracic 
radiographs and visual inspection of the external surface of the liver, which 
represented the full extent of staging investigations for most dogs in the 
control group, may have failed to detect many small or deep parenchymal 
lesions. It is therefore possible that some dogs within the control group had 
undetected metastases at the time of splenectomy. This would effectively 
increase the proportion of stage 3 dogs within the control population, and 
impact on overall survival figures. Therefore, when comparing the outcome 
for dogs in this study, this difference in the quality of staging investigation 
could effectively bias the results in favour of thalidomide. While such a bias 
cannot be excluded, it is reassuring to note that the survival times observed 
for the dogs in the thalidomide group was notably superior to that of dogs 
receiving no therapy in all previously published studies;[9, 13, 24-27] this 
provides some confidence in the ultimate conclusion of this study. This 
limitation could have been overcome by incorporating a placebo arm, which 
would ensure that all dogs in the study underwent the same staging 
evaluation by CT, whilst only 50% of the dogs received medication containing 
the active ingredient. However, this would have doubled the number of CT 
scans required and increased the overall cost of the study. Also, because 
initial data on thalidomide in HSA suggested a beneficial response was 
likely,[21] the author could not, with good conscience, deny patients a 
treatment that carried a reasonable chance of improving their survival. An 
alternative strategy would have been to increase the number of dogs in the 
contemporaneous control population, so that any potential differences in 
Chapter 7: Targeting VEGF with thalidomide - page 264	
staging evaluation between the two groups became less influential in the 
analysis. 
A second limitation of the current study is the potential for bias that can 
occur when comparing the outcome of the treatment group with historical 
literature, or with a population of dogs randomly sourced from a different 
sector of the population. Because these dogs may have owners derived from a 
different financial or social stratum than the dogs enrolled in the study, their 
outcomes may be affected by extraneous factors other than the treatment or 
disease. Furthermore, these owners may have been less inclined to delay 
euthanasia as they did not have the same emotional commitment to the 
objectives of the study. However, this potential bias is largely overcome in the 
current study because all but one dog died due to the development of 
spontaneous bleeding into the abdomen as a result of progression of 
metastatic disease. The decision for euthanasia was therefore influenced 
directly by disease progression, rather than the emotional commitment of the 
owner. 
7.5 Conclusion 
From the results of the current study, thalidomide appears to be well-
tolerated clinically and may significantly improve survival for dogs following 
surgery for splenic HSA. Tumour stage at the start of treatment may be 
important; thalidomide showed improved survival benefits in dogs that had 
no visible metastatic lesions when starting treatment. From these results, the 
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use of thalidomide should be considered as a potential adjuvant treatment for 
dogs with HSA, and for other mesenchymal tumours such as STS. 
In order to evaluate whether thalidomide treatment had any effect on the 
presence of VEGF within tumour, the next study describes an 
immunohistochemical study that compares the metastatic lesions of dogs 
that received thalidomide compared to group of dogs that did not. 
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Chapter 8: 
Analysis of the effect of thalidomide on vascular endothelial 
growth factor in the metastatic lesions of treated patients 
8.1 Introduction 
n the previous chapter, it was determined that survival times for 
dogs with splenic haemangiosarcoma (HSA) were significantly 
lengthened by treatment with thalidomide following splenectomy. 
Thalidomide is known to be a potent suppressor of vascular 
endothelial growth factor (VEGF) production, as well as other cytokines of 
importance in tumour angiogenesis.[1-3] Although the study described in the 
previous chapter showed that thalidomide significantly improved the overall 
survival for dogs with HSA, dogs treated with thalidomide still developed 
metastatic disease which resulted in the death of the dog. This suggests that 
the tumour can continue to stimulate angiogenesis independently of VEGF; 
that thalidomide only partially or temporarily blocks the production of this 
angiogenic protein; or that thalidomide does not significantly decrease VEGF 
within the neoplastic cells. Determining how thalidomide reduces the growth 
of metastasis is important because if a HSA exposed to thalidomide utilises 
other angiogenic pathways to sustain its progression, this would support the 
use of combination treatment with drugs that target these other pathways. 
Alternatively, if thalidomide results in only a minor or partial inhibition of 
I 
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VEGF, then incorporation of other anti-VEGF drugs into the treatment 
protocol may help further decrease VEGF production, allowing greater 
inhibition of cancer growth and metastasis.  
The goal of the current study was to assess whether levels of VEGF were 
lower in metastatic lesions of dogs treated with thalidomide compared with 
the metastatic lesions that occurred in dogs that did not receive thalidomide. 
The detection of reduced VEGF from metastatic tumours from treated dogs 
would support the hypothesis that thalidomide prolongs survival in dogs with 
HSA by inhibiting VEGF production by the neoplastic cells. Further, if VEGF 
was not detectible in the dogs with tumours treated with thalidomide, this 
would support the use of combination therapy to block other angiogenic 
pathways. Conversely, if VEGF is not reduced in the metastatic lesions or 
present at lower levels in the metastases from treated dogs this would 
support the use of other VEGF-blocking drugs as a way to improve the 
survival of dogs with HSA.  
8.2 Materials and Method 
8.2.1 Patients 
Material was sourced from patients enrolled in the study reported in Chapter 
7. Samples of metastatic lesions were collected by cosmetic necropsy. Only 
dogs that had no evidence of metastases by CT examination of the chest and 
abdomen were included in the study. 
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Sections of primary splenic HSA were also used from dogs for which 
metastatic lesions were available. This allowed comparison of VEGF 
immunostaining within the metastatic lesions after thalidomide to 
immunostaining within the primary lesions prior to thalidomide treatment. 
A control population of metastatic HSA lesions was obtained from the 
pathology archive of the School of Veterinary Science, Massey University. 
None of these dogs had received thalidomide or any other anti-angiogenic or 
cytotoxic treatment for the management of their HSA. Tissues were obtained 
during post-mortem from dogs who had died or were euthanased after a 
diagnosis of splenic HSA.  
8.2.2 Immunohistochemistry 
Immunostaining for VEGF of the primary splenic HSA lesions in the treated 
dogs had been performed previously, as described in Chapter 7. 
Tissue samples from the metastatic lesions from both the treatment and the 
control dogs had been stored as formalin-fixed paraffin embedded (FFPE) 
blocks. From these tissues, sections (5µm) were obtained from each 
individual specimen block and mounted onto positively charged glass slides. 
Each section was dewaxed in xylene and rehydrated in a graded alcohol series 
and equilibrated in phosphate buffered saline. VEGF immunostaining was 
performed as previously described in Chapter 4. Briefly, antigen retrieval was 
performed in a decloaker (Biocare Medical) at 100°C for 20 mins (VEGF) in a 
citrate buffer solution (EnVision™ FLEX Target Retrieval Solution (high pH), 
Dako Australia Pty. Ltd,). Immunostaining was then performed using a 
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Sequenza Immunostaining Center (Thermo Fisher Scientific). Endogenous 
peroxidase activity was blocked using a peroxidase-blocking reagent 
(EnVision™ FLEX, Dako Australia Pty. Ltd) for 15 mins. Tissue sections were 
incubated overnight with a 1:300 dilution of mouse antihuman VEGF 
polyclonal antibody [0.33µg /ml] (VEGF (A-20) sc-152: Santa Cruz 
Biotechnology Inc).[4-7] The presence of the antibody was detected using 
diaminobenzidine (DAB, Dako Australia Pty). For each batch of slides, 
positive and negative controls were used. Positive control tissues for VEGF 
were sections of a primary splenic canine HSA that had been used as the 
positive control in Chapter 3; this particular tissue sample was known to 
consistently stain avidly for VEGF. For negative control tissues, the primary 
antibody was omitted. 
8.2.3 Evaluation of immunostaining 
Each slide was assessed by light microscopy and immunostaining of VEGF 
was determined. The origin of the slide was not known to the evaluator 
during assessment of the immunostaining. Immunostaining was only 
evaluated in areas of well-preserved tissue morphology and away from areas 
of necrosis, tissue edges and other artefacts.  
Immunostaining for VEGF was scored using a modification of a previously 
reported scheme.[8] With this system, tumours were scored based on the 
proportion of cells showing evidence of VEGF across 10 non-adjacent and 
non-overlapping fields using the following criteria: 1 (<50% cells weakly 
positive); 2 (<50% cells intensely staining); 3 (≥50% cells weakly positive); 4 
(≥50% cells intensely staining). For dogs that had multiple metastatic lesions, 
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the VEGF scores for all the lesions was determined and the mean score used 
for that dog.  
8.2.4 Statistical analysis 
Statistical analysis was performed using SPSS (SPSS Statistics v26.0.0, IBM, 
New York, NY). The Mann-Whitney-Wilcoxon test was used to compare the 
immunostaining scores of the primary tumour with the metastatic lesions 
from the dogs treated with thalidomide, as well as the difference in the 
immunostaining scores of the metastatic lesions of the treated dogs with the 
control population. When multiple lesions for each dog were examined, the 
average score for all lesions was used for statistical comparison between 
treatment groups. P <0.05 was considered significant. 
8.3 Results 
8.3.1 Thalidomide patients 
Samples had been collected during a cosmetic necropsy examination from 5 
of the 10 dogs that had been diagnosed with a stage II (no evidence of distant 
metastases) and had been treated with thalidomide as described in the 
previous study. Samples of metastases were collected from the liver from all 5 
dogs. Metastases were also sampled from the mesentery in two dogs. Survival 
times after starting thalidomide treatment for these 5 dogs ranged from 157 
to 653 days (mean 368 days).  
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8.3.2 Control dogs 
Four dogs with metastases of a primary splenic HSA were available for this 
study. Metastases were collected from the liver and mesentery from three 
dogs while metastases were collected from liver, mesentery, and lung from 
the remaining dog. 
8.3.3 Immunohistochemical scores 
The immunohistochemical scores for each section of HSA are shown in Table 
8.1. For the thalidomide treated group, immunostaining in the primary 
splenic HSA was widely distributed in all cases, with intense staining in 4 of 5 
cases. In the metastatic lesions, immunostaining scores were between 1 and 
2, with  
Table 8.1: 
VEGF immunostaining scores for treatment and control groups 
Group Case ID VEGF score Average score 
(metastasis) Primary lesion Metastatic lesion 
Control 
50174-a - 4 
3 
50174-b - 2 
49941-a - 3 
3 49941-b - 3 
49941-c - 3 
40792-a - 4 
4 
40792-b - 4 
50542-a - 4 
4 
50542-b - 4 
Thalidomide 
64731-a 4 1 1 
P12016263-a 3 1 
1 
P12016263-b - 1 
79220-a 4 1 1 
P14025177-a 4 2 2 
P14020625-a 4 2 
2 
P14020625-b - 2 
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Figure 8.1: 
Selected photomicrographs (400x) taken from four different metastatic lesions from 
the control group of dogs with haemangiosarcoma. The images show the high 
proportion of cells with intensely positive immunostaining (score 4) for VEGF in the 




Selected photomicrographs (400x) taken from four different metastatic lesions from 
the thalidomide treatment group of dogs with haemangiosarcoma. The metastatic 
lesions from dogs treated with thalidomide had <50% of cells with positive 
immunostaining for VEGF (i.e. score 1 or score 2).  
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less than 50% of cells showing evidence of VEGF protein within the cell 
(Figure 8.1). 
For the control group, positive VEGF immunostaining was widely distributed 
across the tissues with 8 of 9 samples scoring a Grade of 3 or more (Figure 
8.2). 
The mean VEGF score within the metastatic lesions of the 5 dogs treated with 
thalidomide was 3.5 which was significantly higher than the mean VEGF 
score within the metastatic lesions of the 4 untreated dogs (1.4; p=0.02) The 
mean VEGF score within the metastatic lesions of the treated dogs was also 
lower than the mean VEGF score of the primary splenic lesions that were 
taken prior to the commencement of the thalidomide treatment (3,8; p = 
0.02) 
8.4 Discussion 
Metastatic lesions from dogs treated with thalidomide had significantly lower 
VEGF immunostaining than both the original primary HSA tumour as well as 
metastatic lesions from dogs that did not receive this drug. These findings 
suggest that treatment with thalidomide reduces the production of VEGF by 
the tumour cell.  
The ability for thalidomide treatment to reduce VEGF production within a 
cancer cell has been previously demonstrated in studies of human neoplasia. 
In an in vitro study using a cell-culture of human colon cancer cells, 
thalidomide treatment inhibited the expression of both VEGF-A and hypoxia-
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inducible factor – 1⍺ (HIF-1⍺).[9] Another study showed that serum VEGF 
was significantly reduced in multiple myeloma patients treated with 
thalidomide.[10] However, these studies have either relied on in vitro 
evidence of activity using cell cultures or by measuring the serum expression 
of VEGF. Only one previous study has directly evaluated the production of 
VEGF within neoplastic cells obtained from patients treated with 
thalidomide; this showed thalidomide reduced the immunostaining for VEGF 
by cells within prostate cancers.[11] The current study is, therefore, the first 
to demonstrate a positive impact of thalidomide treatment on VEGF 
production in a tumour from a non-human species. Additionally, this is the 
first time that VEGF production by a neoplastic cell within a sarcoma has 
been investigated and the first time that the effect of thalidomide on VEGF 
production in cells within metastatic lesions has been investigated in any 
species.  
Because only a small number of cases were examined in the current study, it 
is possible the observed differences in VEGF immunostaining between the 
two populations are simply be due to natural variances in VEGF activity 
within HSA. This possibility is countered by the findings from previous 
studies that indicate the immunostaining of VEGF in both primary and 
metastatic canine HSA lesions is usually consistently strong.[12, 13] In one 
paper, which utilised a immunostaining scoring method similar to that used 
in the current study, more than 90% of tumours were scored grade 4, with 
the remaining tumours scoring between grades 2-3.[13] None of the tumours 
in that study were scored at 1 or less, which contrasts with the findings of the 
current study where metastatic HSA lesions in 3 of 4 (75%) dogs treated with 
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thalidomide had grade 1 immunostaining.[13] In another study, almost 90% 
of primary splenic HSA had more than 50% of cells with mild to strong 
immunostaining for VEGF; this would be equivalent to Grade 3 and 4 using 
the grading scheme of the current study.[14] This evidence would suggest 
that, even though there were only a limited number of metastatic HSA lesions 
examined from the thalidomide group, it would be unexpected for all of the 
examined tissues to have consistently low immunostaining for VEGF even if 
selection bias was a cause. This supports the hypothesis that thalidomide 
treatment actively reduces the production of VEGF protein within metastatic 
lesions. 
Despite the significant reduction in VEGF in the tumours from dogs that 
received thalidomide, cancer progression was not completely halted with 
almost all dogs ultimately being euthanased due to their tumour. This 
inability to completely prevent cancer growth by inhibiting VEGF activity has 
been revealed by other studies. Although VEGF inhibitors have demonstrated 
clinical efficacy and improved survival in human patients with advanced 
cancer, most patients will eventually relapse.[15-18] Alternative pathways 
that enable angiogenesis to continue even when VEGF has been blocked have 
been described,[15] and include the platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF), hepatocyte growth factor (HGF) and 
angiopoietin pathways. These VEGF-independent signalling pathways are 
able to stimulate endothelial cell migration and vasculogenesis by interaction 
with other receptors.[15, 18]  
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Because of these alternate pathways for angiogenesis, it is unfortunate the 
current study limited its focus to the effects of thalidomide on VEGF only, 
particularly as it is known that thalidomide has a range of other influences on 
other pathways within the tumour. As well as its potent effects on VEGF 
signalling, thalidomide is also known to inhibit the production of other 
angiogenic cytokines including FGF, HGF, interleukins 6  and 1β (IL-6 and 
IL-1β) and tumour necrosis factor-α (TNF-α), amongst others.[1] A more 
complete understanding of the effects of thalidomide on the metastatic lesion 
would have been possible if the presence or absence of these cytokines had 
also been examined. One of the observations at the start of this study was 
that if a HSA exposed to thalidomide is able to utilise other angiogenic 
pathways to sustain its progression, this would support the use of 
combination treatment with drugs that target these other pathways. Because 
the design of the current study was limited in its scope, no conclusion can be 
drawn on whether the tumour growth is simply slowed due to the reduced 
availability of VEGF, or whether other less efficient angiogenic mechanisms 
are brought into play.  
A weakness of the current study is the limited number of cases examined. 
This limitation was mainly due to an inability to collect samples from dogs 
that died after being treated with thalidomide. These dogs typically died 
rapidly and unexpectedly due to spontaneous internal bleeding from a 
metastatic lesion. Although all owners had been asked to consent to a post-
mortem of their dog, the reality was that due to the sudden and unexpected 
grief for the family, the requirement for post-mortem was either forgotten, or 
the veterinarian who performed the euthanasia was unaware of this need. 
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Furthermore, the candidate was often not informed of a dog’s euthanasia 
until a day or two after the event, by which time the body had been sent for 
cremation. As a consequence of these failings, metastatic lesions were 
harvested from only half of the dogs that were diagnosed with stage 2 HSA 
prior to starting thalidomide treatment. The impact of this limited case 
material was minimised because there proved to be a sufficient difference 
between the immunostaining scores between the treated and control tissues 
to draw some conclusions about the possible effects of thalidomide on VEGF 
production. If there had not been such a magnitude of difference, it is likely 
that the small numbers of tissue samples available in the current study would 
have prevented any effect of treatment to be discovered. 
Immunostaining of the primary and metastatic lesions was done using 
different methods. For the primary HSAs, VEGF immunostaining was done 
for diagnostic purposes at a commercial veterinary diagnostic laboratory. In 
contrast, the metastatic lesions were immunostained at Massey University. 
As the intensity of immunostaining contributed to the VEGF score, it is 
possible the metastatic lesions had lower scores because the immunostaining 
method at Massey University resulted in less intense immunostaining than at 
the commercial lab. However, the same antibody was used at Massey 
University and in the commercial lab suggesting a lower intensity was not 
due to lower affinity of the antibody to the VEGF in the metastatic lesions. 
Additionally, high intensity was seen in the metastatic lesions of the 
untreated dogs suggesting that the variance was due to the effects of 
treatment, rather than more extraneous influences. 
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As discussed in Chapter 5, the effects of fixation in formaldehyde and storage 
conditions of the FFPE block can have a variable effect on the integrity of 
proteins within the tissues, which may impact on the extent and intensity of 
immunostaining of cellular proteins.[19] However, for this study, tissues 
from dogs in both the control and treatment group likely experienced similar 
conditions from the time of tissue harvest at surgery or post mortem; in all 
cases, harvested tissue will have been immediately fixed in formaldehyde and 
transported to the laboratory for processing into paraffin blocks within 24 to 
72 hours. This duration of fixation will have a minimal impact on antigen 
detection.[19] The quality of immunostaining is also considered quite stable 
for tissues that have been stored in FFPE blocks for very prolonged 
periods.[19] The one difference between the pre-analytical conditions for the 
tissues from the treatment and control group was the interval from death 
until tissues were harvested at post mortem. For dogs in the treated group, it 
is known that metastatic lesions were harvested almost immediately after 
euthanasia, or within 24 hours at most. However, for dogs in the control 
group it is plausible there will have been a delay of several days from the time 
of death until the dog underwent post mortem examination. The impact of 
post mortem delay on immunohistochemical staining has been studied in 
humans. In one study, no differences were observed in the 
immunohistochemical staining characteristics of several proteins in brain 
tissues despite post-mortem intervals of over 50 hours.[20] However, 
significant increases in VEGF gene expression has been reported in the blood 
of patients after a post mortem delay of over 12 hours.[21] However, no 
changes in VEGF gene expression were observed in the myocardium or 
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pericardial fluid at these same time points. Because VEGF production is 
primarily driven by increases in HIF,[22] it is plausible that profound 
hypoxia at the time of death could cause an acute drive for increased VEGF 
expression within cells in circulation. However, it is unlikely there could be 
any substantial alterations in protein production within other cells in the 
body after death. Based on this evidence, it can be presumed that the 
differences in VEGF immunostaining observed in the current study are not a 
result of variances in tissue handling and storage but do reveal the effects of 
thalidomide on VEGF protein production within the cells. 
In hindsight, it would also have been useful to evaluate the presence of VEGF 
immunostaining in the metastatic lesions from dogs that were diagnosed 
with stage 3 HSA prior to starting thalidomide treatment. In the previous 
chapter it was suggested thalidomide treatment may make less of a difference 
in advanced disease because the angiogenic switch may become self-
sustaining beyond a certain point in tumourigenesis. Anti-angiogenic 
treatments may therefore be less effective against macroscopic lesions that 
have an established tumour vasculature and microenvironment. The 
investigator chose not to include tissues from stage 3 dogs as there was only a 
limited number of tissue samples available. It was also impossible to know 
whether the metastatic lesions that had been randomly sampled at post-
mortem had been present at the start of the study, or whether they had 
developed while thalidomide was being received. These factors would have 
influenced the interpretation of any findings in this small number of dogs. By 
comparison, dogs with stage 2 HSA should not have had any macroscopic 
metastatic lesions at the start of the study, so it could be presumed that any 
Chapter 8: VEGF in metastatic lesions - Page 285 
of the gross tumours harvested at post-mortem would have achieved this 
growth despite continuous exposure to the anti-angiogenic effects of 
thalidomide.  
8.5 Conclusion 
This study provides evidence that the metastatic HSA lesions that developed 
while exposed to thalidomide have a significantly reduced VEGF 
immunostaining compared to both the original primary HSA and metastatic 
HSA lesions from dogs that have not been exposed to this drug. The findings 
of this study support continued investigation into how the diverse effects of 
thalidomide may prove effective in slowing the progression of HSA and other 
soft tissue sarcoma. 
8.6 References 
1. Kumar S, Witzig TE, and Rajkumar SV. Thalidomide as an anti-
cancer agent. J Cell Mol Med, 2002. 6(2): p. 160-74. 
2. Ganjoo K and Jacobs C. Antiangiogenesis agents in the treatment of 
soft tissue sarcomas. Cancer, 2010. 116(5): p. 1177-83. 
3. Adlard JW. Thalidomide in the treatment of cancer. Anticancer 
Drugs, 2000. 11(10): p. 787-91. 
4. Erwin WM, DeSouza L, Funabashi M, Kawchuk G, et al. The biological 
basis of degenerative disc disease: proteomic and biomechanical 
analysis of the canine intervertebral disc. Arthritis Res Ther, 2015. 
17: p. 240-53. 
5. Yang CH, Culshaw GJ, Liu MM, Lu CC, et al. Canine tissue-specific 
expression of multiple small leucine rich proteoglycans. The 
Veterinary Journal, 2012. 193(2): p. 374-380. 
Chapter 8: VEGF in metastatic lesions - Page 286 
6. Platt SR, Scase TJ, Adams V, Wieczorek L, et al. Vascular endothelial 
growth factor expression in canine intracranial meningiomas and 
association with patient survival. J Vet Intern Med, 2006. 20(3): p. 
663-8. 
7. Tivers MS, Lipscomb VJ, Scase TJ, Priestnall SL, et al. Vascular 
endothelial growth factor (VEGF) and VEGF receptor expression in 
biopsy samples of liver from dogs with congenital portosystemic 
shunts. J Comp Pathol, 2012. 147(1): p. 55-61. 
8. Al-Dissi AN, Haines DM, Singh B, and Kidney BA. 
Immunohistochemical expression of vascular endothelial growth 
factor and vascular endothelial growth factor receptor in canine 
cutaneous fibrosarcomas. J Comp Pathol, 2009. 141(4): p. 229-36. 
9. Zhang L, Hannay JA, Liu J, Das P, et al. Vascular endothelial growth 
factor overexpression by soft tissue sarcoma cells: implications for 
tumor growth, metastasis, and chemoresistance. Cancer Research, 
2006. 8770. 66(17): p. 8770-8. 
10. He GL, Xu DR, Zou WY, He SZ, et al. The VAD Scheme versus 
Thalidomide plus VAD for Reduction of Vascular Endothelial Growth 
Factor in Multiple Myeloma: A Meta-Analysis. Biomed Res Int, 2018. 
2018: p. 3936706. 
11. Efstathiou E, Troncoso P, Wen S, Do KA, et al. Initial modulation of 
the tumor microenvironment accounts for thalidomide activity in 
prostate cancer. Clin Cancer Res, 2007. 13(4): p. 1224-31. 
12. Sabattini S and Bettini G. An immunohistochemical analysis of canine 
haemangioma and haemangiosarcoma. J Comp Pathol, 2009. 140(2-
3): p. 158-68. 
13. Yonemaru K, Sakai H, Murakami M, Yanai T, et al. Expression of 
vascular endothelial growth factor, basic fibroblast growth factor, 
and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors. 
Vet Pathol, 2006. 43(6): p. 971-80. 
14. Goritz M, Muller K, Krastel D, Staudacher G, et al. Canine splenic 
haemangiosarcoma: influence of metastases, chemotherapy and 
growth pattern on post-splenectomy survival and expression of 
angiogenic factors. J Comp Pathol, 2013. 149(1): p. 30-9. 
15. Zhao Y and Adjei AA. Targeting Angiogenesis in Cancer Therapy: 
Moving Beyond Vascular Endothelial Growth Factor. Oncologist, 
2015. 20(6): p. 660-73. 
Chapter 8: VEGF in metastatic lesions - Page 287 
16. Aalders KC, Tryfonidis K, Senkus E, and Cardoso F. Anti-angiogenic 
treatment in breast cancer: Facts, successes, failures and future 
perspectives. Cancer Treat Rev, 2017. 53: p. 98-110. 
17. Jayson GC, Kerbel R, Ellis LM, and Harris AL. Antiangiogenic 
therapy in oncology: current status and future directions. Lancet, 
2016. 388(10043): p. 518-29. 
18. Prager GW, Poettler M, Unseld M, and Zielinski CC. Angiogenesis in 
cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res, 
2012. 1(1): p. 14-25. 
19. Engel KB and Moore HM. Effects of preanalytical variables on the 
detection of proteins by immunohistochemistry in formalin-fixed, 
paraffin-embedded tissue. Arch Pathol Lab Med, 2011. 135(5): p. 537-
43. 
20. Blair JA, Wang C, Hernandez D, Siedlak SL, et al. Individual Case 
Analysis of Postmortem Interval Time on Brain Tissue Preservation. 
PloS one, 2016. 11(3): p. e0151615-e0151615. 
21. Gonzalez-Herrera L, Valenzuela A, Marchal JA, Lorente JA, et al. 
Studies on RNA integrity and gene expression in human myocardial 
tissue, pericardial fluid and blood, and its postmortem stability. 
Forensic Sci Int, 2013. 232(1-3): p. 218-28. 
22. Hoeben A, Landuyt B, Highley MS, Wildiers H, et al. Vascular 
Endothelial Growth Factor and Angiogenesis. Pharmacological 
Reviews, 2004. 56(4): p. 549-580. 
 
Chapter 9: Conclusions - Page 288 
Chapter 9 
Conclusions and Future Directions 
9.1 Introduction 
he main aim of the studies contained in this thesis was to 
investigate previously unexamined aspects of soft tissue 
sarcoma (STS) biology to identify new prognostic markers for 
these common neoplasms. This was achieved by establishing a 
large archive of STS that had previously been resected in general practice. 
This tissue was then analysed using immunohistochemistry and reverse 
transcriptase-polymerase chain reaction (RT-PCR) techniques to understand 
the role of two molecules – vascular endothelial growth factor (VEGF) and 
decorin – in influencing tumour behaviour. This study revealed that when the 
tissue stroma surrounding the tumour cells had a strong immunostaining 
intensity for decorin, the risk of tumour-related death was significantly 
reduced. In addition, STS with a high immunostaining for VEGF were more 
than 7 times more likely to recur, and 5 times more likely to cause the death 
of the dog, compared to a STS with low immunostaining. When the 
immunostaining characteristics for VEGF and decorin were combined with 
other patient and tumour features into a predictive algorithm called a 
nomogram, it was possible to determine, with almost 100% accuracy, which 
dogs would remain disease-free 3 years after surgery. Remarkably, this 
prediction was obtained independently of any knowledge about the excisional 
T 
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status of the tumour. This suggests that the presence or absence of these 
molecules in the tumour microenvironment may support the survival and 
progression of residual microscopic tumour cells that remain in the wound 
bed, or alternatively are surrogate indicators of other features of tumour 
biology that impact on recurrence or metastasis.  
The importance of VEGF in the progression of tumour growth was 
subsequently demonstrated by treating dogs with haemangiosarcoma (HSA) 
– a mesenchymal tumour with many characteristics similar to STS – with 
thalidomide. Thalidomide is a potent antagonist of VEGF, but also has a 
number of other modulating influences on the tumour microenvironment.[1] 
Dogs treated with thalidomide survived significantly longer than dogs that 
did not receive this drug, suggesting that thalidomide can slow the ability for 
residual microscopic tumour cells to develop into a grossly visible, and life-
threatening tumour. An analysis of metastatic lesions that developed in dogs 
treated with thalidomide revealed that immunostaining for VEGF was 
significantly reduced. This suggests that thalidomide may be a useful 
adjuvant therapy for dogs with STS that are considered to be at high risk of 
recurrence after surgery, as determined by their VEGF immunostaining 
intensity.  
9.2 Importance of prognostic markers in soft tissue sarcoma 
Surgery is generally accepted to be the best treatment for a STS. Because local 
recurrence was commonly observed in early studies of this tumour,[2] it has 
been traditionally argued that wide resection of normal tissues about the 
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tumour would provide the best outcomes for affected patients.[3, 4] 
However, the results of the retrospective analysis of 350 dogs with STS 
performed in this study suggested that the extent of surgical margins is not 
influential on tumour recurrence or patient survival. This is consistent with 
the findings of other authors,[5-7] and suggests it is likely that some STS 
could be successfully managed with narrow margins. However, there is 
currently no way to determine which STS will be cured by narrow surgical 
margins; many of the existing prognostic indicators that have been described 
- such as size, tumour mobility and histological characteristics such as 
necrosis - lack sufficient distinguishing ability to be used to predict patient 
outcomes with any confidence.[8] These limitations were confirmed in the 
current study, where a nomogram based on clinical characteristics alone had 
a limited ability to identify dogs at risk of recurrence after surgery. Tumour 
grade remains the most validated criteria to be correlated with the extent of 
resection margin, but grade determination may be unreliable in almost 15% 
of cases.[9, 10] In this study, grade alone had a poor ability to predict 
outcome after surgery, with a 53% false-positive and 17% false-negative 
prediction of recurrence. If prognostic markers are to be used to help 
determine the need for adjuvant therapy after surgery, or even to provide a 
guide to the actual surgical margins used to remove the tumour safely, they 
need to be reliable and accurate to enable clinical decisions to be made with 
confidence. 
The prognostic markers selected for evaluation in the current study were 
chosen based on the recognition that a microscopic tumour remnant must re-
establish a vascular supply if it is to grow into a clinically detectable cancer. 
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Both VEGF and decorin have been previously identified as having a pivotal 
role in enabling or supporting the growth of a new blood supply in cancer, a 
process known as angiogenesis. Their role in the prognosis of STS has not 
previously been studied. In the study reported in this thesis, VEGF was 
shown to have an important influence on both recurrence and survival of the 
STS. Evidence of an association between tumour recurrence and the absence 
of decorin within the tissues was less strong, but this may have been due to 
small patient numbers. Because decorin is likely to have a protective 
influence on VEGF isoforms that are strongly matrix-bound by sequestering 
them from cellular interactions, it is unfortunate that efforts to analyse the 
proportions of different splice variants of VEGF within the STS failed. It 
would have been helpful to have this information to allow the relationship 
between VEGF, decorin and tumour progression to be better understood. 
Nevertheless, the results of the study support the use of VEGF or decorin as 
prognostic markers for STS. More work needs to be performed to validate the 
nomogram with another tumour population. Inclusion of information on the 
status of histological margins into the nomogram may also reduce the 
prevalence of false-positive predictions. Because decorin was significantly 
correlated with the histological grade of the tumour, immunostaining could 
also be used to help improve the reliability of this important prognostic 
indicator. 
9.3 Importance of VEGF as a therapeutic target 
Local recurrence of STS after surgery occurs in about 15% of patients.[8] 
Metastatic disease may also develop in up to 40% of dogs. Although 
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chemotherapy and radiotherapy have both been suggested to prevent or slow 
the development of either local or distant recurrence of the STS, the efficacy 
of these treatments is difficult to determine from the current literature. 
Alternative adjuvant treatments for STS are required. 
Having established that VEGF tended to be high in tumours at risk of 
recurrence, the next step in this study was to use this prognostic marker as a 
therapeutic target. Thalidomide was identified as an ideal drug to target 
VEGF with the intent of slowing or preventing tumour regrowth both at the 
original wound site, but also for distant metastasis. In this study, the benefits 
of thalidomide were more obvious in dogs when any residual tumour was too 
small to be detected on CT scan. In these patients, progression of the 
recurrent tumour was significantly slowed, with treatment reducing the daily 
risk of dying from their HSA by 80%. For dogs with Stage 2 HSA receiving 
thalidomide, median survival times increased from 49 days to more than 300 
days; almost a third of the treated dogs lived for more than one year after 
surgery. Benefits of thalidomide treatment were less evident in dogs with 
existing gross metastatic lesions. Macroscopic HSA lesions are fragile and 
prone to spontaneous bleeding. Because thalidomide is not cytotoxic, 
treatment will not make existing metastatic lesions reduce in size, so any 
benefits of treatment may be overshadowed by the increased risk of 
spontaneous, life-threatening haemorrhage in these patients. Examination of 
metastatic lesions in dogs treated with thalidomide revealed that 
immunostaining for VEGF was significantly reduced, but not completely 
inhibited. It is possible that combining thalidomide with directly cytotoxic 
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agents such as doxorubicin may result in a synergistic improvement in the 
outcome for dogs with HSA. 
9.4 Study limitations 
A major limitation of the studies described in this thesis was the inability to 
determine whether the tumour had actually been completely removed by 
surgery. This was because all of the necessary sections of the tumour that 
were required to analyse the margins histologically had not been made 
available when the archive of STS used for this study was created. While it is 
assumed that the surgeon operating on the STS removed all visible traces of 
the tumour, demonstration of a resection margin that was free of tumour 
cells on microscopic examination would have provided more confidence that 
the prognostic markers identified in this study had an independent influence 
on the tumour. While the status of the histologic tumour free margin (HFTM) 
does not necessarily provide a consistent prediction for whether tumour 
recurrence will or will not occur, there would be additional information 
provided by this examination that could have greatly improved the 
conclusions of this study. Previous work in human STS has demonstrated the 
prognostic significance of a tumour profile that is either expansile or 
infiltrative,[11] and also the distribution of satellite lesions that radiate from 
the tumour pseudocapsule. If the tissue sections of STS used in this study 
could have been examined for these characteristics, it is possible the 
nomogram that was developed in this study may have been more accurate at 
predicting patients where tumour recurrence was more likely after surgery. 
Furthermore, correlating the expression of VEGF and decorin with different 
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tumour profiles may also have given more insight into the role of the 
biomolecules in the tumour microenvironment.  
Several other limitations of this study have been discussed in previous 
chapters. It is important to reiterate that the clinical data for the STS used to 
establish the prognostic discoveries in this study was derived retrospectively. 
The tissues used for IHC and RT-PCR had also been fixed in formalin and 
stored in less than ideal conditions for more than 10 years before being 
studied. These factors introduce the potential for bias and inaccuracy, which 
could mean the conclusions of this study may not be valid. It would be 
important to verify the findings of this study with clinical data that has been 
collected prospectively, and to repeat the biomarker assays using tissues that 
have been recently collected to minimise the potential for artefactual 
distortion of the findings.  
In hindsight, it would also have been desirable if a wider panel of 
immunochemical markers was applied, in addition to VEGF and decorin. 
This would have allowed a better analysis of the role the tumour 
microenvironment may have in supporting tumour progression, particularly 
in relation to the formation of the pseudocapsule and the variance in tumour 
cell migration into the surrounding tissues. Some examples of additional 
molecules that could have been studied include: 1) lysyl oxidase (LOX), which 
has been correlated with variations in collagen cross-linkage and tumour 
mobility;[12] and 2) matrix metallopeptidase 9 (MMP-9) and tenascin-C, 
both of which have been shown to play a pivotal role in remodelling of the 
ECM in other cancers.[13] Additional immunostaining for transforming 
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growth factor- β (TGF-β), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) and CD4+Foxp3+ regulatory T cells (Treg) would 
also have improved the understanding of the role of thalidomide, by 
evaluating its immunomodulatory effects on the tumour. However, apart 
from Foxp3, many of the antibodies available against these proteins have not 
been studied in canine tissues, so their inclusion in the study would have 
required validation of the immunostaining protocols.  
9.5 Future directions 
The studies presented in this thesis provide important new insights into the 
biology of STS, and suggest a benefit of using VEGF and decorin to improve 
the prediction of outcome for a STS after surgery. Additionally, knowledge of 
these markers may allow them to be targeted for therapy. However, the 
evidence from these studies are not sufficiently robust to be used to influence 
clinical judgement and treatment strategies for STS. As discussed above, it 
will be important to verify the key findings of this study with another clinical 
population, and to validate the immunostaining characteristics for VEGF and 
decorin using fresh tissue. In addition, prospective validation of the 
nomogram with a new study population needs to be completed, ideally with 
inclusion of data on the status of the histologic margin. This would allow this 
device to become an important tool for a clinician, to help identify dogs that 
may be of risk of recurrence following surgery. These dogs could then 
undergo further surgery or adjuvant treatment such as chemotherapy or 
radiotherapy.  
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For the future, one of the most important pieces of information for the cancer 
surgeon is an accurate determination of the extent of tissue that must be 
removed about a mass to achieve effective local control. Most of the existing 
literature on prognostic markers, including the current studies, have focused 
on providing information for a surgery that has already been performed. Few, 
if any, of these publications have focussed on influencing or directing 
appropriate surgical dosing, or in providing the surgeon with objective 
information to determine the optimal surgical strategy for an individual 
patient. Cancer surgery would be improved if we had foresight about the 
biologic potential of the tumour being operated upon. This would allow the 
surgeon to more confidently titrate the resection margins about a tumour 
based on the actual characteristics of the tumour. The findings of the current 
study lend themselves to two additional areas of investigation that could help 
address this clinical need. Firstly, and as discussed in Chapter 6, 
development of a PCR assay using cellular material harvested from the 
tumour by fine needle aspiration would provide the surgeon with an ability to 
measure the VEGF and decorin expression of the tumour even before surgery 
was performed. Such techniques have been used in several human cancers, to 
provide information about the presence of gene mutations or other 
prognostic features that may impact on prognosis or treatment.[14, 15] If a 
similar technique could be developed for canine STS, this strategy could 
supplant the requirement for an incisional biopsy, thereby providing a cost-
effective and less invasive means of obtaining relevant prognostic 
information about the tumour. 
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The second strategy to provide pre-operative prognostic information about a 
STS, that is currently being investigated, would use whole genome 
sequencing techniques to identify the gene signature that correlates with 
various histological features that are likely to have a prognostic influence on 
STS. Similar strategies have been undertaken for several other canine 
cancers, including mast cell tumour,[16] histiocytic sarcoma,[17] and 
melanoma.[18] The phenotypic traits that would be studied for STS would 
include: 1) histological characteristics such as grade and necrosis, 2) a 
tumour profile that is either expansile or infiltrative; 3) the presence or 
absence of satellite tumour cells beyond the pseudocapsule; 4) increased 
angiogenic potential, based on increased VEGF and/or low decorin levels; 
and 5) tumour mobility. By correlating the genetic fingerprint of the tumour 
with these phenotypic attributes and outcomes for the dog, it is hoped to 
identify genetic markers that are associated with outcome (e.g. recurrence 
after surgery, metastasis and tumour-related death) or provide targets for 
novel treatment options.[19] These technologies can provide detailed, 
genome-wide molecular characterisation, and document thousands of 
individual DNA mutations and other genomic alterations.[20] Currently, it is 
planned to perform a comprehensive transcriptome analysis on a large tissue 
archive of almost 200 STS where the key phenotypic characteristics have 
previously been documented. 
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Appendices 
 
The Appendix contains copies of documents relevant to the studies contained 
in this thesis. This includes: 
 
A1 Copy of soft tissue sarcoma Questionnaire 
A2 Chapter 2 DRC 16-V3: Soft tissue sarcoma in the dog: part 1: A 
current review 
A3 Chapter 2 DRC 16-V3: Soft tissue sarcoma in the dog: part 2:  
Surgical margins, controversies and a comparative review  
A4 Chapter 3 DRC 16-V3: Canine soft tissue sarcoma managed in first 
opinion practice: Outcome in 350 cases 
A5 Chapter 7 DRC 16-V3: Does thalidomide prolong survival in dogs 
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